Parasite diversity and innovative serology: development of Trypanosoma

cruzi lineage‐specific diagnosis of Chagas disease and of prognostic assays for visceral leishmaniasis by Bhattacharyya, T
  
 
 
Parasite diversity and innovative serology: development of Trypanosoma 
cruzi lineage‐specific diagnosis of Chagas disease and of prognostic assays for 
visceral leishmaniasis. 
 
 
Tapan BHATTACHARYYA 
 
 
Thesis submitted in accordance with the requirements for the degree of  
Doctor of Philosophy of the University of London  
 
November 2014 
 
Department of Pathogen Molecular Biology 
 
Faculty of Infectious and Tropical Diseases 
 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE, 
UNIVERSITY OF LONDON 
 
 
 
Funded by European Commission Seventh Framework Programmes for Research: 
‘ChagasEpiNet’ and ‘NIDIAG’ 
 
Research group affiliation:   Professor Michael A. Miles 
  Faculty of Infectious and Tropical Diseases 
 
2 
 
 
 
 
 
I, Tapan Bhattacharyya, confirm that the work presented in this thesis is my own.  
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
 
Tapan BHATTACHARYYA 
November 2014 
  
3 
 
ABSTRACT  
Trypanosoma cruzi and the Leishmania donovani complex are parasitic protozoa 
that, respectively, cause Chagas disease in the Americas, and visceral leishmaniasis, 
predominantly in South Asia, East Africa, and Brazil.  
T. cruzi is divided into the lineages TcI-TcVI. The relationship between infecting 
lineage(s) and spectrum of clinical presentations remains poorly understood. This project 
developed lineage-specific serology to identify an individual’s history of lineage infection. A 
high level of polymorphism in the surface mucin TSSA was identified, and lineage-specific 
synthetic peptides based on this diversity were applied here in ELISA with chagasic sera 
from endemic countries. Peptide TSSApep-II/V/VI, based on a sequence common to those 
lineages, was widely recognised by sera from Southern Cone countries, and also 
unexpectedly by four samples from Ecuador; TSSApep-V/VI, which differs by a single amino 
acid from TSSApep-II/V/VI, was also recognised in these regions. A single TSSApep-IV 
reaction was seen in both Colombia and Venezuela. However, TSSApep-I was rarely and 
weakly recognised among the serum panel. Among the Brazilian patients, a much higher 
proportion of TSSApep-II/V/VI responders had ECG abnormailities than non-responders 
(38% vs. 17%, p<0.0001). 
Rapid diagnostic tests for L. donovani complex infection based on rK39 antigen have 
lower sensitivity in East Africa compared to South Asia. The homologous sequences of rK39, 
and of another proposed diagnostic antigen HASPB, were amplified from a panel of East 
African L. donovani strains, and compared to published sequences, revealing significant 
diversity from rK39 and South Asian sequences, and non-canonical combinations of HASPB 
repeats. Cohorts of Indian and Sudanese VL patients were assayed by ELISA for anti-
Leishmania IgG levels. There was an overall 46.8 – 61.7 fold lower response in the Sudanese 
cohort, as calculated by mean reciprocal log10t50 titres, regardless of antigen source, patient 
gender or age.  
An investigation into the association of IgG subclass reactivity with VL clinical status 
revealed significantly elevated IgG1 levels in patients with active (pre-treatment) VL and 
those with post-therapy relapse compared to those deemed to be cured. A novel prototype 
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rapid immunochromatographic test to detect IgG1 gave > 80% of relapsed VL patients as 
IgG1 positive, and 80% of cured patients as IgG1 negative. 
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1. GENERAL INTRODUCTION 
1.1 Trypanosoma cruzi and Chagas disease 
Chagas disease (American trypanosomiasis) remains an important parasitic disease 
in the Americas. The aetiological agent, the trypanosomatid protozoan Trypanosoma cruzi, 
is transmitted by species of triatomine bugs and is estimated to infect at least 8 million 
people in the endemic region (www.who.int/mediacentre/news/releases/2007/pr36/en/) 
(Figure 1). 
 
 
Figure 1 Distribution of Chagas disease. Endemic region indicated in purple (Morel & 
Lazdins, 2003). 
Early symptoms may include fever, fatigue and generalised oedema, but chronic 
infection can lead to debilitation and death by cardiac and/or intestinal complications. The 
estimated disease burden in endemic countries is over 0.6 million DALYs, with around 
14.000 deaths per annum (Hotez et al., 2009). Genetically diverse, T. cruzi is divided into the 
intra-species lineages TcI-TcVI. The association of genotype with geographical distribution is 
complex: TcI is found from the USA to Argentina in sylvatic cycles of transmission, with 
domestic infection principally north of the Amazon; TcII is found predominantly in human 
infections in the Southern Cone countries, and TcV and TcVI have only, as yet, been 
reported in Southern Cone countries. The different genotypes may also be associated with 
different natural transmission cycles (i.e., the insect vectors and mammalian hosts in sylvatic 
and domestic situations), and the varying symptoms of the disease. A key goal remains the 
clarification of this latter relationship. Despite recent successes in disrupting the vector-
borne transmission cycle in the Southern Cone countries, no prophylactic vaccine or 
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satisfactory chemotherapy exists for Chagas disease, especially in the chronic phase. It 
threatens to emerge as a public health issue beyond the endemic region, where chronically-
infected migrants are a source for parasite transmission.  
1.2 Leishmania donovani complex and visceral leishmaniasis 
The human leishmaniases exhibit a broad range of clinical syndromes, including: 
localised self-healing skin lesions (cutaneous leishmaniasis, CL); nasopharyngeal tissue 
destruction (mucocutaneous leishmaniasis, MCL); hepatosplenomegaly (visceral 
leishmaniasis, VL, ‘kala-azar’); post-kala-azar dermal leishmaniasis (PKDL, a sequel of VL). 
The different diseases are caused by infection by various species of the trypanosomatid 
protozoan Leishmania genus, acquired during bloodmeal feeding by an infected sandfly 
vector. The gravest form is VL; symptomatic disease is usually fatal if 
untreated. The great majority of the estimated 200,000 to 400,000 annual new VL cases are 
found in South Asia, East Africa, and Brazil (Figure 2), with 50,000 deaths per year (WHO, 
2010a; Alvar et al., 2012).  
 
 
Figure 2 Distribution of VL. (Chappuis et al., 2007) 
VL is caused by species of the L. donovani complex. These are L. donovani in East 
Africa and South Asia, and in Latin America L. infantum (historically ‘L. chagasi’) imported 
from Europe in recent centuries. Populations most at risk are among the poorest of society, 
and also non-immune migrants seeking refuge from war or famine in endemic areas. 
Epidemics have been particularly catastrophic. The rise of HIV infection has also been 
followed by an increase in incidence in VL cases worldwide. No prophylactic human vaccine 
exists, and diagnosis is by clinical signs, demonstration of intracellular amastigote forms, or 
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serology. Rapid diagnostic tests based on serology (detection of presence of anti-leishmanial 
antibodies) have proved very sensitive in certain endemic regions, but less so in others, for 
reasons that hither to have been unclear. 
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2. LITERATURE REVIEW 
2.1 Carlos Chagas and the discovery of T. cruzi 
Carlos Chagas (1879-1934), a doctor working in Lassance, southern-central Brazil, 
observed that protozoan flagellates found in faeces of night-biting triatomine bugs caused 
experimentally infected marmosets to develop a circulating trypanosome. Originally naming 
them Schizotrypanum cruzi, he went on to find the parasites circulating in children in 
Lassance with an acute febrile illness (Figure 3). Subsequently, he described the life cycle 
and mammalian host (Chagas, 1909). Emile Brumpt (1877-1951) later showed the 
mechanism of parasite transmission to be through infected bug faeces. 
 
 
Figure 3 Carlos Chagas examining baby. Lassance, Brazil c.1910 (Arquivo Iconográfico da 
Casa de Oswaldo Cruz, Brazil). 
 
2.2 T. cruzi  
2.2.1 Taxonomy 
The taxonomy of T. cruzi is given in Figure 4. The full taxonomic designation 
Trypanosoma (Schizotrypanum) cruzi refers to those trypanosomes of the subgenus 
Schizotrypanum, which undergo intracellular multiplication in vertebrates. 
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Figure 4 Taxonomy of T. cruzi. (WHO, 2002) 
 
2.2.2 Life cycle  
The life cycle of T. cruzi is summarised in Figure 5.  
 
Figure 5 Life cycle of T. cruzi (CDC). 
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After an infected triatomine takes a blood meal, infective metacyclic 
trypomastigotes deposited in its faeces enter the host through the bite wound, abraded 
skin, or intact mucosal membranes, e.g., conjunctiva, invading host cells near the 
inoculation site. Differentiation to intracellular amastigotes occurs. After cycles of binary 
replication, doubling every ~12 hrs, the amastigotes differentiate into trypomastigotes, 
rupture the host cell, releasing this form into the bloodstream, where they can infect 
various cell types and transform into intracellular amastigotes in new sites. Circulating 
trypomastigotes, ingested during a bloodmeal on an infected host by the triatomine, 
transform into epimastigotes in the vector’s midgut, where they multiply before 
differentiating into infective metacyclic trypomastigotes in the hindgut (Figure 6). These are 
eliminated with triatomine faeces and are able to infect the vertebrate host. 
 
 
Figure 6 T cruzi development in the triatomine vector. [A] Ingested epimastigotes and some 
sphaeromastigotes in stomach. [B] Epimastigotes multiply in midgut. [C] Transformation 
into metacyclic  trypomastigotes in rectum. (Garcia et al., 2007) [D]. Epimastigotes. 
 
2.2.3 Ultrastructure 
A schematic of the epimastigote form of T. cruzi is shown in Figure 7. The single 
mitochondrion, which contains the kinetoplast, drives the flagellum which stems from it and 
extends beyond the cell. Figures 7A and 7B depict the epimastigote and trypomastigote 
forms respectively. The kinetoplast contains extranuclear DNA arranged in mini- and 
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maxicircles. The flagellum has nine pairs of peripheral microtubule doublets surrounding a 
central pair (Figure 7C). 
 
Figure 7 T. cruzi ultrastucture. [A] Schematic of epimastigote form. (Docampo et al., 2005) 
[B] Trypomastigote has centrally positioned nucleus, and kinetoplast located towards the 
posterior (Teixeira et al., 2012). [C] Transversal view of thin section of flagellum of T. cruzi. 
Bar = 50 nm. (de  Souza, 2009) 
 
 
 
 
 
 
 
2.2.4 Vertebrate host cell invasion  
Host cell invasion by T. cruzi is a multi-step process involving interaction of parasite 
and host cell-surface molecules. In vitro cultured trypomastigotes express surface 
glycoproteins of the gp85 family, which have extracellular matrix component binding 
capability (Yoshida, 2006). These allow the subsequent enzymatic degradation of the matrix 
surrounding the target host cell, enabling parasite surface molecules such as trans-sialidase 
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(Butler et al., 2013) to interact with, and initiate the invasion of, the host cell. Host proteins 
identified as interacting with T. cruzi include kinin receptor (Todorov et al., 2003) and the 
nerve growth factor receptor TrKa (Melo-Jorge & Pereira, 2007). 
The trypomastigote becomes stably attached to the host cell, and initiates a signaling 
process leading to an elevation of intracellular free Ca2+. Host cell lysosomes are recruited to 
migrate to the trypomastigote attachment site, fuse with the plasma membrane, and allow 
the parasite to enter the host cell in via a parasitophorous vacuole formed by lysosomal 
membranes. T. cruzi-induced Low Density Lipoprotein receptor (LDLr) upregulation in 
infected cells has been shown, the same paper also reporting the role of parasite-bound 
LDLr in lysosome trafficking and fusion to the parasitophorus vacuole (Nagajyothi et al. 
2011). The acid environment of the parasitophorous vacuole favours the activity of Tc-Tox, 
the T. cruzi pore-forming molecule, leading to vacuole disruption. The acidic pH also 
stimulates trypomastigote differentiation into amastigotes, the intracellular replicative 
forms. After these differentiate into trypomastigotes, the host cell is ruptured, and this 
infective stage is released into the bloodstream. (Tan & Andrews, 2002; Manoel-Caetano & 
Silva, 2007) 
 
2.2.5 Vectors 
Several triatomine bug species are particularly important in human T. cruzi 
transmission, due to their ability to colonise human habitations and peri-domestic areas. 
Examples of these, along with geographic distributions, are shown in Figure 8. 
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Figure 8 Triatomine vectors of T. cruzi. [A] R. prolixus taking blood meal through human skin. 
Deposited faeces can be seen. (WHO/TDR/Stammers). [B] T. infestans. (photo credit T. 
Marlais, LSHTM). [C] Distribution in the Americas. 
(nature.com/nature/journal/v465/n7301_supp/box/nature09222_BX2.html). INSET: Miles 
et al., 2009b 
Both sexes are obligate haematophages, requiring at least one blood meal prior to 
progression to the next of their five growth instars. The bugs are often found in domestic or 
peri-domestic environments, where the poor nature of the dwelling’s construction favours 
colonisation by triatomines (Figure 9). Triatomine species emerge from their sanctuaries in 
such dwellings to take a blood meal from the human inhabitants at night. 
 
 
Triatoma infestans  Argentina, Brazil, Bolivia, Paraguay, 
Uruguay, southern Peru 
Rhodnius prolixus    northern South America, Central 
America 
Triatoma dimidiata   northern South America, Central 
America 
Panstrongylus megistus  central & eastern Brazil 
Traitoma brasiliensis  north-eastern Brazil 
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Figure 9 Poorly constructed dwellings as a habitat for triatomine bugs. [A] Example of poor-
quality housing construction. [B] Cracked mud walls providing refuge for triatomine bugs 
(circled). (WHO/TDR/Mark Edwards) 
 
2.2.6 Other routes of infection 
Oral infection. Infected insects, crushed during beverage preparation, have been the 
main source of T. cruzi leading to outbreaks of orally-acquired infection (Shikanai-Yasuda & 
Carvalho, 2011). These have often occurred in periurban and rural areas of non-endemicity. 
Recent instances include contamination of açai juice, the fruit of the palm Euterpe oleracea 
(Nobrega et al., 2009), and contamination of a guava drink, affecting pupils and personnel at 
a school in suburban Caracas (Noya et al., 2010; Segovia et al., 2013).  Murine models of 
oral-route infection have indicated parasite persistence in gastric mucosal epithelium, with 
a key role for parasite surface glycoproteins gp82 in initiating cell invasion (Yoshida, 2008). 
 
Congenital transmission. A report by PAHO gives a figure of over 14,000 annual cases 
of congenital Chagas disease in the Americas (PAHO, 2006). In order to prevent acute 
neonatal infection progressing to chronic, ante-natal serological screening of ‘at risk’ 
pregnant women, detection of living parasites in neonates in umbilical cord or venous 
blood, and serology of infants over 9 months old, in conjunction with benznidazole and 
nifurtimox therapy, are recommended (Carlier et al., 2011). 
Transfusional and organ donation. Donation of blood or organs from infected 
individuals is also a route of T. cruzi infection. Screening of donated blood has formed part 
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of the Chagas disease control programmes (SECTION 1.5), and organ donation has been 
recognised as a route of infection in endemic and non-endemic settings (SECTION 1.4.3) 
 
2.3 Chagas disease 
2.3.1 Clinical manifestations 
Acute Phase. Cases of the acute phase last 6-8 weeks, and are seen mainly in 
children, beginning with the potential development of a nodular, erythematous 
inflammatory response (inoculation chagoma) 1-3 weeks after the bite of the triatomine. 
Entry of the infective metacyclic trypomastigote form of the parasite passed in the feeding 
bug’s faeces into the circulation occurs through the wound, abraded skin, or via the 
conjunctiva. In the latter case, Romaña’s sign (conjunctivitis, unilateral palpebral oedema, 
and preauricular satellite adenopathy) may occur (Prata, 2001) (Figure 10A). 
 
 
Figure 10 Acute phase of Chagas disease. [A] Romañas sign exhibited in left eye of child. [B] 
Blood film showing tryptomastigote (circled) with flagellum. (WHO/TDR/Stammers) 
 
Parasitaemia may be identified by direct examination of blood (Figure 10B). The 
majority of acute cases, however, are not recognised as such, due to the non-specific nature 
of symptoms (fever, fatigue, oedema), and paucity of clinical manifestations. Without 
treatment, around 5% of symptomatic patients die during the acute phase due to severe 
cardiac failure, encephalomyelitis and rarely sudden death (Prata, 2001). 
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Chronic phase. In the 2-4 months following initial infection, acute symptoms recede, 
with parasites rarely detected in peripheral blood. The host immune response against the 
parasite is not sterilizing, i.e., does not destroy the first infection or subsequent challenge 
infections, and the host remains infected for life. The infection may remain clinically latent 
for decades, and most of these ‘indeterminate’ patients remain asymptomatic for life. 
Approximately 30% of infected patients develop the severe form of Chagas disease, in which 
irreversible chronic manifestations involve the heart, gastro-intestinal tract, and nervous 
system. Trypomastigote-infected heart muscle cells form amastigote pseudocysts (Figure 
11A). When these rupture in the myocardium, an acute myocarditis occurs, with 
myocytolysis, vasculitis and fibrosis. A high frequency of arrhythmias is characteristic of 
chronic chagasic heart disease caused by the inflammatory reaction in cardiac tissue. 
Thinning and deficit is preferentially localised in the apex of the left ventricle (apical lesion; 
Figure 11B), and is particularly seen in the Southern Cone region of South America. The 
frequency of this lesion is related to severity of cardiomyopathy, and is accompanied by 
characteristic electrocardiographic changes. Sudden death occurs in over 30% of chronic 
cases, mainly in males around the age of 40 (Prata, 2001). Another feature is the presence 
of chagasic megasyndromes in the southern part of South America. Up to 20% of patients 
develop functional defects in the oesophagus and colon, due to the destruction of the 
myoenteric nervous plexus (Dutra & Gollob, 2008). These are marked by the presence of 
chagasic megaoesophagus (Figure 11C) and megacolon. Dysperistalsis in the oesophagus 
leads to dysphagia, the most important symptom of oesophagopathy, and megacolonic 
syndrome often presents as obstipation. Chagas disease may be reactivated by 
immunosuppression, as occurs in HIV-AIDS, or during organ transplant.  
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Figure 11 Chronic phase of Chagas disease. [A] Section of heart muscle (haemotoxylin & 
eosin stain) showing amastigotes. (WHO/TDR/Stammers)  [B] (Left) Chagasic heart disease 
with apical aneurysm (arrowed); (Right) frontal section of same heart showing mild chamber 
enlargement. (Marin-Neto et al., 2007)   [C] Stages of megaoesophagus: (a) anecstatic, (b) 
mild, (c) moderate, (d) dolichomegaoesophagus. (Prata, 2001) 
  
The course of Chagas disease is represented schematically in Figure 12.  
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Figure 12 Course of Chagas disease. (Rassi Jr et al., 2009) 
 
Parasite load, strain and tissue tropism, and host antiparasite response, 
autoreactivity and genetic background are thought to be implicated in the establishment of 
pathology in Chagas disease, and to explain the range of severity of chronic symptoms 
(Dutra & Gollob, 2008).  
 
2.3.2 Diagnosis 
Many of the generalised signs of infection may not lead to identification of acute 
Chagas disease. T. cruzi may be detected parasitologically in the blood in acute cases, but 
then the parasitaemia decreases to sub-detectable levels. In the chronic phase, 
xenodiagnosis - the feeding of laboratory-reared triatomines on patient blood and 
examination for presence of infection in the bug faeces - and blood culture have been used. 
In this phase, the serological tests used are listed in Table 1 (Anon., 2008). 
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Table 1 Serological tests used in diagnosis in chronic phase of Chagas disease. 
 
TEST BASIS ADVANTAGES DISADVANTAGES 
ELISA Complex 
antigen mix 
High sensitivity, specificity and 
throughput; objective 
quantitative results 
Requires a cold chain, technician, and 
expensive consumable reagents 
IIF Entire 
parasite  
High sensitivity; quantitative 
and qualitative results 
Requires expensive fluorescence 
microscope and technician; low 
processing speed. 
IHA Complex 
antigen mix 
Results in ~2 hours; lack of 
sophisticated equipment; 
quantitative results. 
Lower sensitivity than IFA or ELISA; false 
positives and low reproducibility; 
requires cold chain 
 
Current WHO recommendations are that at least two of these tests be positive for 
definitive serological diagnosis (WHO, 2002). Serological tests use whole cell T. cruzi lysates, 
semi-purified or recombinant antigens for the detection of anti-T. cruzi antibodies, which 
are of the IgG isotype in the chronic phase. A recent WHO comparative evaluation 
undertaken in Latin America on a panel of commercial serological assays (Otani et al., 2009; 
WHO, 2010d) found that EIA performed better than haemagglutination and particle 
agglutination assays, with the confirmatory use of RIPA being used as the gold standard for 
EIA confirmation. 
Rapid diagnostic tets (RDTs) generally take the form of immunochromatographic 
tests, containing whole cell lysates or recombinant antigens bound onto a membrane at a 
‘test’ line, plus a dye-conjugated antibody-binding protein. An example is shown in Figure 
13, for the Chagas Stat-Pak Assay RDT. After the sample (whole blood or plasma/serum, 
depending on manufacturer instructions) is applied in its well, the addition of a larger 
volume of buffer allows antibodies in the sample to be bound by the dye-conjugated 
antibody-binding protein, and migrate by lateral flow through the membrane. If the sample 
contains antibodies against the bound T. cruzi antigen, they become localised and can be 
visualised as a discrete, coloured band on the ‘test’ line (shown on the right in Figure 13). 
The sample continues to migrate along the membrane, where an internal IgG antigen 
‘control’ line is visualised, validating the test in the presence or absence of the ‘test’ line 
visualisation. 
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Figure 13 Example of RDT for Chagas disease.  In this Chagas StatPak Assay are shown the 
outcomes if the sample is negative (left) or positive (right) for the presence of anti T. cruzi 
antibodies. Both samples have bands on the ‘control’ line, thereby validating the test 
reagents and results.  
 
In a recent international multi-centre trial organised by MSF, a panel of 11 
commercialised RDTs was evaluated by National Reference Laboratories in 9 countries 
(endemic and non-endemic) using their own serum bank plus a standard control panel 
(Sanchez et al., 2014). Although overall performance results were reported as being lower 
than those described by manufacturers, six tests were recommended by the authors for 
screening and surveillance as RDTs (with reference laboratory confirmation). Interestingly, 
one of these was Chagas Stat Pak Assay, which was tested but not recommended by the 
authors of the WHO Latin American study described above for screening donated blood. The 
authors of the MSF RDT study also noted that antigenic variability in different geographical 
regions may play a role in RDT performance; Verani et al. (2009) report differences in 
sensitivities in two RDTs between Bolivian and Peruvian samples. 
Diagnosis of cure is assessed by seroconversion (disappearance of anti-T. cruzi 
antibodies); parasite persistence is the sign of therapeutic failure, although this may be 
difficult to demonstrate. However, after treatment of chronic Chagas disease serological 
markers may take many years to disappear, so positive serology is not necessarily indicative 
of active infection. Lack of a proper point-of-care test to assess cure following therapy has 
been listed as a knowledge gap and research priority in a recent WHO report (WHO, 2012) 
requiring biomarker discovery and clinical validation. 
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Another consideration is the possible serological mis-identification of Trypanosoma 
rangeli, a closely-related but non-pathogenic organism, as a false-positive for T. cruzi 
infection (de Moraes et al., 2008), particularly when whole cell lysate is used as antigen. A 
recent proteomic comparison of a T. rangeli strain and a T. cruzi strain identified some 
candidate T. rangeli-specific proteins (Wagner et al., 2013). The genome of a reference T. 
rangeli strain has recently been published (Stoco et al., 2014). 
 
2.3.3 Prevalence 
Prevalence of T. cruzi infection in Latin America is indicated by country in Figure 14. 
 
Figure 14 Prevalence of T. cruzi infection in Latin America. 
(www.nature.com/nature/journal/v465/n7301_supp/full/nature09222.html) 
 
Cases of Chagas disease has been identified in non-endemic regions in Europe, North 
America and Japan in Latin American emigrants (Gascon et al., 2009). The number of T. 
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cruzi-infected individuals living in the USA has been estimated at 300,000 (Bern & 
Montgomery, 2009). Screening of donor blood for T. cruzi in the USA has begun recently 
(CDC, 2007). A WHO report on Chagas disease in Europe describes Spain as having the 
highest numbers of estimated cases (Figure 15; WHO, 2010c), including most of the 
congenital infections in babies born to Latin American mothers. Organ transplant from 
infected individuals has led to reports of Chagas disease in recipients, with recent cases in 
Spain (umbilical cord blood transplantation; Forés et al., 2007) and the USA (heart 
transplantation; Kun et al., 2009).  
 
 
Figure 15 Distribution of cases of T. cruzi infection in Europe. (WHO, 2010c).  
 
In the UK, there have been 44 passively diagnosed cases (D Nolder, LSHTM, Personal 
communication).  A figure of 14000 cases of T. cruzi infection among Latin American 
migrants in the UK was recently estimated (WHO, 2010c). 
 
2.3.4 Treatment and Management 
No prophylactic vaccine currently exists for Chagas disease. The nitroheterocyclic 
compounds nifurtimox (developed by Bayer, 1967) and benznidazole (developed by Roche, 
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1972) have historically been the only available effective drugs for trypanocidal 
chemotherapy (Figure 16). 
 
 
Figure 16 Chemotherapeutic agents to treat Chagas disease. (Wilkinson & Kelly, 2009)  
 
Early treatment by oral chemotherapy during the acute phase requires daily doses 
for 1-4 months (nifurtimox), and 1-2 months (benznidazole), and can cause severe side-
effects. In the case of nifurtimox, these are commonly manifested as gastrointestinal and 
neurological complications; for benznidazole, allergic dermatitis and peripheral neuropathy 
(Marin-Neto et al., 2009; Bern, 2011). Proposed modes of action of these drugs may be 
through an increase in oxidative stress in the parasite, and DNA damage (Wilkinson & Kelly, 
2009). Nifurtimox and benznidazole are prodrugs, and rely on cleavage by a T. cruzi-encoded 
type-I nitroreductase (TcNTR) for activation to become trypanocidal agents; one mechanism 
of drug resistance is caused by loss of this gene or its function (Wilkinson et al., 2008; Mejia 
et al., 2012). A multinational clinical trial of benznizdole to determine whether trypanocidal 
treatment improves prognosis in chronic chagasic heart disease patients (the BENEFIT 
project) is ongoing (Marin-Neto et al., 2009; 
http://clinicaltrialsgov/ct2/show/NCT00123916). The anti-fungal triazoles posaconazole and 
ravuconazole, ergosterol biosynthesis inhibitors, have recently been used in clinical trials as 
novel trypanocides. However, posaconazole did not show efficacy in adult South American 
patients with chronic Chagas disease residing in Barcelona (Molina et al., 2014). 
Ravuconazole, administered in its prodrug form E1224, in trial in chronic inderminate phase 
patients in Bolivia (http://clinicaltrials.gov/ct2/show/NCT01489228?), also has not shown 
promising results. 
An important consideration is that drug tests should consider the genetic diversity of 
T. cruzi (Zingales et al., 2014), further described in SECTION 2.5. 
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Surgical treatment for megacolon (Nahas et al., 2009) and megaoesophagus is 
important in chronic cases.  
 
2.4 Control programmes  
In recent decades, a number of initiatives have been supported by PAHO with the 
aim of controlling the spread of T. cruzi transmission. These programmes have been 
directed towards prevention of transmission by transfusion of donated blood, and by 
residual insecticide spraying of dwellings against the triatomine vectors. These are operated 
through subregional initiatives, as shown in Figure 17. 
 
 
Figure 17 Subregional vector control initiatives against T. cruzi transmission. 
(nature.com/nature/journal/v465/n7301_supp/full/nature09222.html); PAHO. 
 
Some key achievements of INCOSUR are described in Figure 18. 
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Figure 18 INCOSUR. [A] Areas covered by INCOSUR programme delineated in red. [B] Areas 
where vectorial transmission by T. infestans has been interrupted shown delineated. INSET: 
some key achievements of INCOSUR. (PAHO; Schofield et al., 2006).  
In 2008, Guatemala was the first country in Central America to be certified by IPCA 
as being free from transmission by R. prolixus, the main Central American domiciliated 
vector, followed by Mexico in the same year, El Salvador in 2010, Nicaragua, Honduras and 
Costa Rica in 2011, and Belize in 2012 (Hashimoto and Schofield, 2012; PAHO, 2012) 
 
2.5 T. cruzi ecology and epidemiology 
Chagas disease is an anthropozoonosis, in that T. cruzi was initially a parasite of 
sylvatic animals, and became a human infection after triatomine bugs adapted to invading 
human settlements for a food source. Unlike birds and reptiles, all mammals are considered 
at risk from T. cruzi infection, and are thus potential natural reservoirs. The recognition of a 
disparate geographic distribution of chagasic disease syndromes, and aspects of T. cruzi 
biology, led in the 1970s to the first description of distinct parasite ‘strain-groups’ in Brazil, 
derived from human/domicilated animal infections and from sylvatic opossums and 
triatomines (Miles et al., 1977). Using a MLEE approach, the electrophoretic patterns of 
various T. cruzi enzymes revealed two combinations of isoenzyme pattern among the stocks 
investigated, leading to the initial subdivision of T. cruzi into zymodemes, or enzyme groups. 
Later molecular (DNA–based) techniques, such as analysis of the spliced-locus intergenic 
region (SL-IR) of the miniexon gene and 24Sα rDNA (Souto et al., 1996), reinforced the 
dichotomous view of T. cruzi. On the basis of the accumulated data, T. cruzi was classified 
1997 Uruguay: Interruption of vectorial and transfusional transmission 
1999 Chile: Interruption  of vectorial transmission 
2000 Interruption of transmission by T. infestans throughout most of  
           endemic area 
2006 Brazil: formally declared to be free of transmission due to  
           T. infestans. 
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into two principal groups, TcI and TcII (Anon., 1999). TcII was subsequently further divided 
into TcIIa-e (Brisse et al., 2000) based on genetic markers. According to the latest 
recommendations (Zingales et al., 2009), the six lineages are now recognised as TcI - TcVI. 
Lewis et al. (2011) report the recent, anthropic generation of the TcV and TcVI lineages, 
resulting from a hybridisation between TcII and TcIII. A scheme for T. cruzi lineage evolution 
is depicted in Figure 19. 
 
 
Figure 19 Schematic of proposed T. cruzi lineage evolution. (Westenberger et al., 2005) 
Gaunt et al. (2003) used distinct ‘parent’ strains of T. cruzi transfected with different 
drug resistance markers in co-passage through mammalian cell culture to produce hybrid 
double-resistant clones in vitro, showing that the parasite has an extant capacity for genetic 
exchange, involving the fusion of parental genotypes, loss of alleles, and homologous 
recombination.  
The association of lineages with geographical distribution is complex (Figure 20). TcI 
is found as far north as the USA, whereas TcII, TcV, and TcVI predominate in the Southern 
Cone countries, although TcII infection has been reported in Colombia (Zafra et al., 2008). 
Recent evidence has shown TcIII to exist in armadillos from Venezuela to Paraguay 
(Llewellyn et al., 2009b), but is rare in humans. Carrasco et al. (2012) report around 20% of 
human-isolated T. cruzi in Venezuela to be TcIV. TcI is linked to chagasic cardiomyopathy in 
central and northern South America, whereas TcII/TcV/TcVI in the Southern Cone correlate 
in distribution with cardiomyopathy and the presence of chagasic megasyndromes of the 
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colon and oesophagus. An important goal remains to clarify the relationship between 
parasite genotype and clinical outcome. 
 
DOMESTIC
SILVATIC
TcI
TcIV
TcII TcIII
TcV TcVI
 
Figure 20 Approximate distributions of T. cruzi lineages, with cycles of transmission. (M 
Llewellyn, LSHTM) 
 
Yeo et al. (2005) proposed broadly that TcI co-evolved with opossums (Didelphis 
spp.) or Rhodnius in the palm tree niche, whereas, TcIII co-evolved with armadillos (Dasypus 
spp.) in the terrestrial niche (Figure 21). They further suggest that respective historical 
arboreal and terrestrial ecologies of these hosts explain intraspecific diversity of T. cruzi in 
South America, and the separate origins for Chagas disease in the northern and southern 
parts of the continent. 
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Figure 21 Mammalian hosts of T. cruzi. [A] Opossum Didelphis marsupialis. (Universidade 
Federal de Minas Gerais, Brazil). [B] Nine-banded armadillo Dasypus novemcinctus. 
(National Biological Information Infrastructure, USA) 
The different lineages are associated with different ecological niches, natural 
transmission cycles (sylvatic or domestic), and Chagas disease, as summarised in Table 2. 
 
Table 2 Ecological niches and disease associations of T. cruzi lineages. (Miles et al., 2009) 
 Niche Main sylvatic host Main sylvatic 
vectors 
Chagas Disease 
TcI Primarily arboreal Didelphis 
(opossum), other 
arboreal 
Rhodnius spp. North of Amazon: 
cardiomyopathy.  
TcII Domicilated; 
uncommonly 
sylvatic 
? Atlantic forest 
primates 
? Atlantic/Central Brazil. 
Cardiomyopathy, 
megasyndromes. 
TcIII Terrestrial/fossorial Dasypus 
novemcinctus 
(nine-banded 
armadillo) 
Panstrongylus 
geniculatus 
Rarely documented  
TcIV Arboreal primates Primates, bats, etc Rhodnius, 
Triatoma, 
Panstrongylus 
Secondary cause in Venezuela; 
sporadic elsewhere 
TcV Domicilated; rarely 
sylvatic 
? Dasypus 
novemcinctus 
? Southern Cone: 
cardiomyopathy, 
megasyndromes. 
TcVI Domicilated; rarely 
sylvatic 
? ? Southern Cone: 
cardiomyopathy, 
megasyndromes. 
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Lewis et al. (2009) used PCR-AFLP and -RFLP protocols to develop a system for 
lineage identification (Figure 22). 
 
 
Figure 22 Triple assay for discriminating T. cruzi lineages. (Lewis et al, 2009). LSU rRNA = 
large subunit ribosomal RNA gene; HSP60 = heat shock protein 60 gene; GPI = glucose-6-
phosphate isomerase. Corresponding current and previous lineage designations are shown.  
 
The phylogenetic relationships between lineages have been explored by the use of 
multilocus sequence typing (MLST) targets. Concatenated sequences from four loci were 
used to group a panel of T. cruzi isolates into clades, as shown in Figure 23 (Yeo et al, 2011). 
By this analysis, two groupings, one comprised by TcII, TcV and TcVI, and the other by TcI, 
TcIII and TcIV emerged. 
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Figure 23 Phylogenetic relationships of T. cruzi lineages.  (Yeo et al., 2011) 
 
Even within individual lineages, the situation appears more complex than previously 
understood. Typing based on TcI SL-IR has revealed sub-groups TcIa-e (Falla et al., 2009; 
Cura et al., 2010; Tomasini et al., 2010). Llewellyn et al. (2009a) described human isolates 
restricted to two distinct groups within a broad panel of TcI strains by multilocus 
microsatellite typing (MLMT) typing. Ocaña-Mayorga et al. (2010), described two discrete 
populations of TcI, one predominantly domestic/peri-domestic, the other silvatic, in 
Ecuador.  
Of interest is the different tissue tropisms of different lineages, which has been 
reported with analysis of T. cruzi DNA from different organs using patient samples taken 
from heart and oesophagus (Vago et al., 2000) or blood and heart (Burgos et al., 2010); 
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recent murine studies have also reported different myocarditis patterns (Rodriguez et al., 
2014). 
Recently, a new genotype of T. cruzi restricted to bats, called TcBat, related to TcI, 
has been described from Brazil (Marcilli et al., 2009), Panama (Pinto et al., 2012) and 
Colombia (Ramirez et al., 2013). 
However, of crucial importance are the current limitations of identifying infecting 
lineage: i) direct genotyping of T. cruzi by direct PCR on blood or cultured isolates is only 
feasible when there is a sufficient circulating parasitaemia, which is confounded by the 
sequestration of the parasite in host tissues in the chronic phase, possibly in a lineage-
dependent manner, and the prospect of lineage selection bias during culture; ii) current 
serological methods to detect antibodies against T. cruzi give no information on infecting 
lineage(s) and are not designed for that purpose. 
 
2.6 T. cruzi reference genome sequencing 
Table 3 lists the T. cruzi strains representative of their lineages for which reference 
genomes have been sequenced.  
Table 3 Reference genomes of T. cruzi lineages. 
Lineage strain Reference 
TcI Silvio X10/1 Franzén et al., 2011 
TcI JR4 cl1 Unpublished a 
TcI Dm28c Grisard et al., 2014 
TcII Esmeraldo cl3 Unpublished a  
TcVI CL Brener El-Sayed et al., 2005 
T. c. 
marinkelleib 
B7 cl 11 Franzen et al., 2012 
 
a accessible via http://tritrypdb.org; b bat-associated subspecies 
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As it had been well characterised experimentally, CL Brener (TcVI) was chosen as the 
strain for the first T. cruzi genome sequence (El-Sayed et al., 2005). As shown in Figure 19, 
TcV and TcVI are now understood to be hybrids of TcII and TcIII; thus for the CL Brener 
genome the two contributing haplotypes were named Esmeraldo-like (TcII) and non-
Esmeraldo-like (TcIII). Additionally, over 50% of this genome was found to consist of 
repeated sequences. The genome of a representative TcI strain, Sylvio X10/1, was 
subsequently sequenced as a non-hybrid, evolutionarily distinct, comparison (Franzén et al., 
2011). The TcI Sylvio X10/1 haploid genome was estimated to be smaller than that for TcVI 
CL Brener (44 Mb vs. 55 Mb). The two genomes were reported to have highly conserved 
gene synteny and core gene complement, but although 6 ORFs in CL Brener were not found 
in Sylvio X10/1, no Sylvio X10/1-specific genes were identified. The comparative genomic 
analysis also found a differential expansion in sequences corresponding to surface antigen 
repertoires and other multicopy gene families, with the CL Brener genome estimated as 
having ~6Mb of extra haploid sequence related to these multigene families compared to 
Sylvio X10/1. As surface molecule genes are major contributors to the repetitive nature of 
the CL Brener genome, this was concluded by the authors to underlie most of the haploid 
genome size difference between the two T. cruzi lineages, having the potential to enhance 
functional plasticity. 
 
2.7 Research needs: Chagas disease 
As described herein, Trypanosoma cruzi is now understood to be a complex of 
diverse genotypes, possessing the capacity for genetic exchange, and displaying differing 
geographical distributions in terms of Chagas disease symptoms and severity, sylvatic hosts, 
and transmission cycles. Control programmes underway in recent years have the potential 
to achieve even greater successes in interrupting transfusional and vector-borne 
transmission. Relevant to this project, Coura (2007) lists a ‘top ten of Chagas disease needs’ 
including ‘3. To improve a specific and fast test for TcI-TcVI infections’ and ‘4. To standardize 
the techniques for serological diagnosis and control of cure evaluation’.  
Thus, there is the key question of the identification of an individual’s history of T. 
cruzi lineage infection. As described above, molecular (DNA) techniques have their 
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limitations, so an indirect approach is required. Such a method would be based on the 
identification of lineage-specific antigens and the development of a serological assay to 
exploit differential antibody reponses to these.  
Aims and objectives for the work on T. cruzi presented in this thesis are described in 
SECTION 3.1. 
 
2.8 Discovery of Leishmania 
In 1903, William Leishman (1865-1926) and Charles Donovan (1863-1951) both 
reported observations of intracellular bodies in samples from ‘kala-azar’ patients in India 
(Figure 24; Leishman, 1903; Donovan, 1903). In the same year, Ronald Ross (1857-1932) 
gave the name Leishmania donovani to these intracellular parasite stages (Ross, 1903). 
Person-to-person transmission was later demonstrated to be mediated by the sandfly 
(Swaminath et al., 1942). 
 
 
Figure 24 Leishman and Donovan. [Left] William Leishman. [Centre] Charles Donovan. (both 
http://dna.kdna.ucla.edu/parasite_course-old/leish_files/subchapters/Historical.htm). 
[Right] Spleen smear preparation from patient described in Leishman (1903). 
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2.9 Leishmania spp. 
2.9.1 Taxonomy  
The taxonomy of Leishmania to genus level is shown in Figure 4. Leishmania are 
classified into the two subgenera Leishmania (Leishmania), and Leishmania (Viannia). 
Taxonomy to species level is shown in Figure 25. 
 
 
Figure 25 Taxonomy of Leishmania. * = species status under discussion. (WHO, 2010b) 
 
2.9.2 Life cycle 
The life cycle of Leishmania is summarised in Figure 26.  
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Figure 26 Leishmania life cycle. (CDC) 
Leishmania promastigotes are transmitted to humans through the proboscis of female 
sandflies (Phlebotomus spp. and Lutzomyia spp. in the Old and New World respectively) 
during bloodmeal feeding. Following internalisation by local dermal macrophages and 
dendritic cells, flagella are lost, and transformation into proliferative amastigote forms leads 
to cell lysis, and phagocytosis by other cells. Upon taking a bloodmeal containing infected 
host macrophages, amastigotes are liberated in the sand fly gut, transform into 
promastigotes, and migrate to the proboscis (described in more detail in SECTION 2.9.3). 
 
2.9.3 Vectors 
The vectors for L. donovani are Phlebotomus argentipes in South Asia, Phlebotomus 
martini and Phlebotomus orientalis in East Africa, and Lutzomyia  longipalpis for L. infantum 
in the Americas (Figure 27). 
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Figure 27 Sandfly vectors of Leishmania. [A] Phlebotomus sp. (Old World vector). (CDC) [B] 
Lutzomyia longipalpis (New World vector). 
(www.plospathogens.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fimage.
ppat.v05.i08.g001&representation=PNG_S) 
Leishmania are classified into the two subgenera Leishmania (Leishmania) and 
Leishmania (Viannia). In Leishmania (Leishmania), promastigote development occurs in the 
sandfly midgut (suprapylarian development), whereas it occurs in the hindgut (peripylarian 
development) for Leishmania (Viannia). Species of the subgenus L. (Viannia) are restricted 
to the New World. Suprapylarian development, the better understood of the two, is briefly 
described here (Kamhawi, 2006; Bates, 2007). Leishmania amastigotes ingested by the 
anthropophilic sandfly during bloodmeal feeding transform first into procyclic 
promastigotes in the blood bolus, then into motile nectomanad promastigotes (Figure 28). 
These migrate along the midgut epithelium by binding of surface lipophosphoglyan to a 
receptor in the sandfly gut. Subsequent transformation into replicative leptomonad 
promastigotes in the anterior midgut precedes differentiation into non-replicative infectious 
metacyclic promastigotes and also haptomonad promastigotes, which attach to and plug 
the opening of the stomodeal valve. Promastigote secretory gel produced by leptomanads 
fills the thoracic midgut limen; the resulting ‘blocked fly’ effect enhances regurgitation of 
metacyclic promastigotes into the host during bloodmeal feeding (Rogers et al., 2004).  
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Figure 28 Leishmania development in the sandfly vector (suprapylarian). PSG = 
Promastigote secretory gel. (Kamhawi, 2006) 
 
2.10 Visceral leishmaniasis 
2.10.1 Clinical manifestations  
Following infection from a female sandfly, the incubation period can range from 10 
days to over 1 year, and usually disease onset is gradual. Common symptoms are fever, 
malaise, shivering/chills, weight loss, anorexia and discomfort in the left hypochondrium. 
Clinical signs are non-tender splenomegaly, sometimes with hepatomegaly, wasting and 
pallor of mucous membranes (Figure 29A). Lymphadenopathy may be present (particularly 
in Sudan) and be the only clinical manifestation. Darkening of the skin of the face, abdomen, 
hands, and feet may be found in India (Hindi: kala-azar = black fever). In Sudan, a 
Leishmania-containing cutaneous nodule or ulcer or a mucosal lesion may be present. Signs 
of malnutrition (oedema, skin and hair changes) develop as the disease progresses. In 
advanced stages, intercurrent infections by other pathogens are common (WHO, 2010b). 
Post-Kala Azar Dermal Leishmaniasis (PKDL), characterized by a hypopigmented macular, 
51 
 
maculopapular, and nodular rash, may occur in patients who are cured of VL and otherwise 
well (Figure 29B). 
 
 
Figure 29 Clinical manifestations of VL. [A] Splenomegaly. (www.sciencephoto.com) [B] 
PKDL (www.who.int/leishmaniasis/Viscerial_Leishmaniasis_hr.jpg) 
PKDL is found in both East Africa and South Asia, with differing epidemiological 
features, as listed in Table 4 (Zijlstra et al., 2003). 
 
Table 4 Epidemiological features of PKDL in Sudan and India. (Zijlstra et al., 2003) 
 Sudan India 
Frequency following treated VL 50 % 5-10% 
Most common interval after VL 0-6 months 2-3 years 
Age & sex distribution Children (mean age 6 yrs), 
 equally male and female 
Young adults, 
 male predominance 
 
PKDL may have role in maintaining a reservoir population of L. donovani, 
contributing to disease persistence in the community. The inter-relationship between 
manifestations of Leishmania infection in Sudan is shown in Figure 30 (Zijlstra et al., 2003). 
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Figure 30 Inter-relationship between manifestations of Leishmania infection in Sudan. Line 
thickness corresponds with likelihood of occurrence. (From Zijlstra et al., 2003) 
Elevated levels of the immunosuppressive cytokine interleukin-10 (IL-10) in the 
serum, and elevated IL-10 mRNA in spleen or bone marrow, have been often reported in VL 
(Nylen and Sacks, 2007); IL-10–neutralising monoclonal antibodies promoted amastigote 
clearance ex vivo in splenic aspirate cells from VL patients (Gautum et al., 2011). There is a 
mixed Th1/Th2 response in human VL (WHO, 2010b). 
 
2.10.2 Diagnosis  
Clinically suspected cases are those exhibiting fever for more than 2 weeks and 
splenomegaly in the absence of malaria (WHO, 2010b). Parasitological diagnosis, by 
demonstration of amastigote in lymph node, spleen, or bone marrow tissue smear, is the 
definitive diagnosis (Figure 31). 
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Figure 31 L. donovani amastigotes inside infected macrophage. Light micrograph of spleen 
tissue section. (www.sciencephoto.com). 
 Serological (anti-Leishmania antibody) tests include ELISA, IFAT, and DAT (Srivastra 
et al., 2011). For the last few years, the RDT for VL widely used has been the rK39 ICT, based 
on a kinesin-related gene product, LcKin, identified by screening a Brazilian L. infantum (L. 
chagasi) genomic library with serum of an L. donovani patient (Burns et al., 1993). A part of 
the coding sequence, comprising a 46 aa region followed by 6.5 x 39 aa repeats, forms the 
recombinant diagnostic protein rK39, used in the RDT bound on an ICT strip. The presence 
of anti-Leishmania antibodies in the patient sample can be visualised in a few minutes after 
application by the presence of a coloured band on the test strip, in the same manner as 
described in Section 2.3.2. An example for the rK39 RDT (BioRad Laboratories) used with 
Sudanese VL sera is shown in Figure 32.  
 
Figure 32 rK39 RDT for VL. Sudanese sera were applied to the RDT. The presence of a band 
at the L line indicates the presence of anti-Leishmania IgG. NEHC = non-endemic healthy 
control. 
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In recent multicentre evaluations, the use of the rK39 ICT RDT reported less success 
in East Africa than in the Indian subcontinent for point-of-care diagnosis of VL (Tables 5 & 6; 
Boelaert et al., 2008; Cunningham et al., 2012). 
Table 5 Boelaert et al., 2008: Prevalence in the test sample and sensitivity and specificity of 
rK39 dipstick (with 95% CI).  
 
 East Africa South Asia 
 Ethiopia Kenya Sudan India Nepal 
Prevalence  57.2 (40.5-73.4)  60.9 (54.7-66.7)  37.0 (31.0-43.2)  79.6 (75.1-83.7)  71.0 (63.5-77.9)  
Sensitivity  75.4 (55.9-90.5)  84.7 (78.6-89.8)  77.9 (69.2-85.6)  99.6 (98.4-100)  96.5 (92.1-99.2)  
Specificity 70.0 (46.3-88.9) 89.9 (83.2-95.1) 91.8 (86.7-96.2) 90.0 (81.2-96.4) 90.9 (80.8-97.5) 
 
Table 6 Cunningham et al., 2012: Sensitivity and specificity of rK39 rapid diagnostic tests 
(with 95% CI).  
  East Africa Brazil Indian subcontinent 
‘DiaMed-IT 
Leish’  
(Bio-Rad) 
Sensitivity 87.2% (82.5%-90.8%) 92.0% (87.8%–94.8% 98.8% (96.5%–
99.6%) 
Specificity 96.4% (93.3%–
98.1%) 
95.6% (92.2%–
97.5%) 
97.6% (94.8%–
98.9%) 
‘KalaAzar Detect’ 
(InBios) 
Sensitivity 67.6% (61.6%–
73.1%) 
84.7% (79.7%–
88.7%) 
99.6% (97.8%–
99.9%) 
Specificity 90.8% (86.6%–
93.8%) 
96.8% (93.9%–
98.4%) 
96.0% (92.8%–
97.8%) 
 
 Underlying explanatory factors for this differential regional sensitivity may reside in 
molecular divergence between East African L. donovani kinesin gene homologues and the 
Brazilian L. infantum (L. chagasi)-derived rK39 sequence and/or may be due to differential 
immunocompetence and antibody levels produced among African and Asian human 
populations.  
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The first two of the 39 aa repeats of Sudanese L. donovani kinesin homologue LdKin 
(Gerald et al., 2007), flanked by sequences of the L. donovani antigens HASPB1 and HASPB2 
(Alce et al., 1999), comprise rK28 (Figure 33), a novel synthetic recombinant protein for 
diagnosis of VL, designed to be an improvement on rK39 (Pattabhi et al., 2010, Vaish et al., 
2012). HASPB proteins are expressed on the surface of infective promastigotes and 
amastigote. The first 3 x 14 aa repeats of HASPB1 are incorporated into rK28, along with the 
complete ORF of HASPB2, which includes three imperfect consecutive repeats, 2 x 14 aa and 
1 x 13 aa. 
 
 
 
Figure 33 Synthetic gene rK28. Comprised by repeats of HASPB proteins flanking Sudanese-
derived kinesin repeats. 
 
An additional aspect of the current serological tests is that they may give positive 
results post-cure and so cannot readily diagnose relapse, and can also indicate the presence 
of anti-leishmanial antibodies in asymptomatics living in endemic areas, but with no VL 
history (WHO, 2010b). A large Indian/Nepalese population study reported an association 
between higher DAT and/or rK39 titres and risk of progression from asymptomatic to 
symptomatic VL (Hasker et al., 2014); in a long-term follow-up of 55 rK39 seropositive 
asymptomatic cases in India 69% developed VL and 31% remained asymptomatic (Singh et 
al., 2002). The proportion of seropositive asymptomatic individuals that progresses to 
symptomatic VL has been reported to vary between endemic regions, as shown in Table 7. 
Currently there is no rapid diagnostic test that determines or predicts which asymptomatic 
carriers will progress to active VL. 
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Table 7 Asymptomatic progression to VL. Reports of the proportions of asymptomatic 
seropositive individuals who either remain symptom-free or do progress to symptomatic VL 
are expressed as ratios. 
Country Non progressors: 
progressors 
Reference 
Sudan 1:2.4 Zijlstra et al., 1994 
Kenya 4:1 Schaefer et al., 1995 
Brazil 8:1 Evans et al., 1992 
Bangladesh 4:1 Bern et al., 2007 
India & Nepal 8.9:1 Ostyn et al., 2011 
Spain 50:1 Moral et al., 2002 
 
2.10.3 Treatment and management 
Historically, the standard first-line chemotherapeutic agents to treat VL have been 
the pentavalent antimonials sodium stibogluconate and meglumine antimoniate, 
administered by injection, although development of resistance to antimonials has emerged 
in India (Chakravarty & Sundar, 2010), possibly caused by chronic exposure to arsenic in 
drinking water (Perry et al., 2013). More recent anti-leishmanials include amphotericin B, 
paromomycin, and miltefosine (WHO, 2010b) (Figure 34).  
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Figure 34 Chemotherapeutic agents to treat VL. [A] sodium stibogluconate. 
(www.speciation.net) [B] Amphotericin B. (www.ambisome.com) [C] Miltefosine. 
(www.caymanchem.com) 
In South Asia, amphotericin B in liposomal formulation (AmBisome) is the preferred 
treatment, followed by combination therapies (AmBisome with miltefosine or 
paromomycicn, or miltefosine with paromomycin) (WHO, 2010b). The primary target for 
amphotericin B is the surface membrane ergosterol (human cells have cholesterol as their 
major surface membrane sterol), thus parasite destruction can be achieved without 
amphotericin B uptake by the host. In East Africa, pentavalent antimonials with 
paromomycin or in combination or monotherapy remain the preferred treatment choices 
(WHO, 2010b). 
According to a WHO/TDR publication, VL treatment outcomes are assessed twice, an 
inital outcome on the last day of drug treatment, and a final outcome six months after the 
last drug was taken (WHO, 2010e). The main outcomes, as listed therein, are given in Table 
8. 
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Table 8 Treatment outcomes in VL (WHO, 2010e). 
 Outcome Case definition 
Initial assessment  
(last day of drug 
treatment)  
Initial cure A full course of drugs has been completed 
AND the patient has clinically improved. 
Clinical criteria for cure should be assessed 
as no fever + regression of enlarged spleen 
+ return of appetite and/or gain in body 
weight. 
Non-response Signs and symptoms persist or recur. 
Switch to a second-line drug because of no 
response to the first-line drug. 
Side-effects related switch Side-effects necessitate a change of 
treatment. 
Death Any death, whether or not related to VL. 
Default The patient does not complete treatment 
and/or does not present for assessment 
after treatment. 
Final assessment  
(6 months after 
last drug taken) 
Final cure An initial cure patient who is symptom-free 
at six months after the end of treatment. 
Relapse Any reappearance of KA symptoms within 
a period of six months after the end of 
treatment. 
Death Any death, whether or not related to VL. 
Loss to follow-up Patient does not present for assessment at 
six months. 
 
However, Rijal et al., (2013), in following up miltefosine–treated patients for up to 12 
months after completion of therapy found a relapse rate of 20% (24/120 patients) in their 
studied cohort in Nepal. 
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As shown in Table 8, criteria for assessing cure after VL therapy are clinical. The 
requirement for an established biomarker of cure in VL, its clinical validation and 
incorporation into a point-of care test have been identified as knowledge gaps and research 
priorities in a recent WHO report (WHO, 2012). 
 
2.11 Control strategies 
In 2005, a regional strategic framework for VL elimination was agreed by the 
endemic countries of India, Nepal, and Bangladesh, with the target to reduce annual 
incidence to < 1/10, 000 population at district/sub-district level by 2015 (WHO, 2005). It 
describes the following factors as favourable for VL elimination: man is the only reservoir 
host; P. argentipes is the only known vector; availability and effectiveness of oral 
miltefosine; availability of reliable rK39 tests; past effectiveness of indoor residual spraying 
to control vector; political commitment; focusing of elimination efforts in endemic districts. 
However, the following constraints are mentioned: incomplete or inappropriate treatment 
from private doctors/quacks [sic]; delay in treatment favouring continued transmission; 
resistance to antimony drugs; persistence of reservoir in undetected and untreated PKDL; 
summer outdoor sleeping exposes to peri-domestic vectors; expense of treatment for 
poorest people. 
  Indoor residual spraying of organochlorines (e.g., DDT) has been the main strategy to 
control endophilic sandfly vectors in South Asia (WHO, 2011). Preparedness for, rapid 
assessment of, and response to, epidemic outbreaks has also described as a component of 
control strategies (WHO, 2010b).  
 
2.12 L. donovani complex population structure 
MLEE has been the ‘gold standard’ for Leishmania typing to species level; the 
Montpelier system (MON) is based on 15 enzymes (Rioux et al., 1990). Drawbacks of MLEE 
typing come from the need to have a large culture of parasite, protein electrophoresis 
equipment, and the reliance on electrophoretic mobilities of proteins that does not resolve 
individual amino acid polymorphisms (conserved or non-conserved) caused by coding DNA 
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changes. More recently, molecular biology techniques based on MLST (Mauricio et al., 2006; 
Zemanova et al., 2007) and MLMT have been used to provide greater resolutive power for 
the L. donovani complex. Lukeš et al. (2007) showed that the genetic structure of L. 
donovani complex is determined mainly by geography rather than MLEE-based taxonomy or 
clinical outcome, and proposed an evolutionary hypothesis for the origin and dispersal of 
Leishmania. (Figure 35A,B). The evolution of Leishmania was proposed to have taken place 
in South America ~46-36 mya (Figure 35A). Subsequent dispersal via the Bering land bridge 
was into Asia, where, 25-15 mya, the ancestor of L. donovani complex diverged from other 
species. Further dispersal led to the emergence of L. infantum ~1 mya in Central Asia and 
moving into Europe, while L. donovani entered East Africa and South Asia. L. infantum was 
introduced to the Americas from Iberia by human activities multiple times during the last 
500 years; historically this has been called L. chagasi (Kuhls et al., 2011). When New World 
Lutzomyia became competent vectors for these parasites, VL was thus established in this 
region. In this thesis and its annexes, the term ‘L. infantum (L. chagasi)’ is used to describe 
these parasites. 
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Figure 35 L. donovani complex population structure, evolution and dispersal. [A] Proposed 
model of Leishmania evolution and dispersa. MYA = millions of years ago. [B] Genotype is 
strongly correlated with geographical origin (Lukes et al., 2007). [C] MLMT identifies six 
populations (Kuhls et al., 2007). 
Kuhls et al. (2007) used MLMT to define six genetically distinct populations of L. 
donovani complex in VL endemic regions (Figure 35C), and reported that allelic diversity in 
Africa, although lower than in the Mediterranean region, was greater than in India. Another 
MLMT study showed a high degree of homogeneity among South Asian L. donovani (Alam et 
al., 2009).  
Hybrids and genetic exchange between Leishmania of the same species, and 
between different species, have been described naturally and experimentally (Tables 9 and 
10). 
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Table 9 Natural hybrids of Leishmania spp. 
Isolated from Assay Species n Reference 
Homo sapiens,  Nicaragua MLEE L. panamensis – L. braziliensis 8 Darce et al., 
1991 
Canis familiaris and 
Psammomys obesus, Saudi 
Arabia 
MLEE, DNA 
probes 
L. major  - L. arabica 2 Kelly et al., 
1991 
Homo sapiens,  NIcaragua MLEE, DNA 
probes 
L. panamensis – L. braziliensis 11 Belli et al., 
1994 
Homo sapiens, Peru MLEE, RAPD, 
DNA probes 
L. braziliensis – L. peruviana 4 Dujardin et 
al., 1995 
Homo sapiens, Venezuela MLEE L. braziliensis – L. guyanensis 4 Delgado et 
al., 1997 
Homo sapiens, Ecuador MLEE, RAPD L. braziliensis – L. 
panamensis/guyanensis 
4 Bañuls et al., 
1997 
Homo sapiens, Portugal  MLST, MLEE L. infantum - L. major 2 Ravel et al., 
2006 
Homo sapiens and Canis 
familiaris, Peru 
MLEE, MLMT L. braziliensis – L. peruviana 26 Nolder et al., 
2007 
Homo sapiens and Canis 
familiaris, Tunisia 
MLST L. infantum- L. infantum 4 Chargui et al., 
2009 
Homo sapiens, Ethiopia AFLP L. donovani – L. aethiopica 1 Odiwour et 
al., 2011 
Phlebotomus tobbi and 
Homo sapiens, Turkey 
Whole genome 
sequencing 
L. infantum a Rogers et al., 
2014 
Homo sapiens, Ethiopia MLMT, MLST L. donovani  - L. donovani   4 Gelanew et 
al., 2014 
 
a Authors report patchy heterozygosity and SNP density across sample set. 
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Table 10 Experimental hybrids of Leishmania spp. 
System Method Species Reference 
Phlebotomus duboscqi Drug resistance transfer L. major - 
L. major 
Akopyants et al., 2009 
Phlebotomus 
perniciosus and 
Lutzomyia longipalpis 
Fluorescence gene 
transfer 
L. donovani -  
L. donovani 
Sadlova et al., 2011 
In vitro  Drug resistance transfer L. infantum - 
L. major 
Coelho et al., 2012 
 
 
2.13 Leishmania reference genome sequences 
Table 11 lists the Leishmania spp. for which reference genomes have been 
sequenced. Strains are identified by WHO nomenclature HOST/COUNTRY/YEAR/STRAIN. 
Table 11 Reference genomes of Leishmania spp. 
Species & strain Isolated from Origin Reference 
L. major MHOM/IL/81/Friedlin Homo sapiens Israel Ivens et al. (2005) 
L. braziliensis MHOM/BR/75/M2904 Homo sapiens Brazil Peacock et al. (2007) 
L. infantum MCAN/ES/98/LLM-877 (JPCM5) Canis familiaris Spain Peacock et al. (2007) 
L. mexicana MHOM/GT/2001/U1103 cl25 Homo sapiens Guatemala Rogers et al. (2011) 
L. donovani MHOM/NP/2003/BPK282/0 cl4 Homo sapiens Nepal Downing et al. (2011) 
L. amazonensis MHOM/BR/71973/M2269 Homo sapiens Brazil Real et al. (2013) 
 
The L. infantum reference genome size was reported as 32.1 Mb (Peacock et al., 
2007; Rogers et al., 2011). A comparison of the three hither-to sequenced genomes 
revealed 5 L. major-specific, 26 L. infantum-specific, and ~47 L. braziliensis specific genes 
(Peacock et al., 2007). Downing et al. (2011) published an assembled draft of the reference 
L. donovani genome strain, BPK282/0  cl4 originating from Nepal, which was chosen on the 
basis of being antimonial-sensitive and representative of the most common microsatellite 
group in South Asia (as identified by Alam et al., 2009). The genome size was 32.4 Mb, and 
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annotated by identifying orthologous genes from the L. infantum genome. Although L. 
donovani diversity in the region is low, the genome sequencing of an additional 16 clinical L. 
donovani strains form India and Nepal resolved a population structure beyond that found 
with MLMT. 
2.14 Research needs: visceral leishmaniasis 
The Expert Committee Report on the Control of the Leishmaniases (WHO, 2010b) 
describes laboratory research needs for VL, of which the most relevant to this project is 
‘research and development of rapid tests for the diagnosis of VL and tests for cure based on 
antigen and nucleic acid detection.’  
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3. AIMS AND OBJECTIVES  
3.1 Trypanosoma cruzi and Chagas disease 
Aim: To analyse molecular diversity within T. cruzi, identify lineage-specific antigenic 
epitopes, and apply them to determine serologically an individual’s history of exposure to T. 
cruzi lineages. Objectives: 
1) compare inter-lineage diversity in antigen genes by molecular analysis of the 
surface mucin TSSA, across a panel of strains encompassing T. cruzi genetic and 
ecological diversity [ANNEX 1]; 
2) development of a T. cruzi lineage-specific serology: design and use of synthetic 
peptides, based on the identified lineage-specific TSSA sequences, in ELISAs for 
differential serology with human chagasic sera [ANNEX 2]. 
3.2 L. donovani complex and visceral leishmaniasis 
Aim: To determine the factors underlying the reported lower levels of sensitivity of rapid 
diagnostic tests among East African compared to South Asian human populations. 
Additionally, IgG subclass responses among VL patients of different clinical status are 
investigated as a potential biomarker. Objectives:  
3) analyse the molecular diversity of diagnostic kinesin and HASPB antigens: PCR 
amplification and sequencing of kinesin and HASPB genes across a panel of East 
African L. donovani strains; comparative geographical analysis with reference to 
GenBank-accessible sequences [ANNEX 3]; 
4) compare Indian and Sudanese VL patient serological responses: production of 
whole cell lysates of representative Sudanese and Indian L. donovani strains; 
compare differential anti-Leishmania IgG responses between Indian and Sudanese VL 
patient cohorts [ANNEX 4]; 
5) analyse IgG subclass responses in Indian and Sudanese VL patients: compare IgG 
subclass profiles in patients with different clinical status [ANNEX 5]; 
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6) adapt anti-Leishmania IgG1 detection to a lateral flow RDT for application at 
point-of-care [ANNEX 5]. 
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4. MATERIALS AND METHODS 
Descriptions of all reagents and protocols are described in the relevant publication(s) in 
Section 5 ANNEXES. Commonly used techniques are described here. 
4.1 Parasite strains 
Trypanosoma cruzi: Strains encompassing lineages TcI-TcVI used in this project are listed in 
ANNEX 1 Bhattacharyya et al., 2010 Table 1.  
Leishmania donovani complex: Strains used in this project are listed in ANNEX 3 
Bhattacharyya et al., 2013 Table 1. 
4.2 Oligonucleotide sequences 
Table 12 lists the oligonucleotides used as PCR and internal sequencing primers in ANNEXES 
1, 2 & 3. All oligonucleotides synthesised by Eurofins MWG Operon. 
Table 12 Oligonucleotides used as PCR and internal sequencing primers.  
 Target  Forward/Reverse Sequence  (5’ – 3’) Section 
T. cruzi TSSA  T5/ATG/E 
EMT5/A 
CGGAATTCATGACTACGTGCCGTCT 
TTTGAGGAGGCTTCTGCTTC 
ANNEX 1 
 RNA binding 
protein, putative 
*MenTcI For 
*MenTcI Rev 
ATGCCACAATCGAAACCAAG 
TCACAACAAACGTTTGGCTG 
ANNEX 2 
L. donovani 
complex 
Kinesin 
 
[Sequencing 
primer] 
*LdonK39 for 
*LdonK39 rev 
 
 
*HASPB1intern 
GAGCTCGCAACCGAGT 
CTGRCTCGCCAGCTCC 
                (R= A/G) 
 
GATGAACGACTCTGCC 
ANNEX 3 
 HASPB      
 
[Sequencing 
primer] 
*LdonHASPB1for 
*LdonHASPB1rev 
 
*HASPB1 intern 
CATAAAACCACTGAGGC 
ATCTTCGTTCTTCTCCTG 
 
GATGAACGACTCTGCC 
ANNEX 3 
*= designed by the author for this project. 
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4.3 PCR, DNA Electrophoresis and cycle-sequencing.  
PCR: General composition per 20 μl reaction volume in 0.2 ml capped tubes: 
Reagent amount concentration 
10x NH4 buffer 2 μl 1x 
50mM MgCl2 0.6 μl 1.5mM 
2mM dNTPS 0.4 μl 40 μM 
10pmol/ul Forward primer 1 μl 0.5 pmol/ μl (= μM) 
10pmol/ul Reverse primer 1 μl 0.5 pmol/ μl (= μM) 
BioTaq Polymerase 0.2 μl 1 U 
H2O To volume  
Template DNA 1 -2 μl   
 
1 x cycle:  95 °C for 2 mins 
25 cycles: 95 °C for 30 secs / Anneal temperature* for 30 secs / 72°C for 30-60 secs* 
1x cycle: 72 °C for 10 mins 
* varies according to the expected amplicon 
DNA electrophoresis: DNA (amplicons) was added to loading buffer, and electrophoresed on 
a gel of appropriate percentage of agarose (Bioline), containing 0.2 µg/ml EtBr, in 1xTAE 
buffer. DNA size standard marker was also loaded on each gel. Following electrophoresis, 
the gel was visualised and image-captured under UV using the GeneGenius BioImaging 
System (Syngene). 
Cycle sequencing: General composition per 10 μl reaction volume in 0.2 ml capped tubes: 
Reagent amount 
BigDye® Terminator v3.1 RR-100 0.5 μl 
5x dilution buffer 1.7 μl 
3.2 pmol/ μl primer 1 μl 
Template DNA 1-2 μl 
H2O To volume 
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Following 25 x cycles, comprising steps at 96 °C for 30 secs, 50 °C for 20 secs, and 60 °C for 4 
mins, the resulting extension products were purified. Reactions were transferred to 1.5 ml 
tubes on ice, containing 32 μl of 95% EtOH and 8 μl ddH2O. Following 15 min incubation, the 
samples were spun at 13000 rpm in a bench top microfuge for 20 mins. The pellets were 
washed by 50 μl of 70 % EtOH, and dried at 90°C for 1 min. Sequencing was performed on 
an ABI3730 machine (Applied Biosystems). Sequencing analysis and alignments were 
performed using Bioedit software (Hall, 1999). 
4.4 Peptide synthesis 
‘In-house’ peptide synthesis was performed in collaboration with Dr A. Falconar, 
LSHTM. The automated systems used were ‘SMPS350 Peptide Synthesiser’ (Zinsser 
Analytic), and an ‘Apex396 Peptide Synthesiser’ (Aapptec). Additionally, peptides were 
produced commercially by Genosphere Biotechnologies. A detailed description of the 
synthesis and purification of peptides, from Dr Falconar, is given in ANNEX 2 Bhattacharyya 
et al., 2014. A brief overview of the synthesis process, based on the sequential addition of 
amino acid residues (initially protected at the α-amino and R side chains) to a solid phase 
support in the overall direction C → N, is given here (Figure 36). 
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Figure 36 Overall peptide synthesis scheme. Adapted from White and Dörner (eds.), 
Synthesis Notes, Novabiochem Peptide Synthesis catalogue 2008/2009. 
A C-terminal cysteine residue linked to resin was used to prime the synthesis of each 
peptide. After removal of the N-α-protecting group by piperidine, subsequent amino acids 
were coupled. DMF was used in washing steps. A PEG spacer was coupled after the last 
amino acid residue (always glycine), and a terminal biotin group was added to each peptide. 
R-side chain deprotection and cleavage from the resin was then done. Thus, the final 
composition of the synthesised peptide is depicted in ANNEX 2 Bhattacharyya et al., 2014 
Figure 1A. Following cleavage from the resin, peptides were purified by reverse-phase HPLC. 
Eluted peptide fractions were freeze-dried and stored at -85 °C. 
4.5 Sources of human samples 
Chagas disease: Hospital das Clinicas, Goiânia, Brazil; Universidad Mayor de San Simon,  
Cochabamba, Bolivia; Universidad Nacional de Salta, Argentina; Universidad Central de 
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Venezuela, Caracas, Venezuela; Universidad de los Andes, Bogotá, Colombia; Pontificia 
Universidad Católica del Ecuador, Quito, Ecuador. 
 
VL: Banaras Hindu University, Varanasi, India; University of Khartoum, Sudan. 
4.6 ELISA 
Chagas disease: Protocols for confirming boitinylation of synthetic peptides (a proxy for 
peptide integrity) and performing lineage-specific serology are given in ANNEX 2 
Bhattacharyya et al., 2014 
VL: Protocols for comparative serology of Indian and Sudanese VL plasma, and IgG subclass 
in different clinical states, are given, respectively, in ANNEX 4 Bhattacharyya et al., 2014 and 
ANNEX 5 Bhattacharyya et al., 2014.  
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ANNEX 1: Bhattacharyya T, Brooks J, Yeo M, Carrasco HJ, Lewis MD, Llewellyn MS, 
Miles MA (2010). Analysis of molecular diversity of the Trypanosoma cruzi 
trypomastigote small surface antigen reveals novel epitopes, evidence of positive 
selection and potential implications for lineage-specific serology. Int J Parasitol 40 
921-928 
ANNEX 2: Bhattacharyya T, Falconar A, Luquetti A, Cosatles J, Grijalva M, Lewis M, 
Messenger L, Tran T, Ramirez JD, Guhl F, Carrasco H, Diosque P, Litvinov S, Miles MA 
(2014). Development of peptide-based lineage-specific serology for chronic Chagas 
disease: geographical and clinical distribution of epitope recognition. PLoS Negl Trop 
Dis 8 e2892 
Leishmania donovani complex and visceral leishmaniasis 
ANNEX 3: Bhattacharyya T, Boelaert M, Miles MA (2013). Comparison of visceral 
leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals 
extensive diversity and continent-specific polymorphisms. PLoS Negl Trop Dis 7 
e2057 
ANNEX 4: Bhattacharyya T, Bowes DE, El-Safi S, Sundar S, Falconar AK, Singh OP, 
Kumar R, Ahmed O, Boelaert M, Miles MA (2014). Significantly lower anti-Leishmania 
IgG responses in Sudanese versus Indian visceral leishmaniasis. PLoS Negl Trop Dis 8 
e2675 
ANNEX 5: Bhattacharyya T, Ayandeh A, Falconar A, Sundar S, El-Safi S, Gripenberg M, 
Bowes D, Thunissen C, Singh OP, Kumar R, Ahmed O, Eisa O, Saad A, Pereira SS, 
Boelaert M, Mertens P, Miles MA (2014). IgG1 as a potential biomarker of post-
chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid 
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Bhattacharyya T, Burleigh B. Trypanosoma cruzi I chronic chagasic cardiomyopathy 
and Chagas disease reactivation in Boston, Massachusetts, USA.  
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PUBLICATIONS ARISING: Trypanosoma cruzi and Chagas disease 
 
ANNEX 1: Bhattacharyya T, Brooks J, Yeo M, Carrasco HJ, Lewis MD, Llewellyn MS, Miles MA 
(2010). Analysis of molecular diversity of the Trypanosoma cruzi trypomastigote small 
surface antigen reveals novel epitopes, evidence of positive selection and potential 
implications for lineage-specific serology. Int J Parasitol 40 921-928 
 
Key points, novel results and implications 
 The T. cruzi surface mucin trypomastigote small surface antigen (TSSA) had been 
previously described as displaying sequence dimorphism between TcI and the then 
grossly-described TcII (now TcII-TcVI) lineages, and differential serology based on the 
antigenic properties of these sequences had led those authors to conclude that 
Chagas disease is due to infection by ‘TcII’ only (Di Noia et al., 2002). 
 Here, the diversity of the TSSA gene was examined across a panel of T. cruzi isolates 
from TcI-TcVI lineages, encompassing the geographical and ecological range of this 
species. 
 A greater diversity in the TSSA coding region, reflected in the predicted amino acid 
sequence, was identified. All TcI strains possessed their previously described 
sequence in the polymorphic region, whereas all TcII, TcV, and TcVI strains shared a 
common sequence, with TcV and TcVI strains possessing an additional haplotype 
coding for a single amino acid point substitution, not previously reported. TcIII and 
TcIV were revealed to contain their own lineage-specifc sequences, also reported 
here first. 
 Analysis of the TSSA coding sequences among the panel inferred greater 
phylogenetic affinities of TcIII and TcIV to TcI than to TcII, TcV or TcVI, in agreement 
with published multilocus studies; a high ratio of non-synonymous to synonymous 
nucleotide substitutions (ω = 1.233) indicated that the TSSA gene has been under 
positive selection pressure. 
 Thus the demonstration here of a greater diversity of lineage-specific TSSA epitopes 
within TcII–TcVI has implications for seroepidemiological studies of Chagas disease 
based on this antigen. 
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Candidate’s contribution: 
The candidate performed all the PCRs, gel electrophoresis, DNA sequencing 
preparation, sequence alignment, and most of the RFLP assays, of the TSSA gene as 
described in this publication. The candidate prepared the first draft of the manuscript, 
which was accepted for publication by Int J Parasitol in January 2010 following academic 
peer review.  
 
 
(Double-click on image to view embedded document) 
The results described above were then applied to the design and use of synthetic 
peptides for T. cruzi lineage-specific serology, as described in the following section (ANNEX 2 
Bhattacharyya et al., 2014). 
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Chagas disease, caused by infection with the zoonotic protozoan
Trypanosomacruziand transmittedby triatominebugs, remains ama-
jor parasitic disease in the Americas, infecting at least eight million
people (www.who.int). Chronic human infection can lead to debilita-
tion and death by cardiac and/or intestinal complications, with a
disease burden of 0.7 million disability-adjusted life years (DALYs)
and 14,000 deaths annually (Hotez et al., 2009). Trypanosoma cruzi
has in recent years been genotypically divided into the six intra-spe-
cies lineages (discrete typingunits,DTUs)TcI andTcIIa–e (Brisseetal.,
2000), now renamed TcI–VI (Zingales et al., 2009), with TcV and VI
derived from hybridisation between TcII and III (Machado and Ayala,
2001;Gaunt et al., 2003;Westenberger et al., 2005). The geographical
distribution of the DTUs is complex: TcI is found as far north as the
USA; in contrast TcII, V and VI predominate in the southern conesitology Inc. Published by Elsevier
s paper are available in the
Accession Nos. GU059921–
x: +44 207 636 8739.
(T. Bhattacharyya).countries, althoughhumanTcII infection hasbeen reported inColom-
bia (Zafra et al., 2008). The different genotypesmay also beassociated
with varying disease symptoms and natural transmission cycles (syl-
vaticordomestic). TcI is linked to chagasic cardiomyopathy inCentral
and northern South America, whereas TcII, V and VI in the southern
cone correlate with cardiomyopathy and the presence of chagasic
megasyndromes of the colon and oesophagus (Prata, 2001). TcIII
and IV, predominantly found in sylvatic transmission cycles, are also
capable of human infection. Yeo et al. (2005) proposed that, broadly,
opossums are the natural hosts of TcI, armadillos hosts of several
lineages of TcII–VI, and that their respective arboreal and terrestrial
ecologies explain intra-speciﬁc diversity of T. cruzi in South America
and the separate origins forChagas disease in thenorthern and south-
ern parts of that continent. Despite recent successes in disrupting
vector-borne transmission in southern cone countries (Schoﬁeld
et al., 2006) and the launch of the World Health Organization
(WHO) Global Network for Chagas Elimination (www.who.int/
mediacentre/news/releases/2007/pr36/en/), Chagas disease remains
a major public health issue in Latin America (Reithinger, 2009).
Trypanosoma cruzi mucins – surface glycoproteins with a high
level of O-glycosylation at serine or threonine amino acid residuesLtd. All rights reserved.
922 T. Bhattacharyya et al. / International Journal for Parasitology 40 (2010) 921–928– comprise a large (>800) gene family (El-Sayed et al., 2005) be-
lieved to play a key role in host immune evasion and in maintain-
ing infection (Buscaglia et al., 2006). The majority of mucin genes
belong to the multi-gene sub-families TcMUC I and TcMUC II. Di
Noia et al. (2002) assigned a bi-allelic single-copy gene to a third
mucin family (TcMUC III), the two alleles of which were reported
to correspond in distribution with lineages TcI and TcII–VI, respec-
tively. Antisera raised against a recombinant protein product of
this gene from strain CL Brener (TcVI) identiﬁed the native form
expressed on the surface of cell-derived trypomastigotes (equiva-
lent to bloodstream form trypomastigotes frommammalian hosts).
The protein was thus named the trypomastigote small surface anti-
gen (TSSA). They also reported: (i) PvuII digestion of a TSSA PCR
product occurred only for TcI, not TcII–VI; (ii) the major antibody
(Ab)-recognition epitope was restricted to a 10-amino acid region
in TcII–VI (41-KPATGEAPSQ-50) where TcI versus TcII–VI differ-
ences clustered, with no immunological cross-reactivity between
TSSA-I and TSSA-II isoforms. In a survey of chagasic patient sera
from Argentina, Brazil and Chile, anti-TSSA antibodies were attrib-
utable only to the TcII–VI isoform, leading to the proposition that
TSSA is the ﬁrst serological marker to identify a T. cruzi lineage in
human infection and that TcII–VI, not TcI, is the cause of Chagas
disease. However, the Di Noia et al. (2002) study was based on a
genotypically narrow range of T. cruzi strains, including those
grossly categorised as TcII–VI, and on sera from a limited geo-
graphical area, as was later acknowledged (Buscaglia et al.,
2006). Furthermore, TcI is known to cause severe and fatal Chagas
disease with myocarditis in Venezuela (Miles et al., 1981a; Añez
et al., 2004) and north-eastern Brazil (Teixeira et al., 2006).
Here, we determine the nucleotide (nt) and predicted amino acid
sequence of a fragment of the TSSA gene across a panel of 25 T. cruzi
strains representing a geographical and genotypic range that
encompasses all describedDTUs. A greater diversity is revealed than
previously reported, including in the PvuII digest pattern, and in the
region spanning the reported Ab-recognition epitope. The epitope
considered speciﬁc for TcII–VI is shown to identify only TcII, V and
VI. In addition, the peptide described as TcI-speciﬁc shares key fea-Table 1
Panel of biological clones of Trypanosoma cruzi strains used in this trypomastigote small su
brackets.
Discrete typing unit Strain Origin
TcI Sylvio X10/1 Belém, Brazil
Cutia cl1 Espiritu Santo, Brazil
Sp104 cl1 Region IV, Chile
P209 cl93 Sucre, Bolivia
OPS21 cl11 Cojedes, Venezuela
92101601P cl1 Georgia, USA
TcII[IIb] TU18 cl93 Tupiza, Bolivia
CBB cl3 Region IV, Chile
Mas cl1 Brasilia, Brazil
IVV cl4 Region IV, Chile
Esm cl3 São Felipe, Brazil
TcIII[IIc] M5631 cl5 Selva Terra, Brazil
M6241 cl6 Belém, Brazil
CM17 Meta, Colombia
X109/2 Makthlawaiya, Paragu
TcIV[IIa] CanIII cl1 Belém, Brazil
92122102R Georgia, USA
Dog Theis Oklahoma, USA
TcV[IId] MN cl2 Region IV, Chile
Bug 2148 cl1 Rio Grande do Sul, Bra
SO3 cl5 Potosi, Bolivia
SC43 cl1 Santa Cruz, Bolivia
TcVI[IIe] CL Brener Rio Grande do Sul, Bra
P63 cl1 Makthlawaiya, Paragu
Tula cl2 Tulahuen, Chiletures with TcIII and IV. We demonstrate that the bi-allelic descrip-
tion of the TSSA gene is not sufﬁcient when all DTUs are examined,
and that on the restrictedbasis of this gene, TcIII and IV share greater
inferred phylogenetic afﬁnitieswith TcI thanwith TcII, V and VI. The
identiﬁcation of lineage-speciﬁc epitopes within TcII–VI indicates a
revisedpotential differential serology for epidemiological surveys of
T. cruzi using this antigen.
2. Materials and methods
Table 1 lists the T. cruzi strains used in this study and their ori-
gins, all of which were biological clones. The PCR primers T5/ATG/E
and EMT5/A, as described in Di Noia et al. (2002), were used to am-
plify an approximately 190 bp region of the TSSA gene from geno-
mic DNA across the panel of strains listed in Table 1. Reactions
comprised of 1 NH4 reaction buffer, 1.5 mM MgCl2 (Bioline,
UK), 40 lM dNTPs (NEB, UK), 10 pmol of each primer and 1 U BioT-
aq DNA polymerase (Bioline). Ampliﬁcation conditions were: one
cycle at 94 C for 3 min; 25 cycles at 94 C for 30 s, 50 C for 30 s,
72 C for 30 s; and one cycle at 72 C for 10 min. PCR products were
digested using 2 U PvuII (Promega, UK) and separated by electro-
phoresis on 2.5% agarose gels (Bioline). DNA sequencing was
achieved using a BigDye Terminator v3.1 RR-100 kit (Applied Bio-
systems, UK) according to standard protocols. Sequence alignment
was performed using BioEdit software (Hall, 1999), phylogenetic
analysis using MEGA4 software (Tamura et al., 2007), and non-syn-
onymous/synonymous nt substitutions per site ratios (dN/dS; x)
were calculated using SNAP software (Korber, 2000) employing
the method of Nei and Gojobori (1986) with a Jukes-Cantor correc-
tion (http://hcv.lanl.gov/content/sequence/SNAP/SNAP.html).
3. Results
3.1. Alignment of TSSA gene fragment DNA sequences
Fig. 1A shows the nt polymorphisms within and between DTUs
for the TSSA gene fragment across the panel of strains described inrface antigen (TSSA) comparison. Previous nomenclature for TcII–VI[IIa–e] is shown in
Host Reference
Homo sapiens Miles et al. (1978)
Dasyprocta agouti Brenière et al. (1998)
Triatoma spinolai Brenière et al. (1991)
H. sapiens Brenière et al. (1998)
H. sapiens Brisse et al. (2000)
Didelphis marsupialis Barnabé et al. (2001)
Triatoma infestans Brenière et al. (1998)
H. sapiens Brenière et al. (1991)
H. sapiens Brisse et al. (2000)
H. sapiens Brenière et al. (1998)
H. sapiens Miles et al. (1977)
Dasypus novemcinctus Miles et al. (1981b)
H. sapiens Tibayrenc and Ayala (1988)
Dasypus sp. Brisse et al. (2000)
ay Canis familiaris Chapman et al. (1984)
H. sapiens Miles et al. (1978)
Procyon lotor Sturm et al. (2003)
Canis familiaris Barnabé et al. (2001)
H. sapiens Brisse et al. (2000)
zil T. infestans Souto et al. (1996)
T. infestans Brenière et al. (1991)
T. infestans Tibayrenc and Miles (1983)
zil T. infestans Brisse et al. (1998)
ay T. infestans Chapman et al. (1984)
H. sapiens Tibayrenc and Ayala (1988)
Fig. 1. Inter-discrete typing unit (DTU) diversity in the trypomastigote small surface antigen (TSSA) gene sequences. (A) Nucleotide polymorphisms within and between DTUs
of the TSSA gene fragment across the panel of Trypanosoma cruzi reference strains. (B) Nucleotide heterozygosity in the CL Brener strain is represented by the degenerate
symbols W, K and R. GenBank™ accession numbers refer to sequences derived in this study. Previous nomenclature for TcII–VI[IIa–e] is shown in brackets.
T. Bhattacharyya et al. / International Journal for Parasitology 40 (2010) 921–928 923Table 1. For the hybrid strains from TcV and TcVI, certain nt peaks
showed heterozygosity not recognised by the DNA sequencer
basecaller software but observed on visual inspection of the elec-
tropherograms. These are represented by the data for the CL Brener
strain (TcVI, Fig. 1B), and are depicted in the alignment by the
degenerate symbols W (=A/T), K (=G/T) and R (=A/G). All sequences
presented in Fig. 1A were derived in this study, and can be found in
full under GenBank™ Accession Nos. GU059921–GU059937 andGU075671–GU075678; where sequences for certain strains had
previously been submitted to GenBank™, these can be found with
Accession Nos. AY367107–AY367113 and AF036443.
3.2. PvuII digest of TSSA PCR products
Sequencing of the TSSA PCR products revealed that the recogni-
tion site for PvuII (CAG;CTG, nts 125–130) is present in the
Fig. 2. PvuII digest of the trypomastigote small surface antigen (TSSA) PCR products. PCR products are shown after digestion, and pre-digested TSSA PCR product from Sylvio
X10/1 is also shown. Previous nomenclature for TcII–VI[IIa–e] is shown in brackets.
Table 2
Summary of PvuII digests of the trypomastigote small surface antigen (TSSA) PCR products of reference strains, with additional strains used by aDi Noia et al. (2002). Previous
nomenclature for TcII–VI[IIa–e] is shown in brackets.
Discrete typing unit PvuII site presence (CAG;CTG)
or absence (CAGCTA)
Strains Digest products (approx. size)
TcI CAG;CTG Sylvio X10/1, 9, W250, X11161, X11541,
CA-I/72a
125 bp + 65 bp
TcII[IIb] CAGCTA CBB cl3, Rita, Ya 190 bp (undigested)
TcIII[IIc] CAG;CTG M5631 cl5, MA26X, M6241 125 bp + 65 bp
TcIV[IIa] CAG;CTG CanIII, X11494, ERA 125 bp + 65 bp
TcV[IId] CAG;CTG
CAGCTA
MN cl2, Bug 2148 cl1, SO3 cl5, SC43 Cl1 190 bp (undigested) + faint 125 bp
TcVI[IIe] CAG;CTG
CAGCTA
CL Brener, P63 cl1, Tula cl2 190 bp (undigested) + faint 125 bp
924 T. Bhattacharyya et al. / International Journal for Parasitology 40 (2010) 921–928sequences for TcI, III and IV but not TcII (CAGCTA). TcV and VI show
heterozygosity at the 30 nt of the PvuII site (nt 130, Fig. 1B), leading
to the predicted presence of both a functional and abolished
restriction site in these strains. Di Noia et al. (2002) used PvuII
digestion of the TSSA PCR products to discriminate TcI from TcII–
VI, yielding 122 and 68 bp fragments for TcI, indicating that TcII–
VI were not digested. However, our wider in silico analysis indi-
cates that the TcIII and IV PCR products can also be digested by this
enzyme, TcII cannot, and lineages TcV and VI would be predicted to
show a hybrid digest pattern. To investigate this further, TSSA PCR
products representative of the DTUs including hybrid strains were
digested by PvuII, and the resulting samples run on a 2.5% agarose
gel as shown in Fig. 2.
In conﬁrmation of the in silico comparison, TcII was not di-
gested whereas TcI, III and IV produced two fragments of predict-
able size. Digests from the hybrid lineages gave the undigested PCR
product plus a faint 125 bp digest product (the 65 bp not being
readily visualised on ethidium bromide-stained gels), reﬂecting the
patterns of the TcII and III parents. Further conﬁrmation of these
digest patterns for reference strains is shown in Table 2.3.3. Amino acid diversity in TSSA
Fig. 3 shows the predicted amino acid sequences encoded by the
TSSA gene fragment across the DTUs, including the amino acid
changes resulting from the nt polymorphisms in the TcV and VI
strains.
Several interesting features of the predicted amino acid se-
quences were observed. Firstly, using peptide scanning, the 10-
amino acid region 41-KPATGEAPSQ-50 in TcII–VI was described
as the Ab-recognition epitope that elicited the highest response
with chagasic sera and allowed discrimination between TcI and
TcII–VI (Di Noia et al., 2002). However, the amino acid sequences
depicted in Fig. 3A reveal that this allele, although present in allTcII, V and VI strains examined here, is not found in either TcIII
or IV. Second, in agreement with Di Noia et al. (2002), there is an
absence of nt 106–108 in TcI compared with all of the TcII–VI
strains (Fig. 1A), leading to an in-frame loss of residue Ser36 in
the predicted amino acid sequence. This residue is part of the ami-
no acid region identiﬁed in that publication as comprising a minor
Ab-binding epitope. Thirdly, within the region encompassing resi-
dues 40–51, speciﬁc residues (Lys40Ala44Pro50Ser51) group TcI, III
and IV whereas residues 39 and 42 split TcIII and IV. Last, for the
hybrid strains TcV and VI the nt heterozygosity (shown in
Fig. 1B) was predicted to result in amino acid changes in codons
20, 31 and 44.
3.4. Phylogenetic analysis based on TSSA sequences
Phylogenetic relationships of the TSSA nt sequences were ana-
lysed by reconstructing a Neighbour-Joining phylogeny based on
p-distance (Fig. 4), taking into account the nt heterozygosity in
the TcV and VI strains.
3.5. dN/dS ratio analysis of TSSA sequences
By comparing two DNA sequences and calculating the ratio of
non-synonymous (changes amino acid, dN) and synonymous (does
not change amino acid, dS) nt substitutions per site, a ratio of dN/
dS greater than 1 can be used as an indicator that diversifying or
positive selection has acted upon that sequence (Yang and Bielaw-
ski, 2000). Analysis of the TSSA sequences gave a dN/dS ratio
x = 1.233.4. Discussion
Understanding of the genetic diversity of T. cruzi has led to the
description of intra-species lineages, or DTUs, and important in-
Fig. 3. Inter-discrete typing unit (DTU) diversity in the trypomastigote small surface antigen (TSSA) protein. (A) Predicted amino acid sequences of the TSSA gene fragment of
the Trypanosoma cruzi strains, including alternative residues encoded by the nucleotide heterozygosity shown in Fig. 1B. Colours indicate non-conserved residues. (B)
Distribution of nucleotide polymorphisms leading to amino acid changes. Codons marked * showed presence of split peaks (see Fig. 1B). Previous nomenclature for TcII–
VI[IIa–e] is shown in brackets.
T. Bhattacharyya et al. / International Journal for Parasitology 40 (2010) 921–928 925sights have been gained into their geographic range, mammalian
hosts and natural transmission cycles (Miles et al., 2009). However,
a key goal remains to clarify the relationship between parasite
genotype and clinical symptoms.
In this study, we analysed a fragment of the TSSA gene previ-
ously reported to contain a TcII–VI-speciﬁc immunogenic region,
across a panel of T. cruzi strains representing the genotypic and
geographical range of DTUs. We found a greater diversity at both
the nt and amino acid levels than had been described. The PvuII
digestion patterns revealed here also identify differences within
the TcII–VI DTUs. To date, TSSA has been reported as the only T.
cruzi antigen that provides a serological marker to identify TcII–
VI infection. However, we demonstrate that the described TSSA-II
epitope is present in only TcII, V and VI, not in TcIII and IV, and
overall TSSA is signiﬁcantly more diverse in amino acid structure
than previously described, particularly in the major Ab-recognition
epitope (41-KPATGEAPSQ-50). The steric polymorphism suggested
here may also have immunogenic implications in the mature gly-
coprotein. The presence of Ile31Ala44 in TcIII and IV in place of
Ser31Thr44 in TcII (Fig. 3A) would prohibit O-glycosylation at these
residues and thus alter mucin formation. This may also have rele-
vance if mucins have immunomodulatory effects on the persis-
tence of parasite infection (Buscaglia et al., 2006). Fig. 1B shows
that the TcV and VI strains display allelic heterozygosity at thesecodons, in agreement with their origin as the result of a hybridisa-
tion process between TcII and III. This is also reﬂected by the PvuII
digests of these strains, where the heterozygosity at nt 130 results
in the presence of a hybrid TcII/III digest pattern.
The phylogenetic relationships depicted in Fig. 4 indicate afﬁn-
ities between TcI, III and IV, supporting the revised T. cruzi nomen-
clature (Zingales et al., 2009), which considers these DTUs
independently, not as sub-groups within the previous TcIIa-e
nomenclature. The dN/dS ratio for TSSA was >1, showing that TSSA
heterogeneity, reﬂected at the amino acid level, is likely a result of
signiﬁcant positive selection pressure favouring diversiﬁcation of
the protein. By comparison, house-keeping genes under negative
selection pressure typically have dN/dS ratios <1, for example, for
T. cruzi glucose-6-phosphate isomerase (GPI) sequences
(x = 0.112) (M. Lewis, unpublished data). This lends further sup-
port to the suggestion that the TSSA divergence has functional sig-
niﬁcance and that TSSA has an important role in the host–parasite
relationship. Furthermore, when its mammalian-stage restricted
expression is also considered, this indicates that vertebrate im-
mune systems have probably been the source of selection pressure.
A postulated role may be found in the process of host cell invasion
by T. cruzi, which is a multi-step process involving interaction of
numerous parasite and host cell-surface molecules. Steps include
host intracellular Ca2+ accumulation, lysosome recruitment to the
Fig. 3 (continued)
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bloodstream-stage expressed cell surface mucin, the diversity in
TSSA could have implications for differential invasiveness between
DTUs. The presence of distinct TSSA alleles in the genomes of TcV
and VI strains may give them a putative selective advantage over
non-hybrid strains. The well-characterised glycoproteins gp82
and gp85, both known to be involved with cell invasion (Yoshida,
2006), may also beneﬁt from further study to evaluate the extent
of stable polymorphism between lineages.
Work is now needed to examine whether the inter-DTU TSSA
protein sequence variation described here can be exploited to dis-
criminate further the DTUs in human infections, and enhance the
understanding of the immunology and molecular epidemiology
of the parasite across a wider geographical context. Di Noia et al.
(2002) used a smaller set of T. cruzi strains than in this study, cov-
ering a narrower range of DTUs, and the chagasic sera used were
from the southern cone countries only where TcII, V and VI are
the DTUs most commonly found. We show here that the epitope
previously identiﬁed as being characteristic of TcII–VI infection
clearly only has the potential to detect serologically TcII, V and
VI, so infection by TcIII or IV will be missed. Nonetheless, a serolog-
ical test to distinguish TcII, V and VI from TcI, III and IV may stillhave utility. The genetic diversity and ecological niches of TcIII
and IV are only recently beginning to be understood in sufﬁcient
detail. New hosts and a wider geographical distribution of TcIII
have recently been reported (Llewellyn et al., 2009; Marcili et al.,
2009a), while TcIV has been shown to be prevalent in several pri-
mate species and to be involved in oral transmission to humans in
Amazonia (Marcili et al., 2009b).
A serological assay with the ability to discriminate immuno-
dominant epitopes across the DTUs will allow identiﬁcation of an
individual’s historic and extant lineage infections and aid investi-
gation of clinical and epidemiological relationships. If appropriate
successful tests can be devised, these may also be applicable to epi-
demiological tracking of the origins of infection in non-endemic
areas caused as a result of transfusion, organ donation or vertical
transmission routes. Screening of donor blood has begun recently
in Europe (Gascon et al., in press) and the USA (www.cdc.gov/
mmwr/preview/mmwrhtml/mm5607a2.htm).
This study demonstrates greater TcII–VI TSSA diversity than
previously described in the nt sequence, PvuII-digest typing and
amino acid diversity, crucially in the region described as the major
Ab-binding epitope. By revealing the fuller extent of diversity and
consequent implications for TSSA-based assays of T. cruzi infection,
Fig. 4. Bootstrap test for Neighbour-Joining using trypomastigote small surface antigen (TSSA) gene sequences described in this study. Numbers indicate bootstrap values for
the cluster nodes following 1,000 replicates. Previous nomenclature for TcII–VI[IIa–e] is shown in brackets.
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investigation of Chagas disease by the use of these lineage-speciﬁc
epitopes for discriminatory serological assays.Acknowledgements
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ANNEX 2: Bhattacharyya T, Falconar AK, Luquetti AO, Costales JA, Grijalva MJ, Lewis MD, 
Messenger LA, Tran TT, Ramirez JD, Carrasco HJ, Diosque P, Garcia L, Litvinov SV, Miles MA 
(2014). Development of peptide-based lineage-specific serology for chronic Chagas disease: 
geographical and clinical distribution of epitope recognition. PLoS Negl Trop Dis 8 e2892 
Key points, novel results and implications 
 The identification of a much greater diversity within the polymorphic region of the 
trypomastigote small surface antigen (TSSA) among T. cruzi lineages has been 
described in ANNEX 1 Bhattacharyya et al., 2010. 
 Here, synthetic lineage-specific epitope peptides based on this greater diversity were 
used in ELISA with sera from chagasic patients from throughout South America, in 
order to identify lineage-specific serological reactions. 
 79/113 (70%) of samples from Brazil, Bolivia, and Argentina recognised the TSSA 
epitope common to lineages TcII/TcV/TcVI, in agreement with previous descriptions 
of the distribution of these lineages. Comparison with clinical information showed 
that a higher proportion of Brazilian TSSApep-II/V/VI responders had ECG 
abnormalities than non-responders (38% vs 17%; p<0.0001). 
 Among northern sera 4/20 (20%) from Ecuador reacted with TSSApep-II/V/VI. Also, 
1/12 Venezuelan and 1/34 Colombian samples reacted with TSSApep-IV, in the first 
demonstration of a specific serological reaction against this lineage. 
 In addition, a proposed TcI-specific epitope, described elsewhere (Mendes et al., 
2013), was demonstrated here to be highly conserved across lineages and therefore 
not applicable to lineage-specific serology. 
 These results demonstrate the considerable potential for synthetic peptide serology 
to investigate the infection history of individuals, geographical and clinical 
associations of T. cruzi lineages 
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Abstract
Background: Chagas disease, caused by infection with the protozoan Trypanosoma cruzi, remains a serious public health
issue in Latin America. Genetically diverse, the species is sub-divided into six lineages, known as TcI–TcVI, which have
disparate geographical and ecological distributions. TcII, TcV, and TcVI are associated with severe human disease in the
Southern Cone countries, whereas TcI is associated with cardiomyopathy north of the Amazon. T. cruzi persists as a chronic
infection, with cardiac and/or gastrointestinal symptoms developing years or decades after initial infection. Identifying an
individual’s history of T. cruzi lineage infection directly by genotyping of the parasite is complicated by the low parasitaemia
and sequestration in the host tissues.
Methodology/Principal Findings: We have applied here serology against lineage-specific epitopes of the T. cruzi surface
antigen TSSA, as an indirect approach to allow identification of infecting lineage. Chagasic sera from chronic patients from a
range of endemic countries were tested by ELISA against synthetic peptides representing lineage-specific TSSA epitopes
bound to avidin-coated ELISA plates via a biotin labelled polyethylene glycol-glycine spacer to increase rotation and ensure
each amino acid side chain could freely interact with their antibodies. 79/113 (70%) of samples from Brazil, Bolivia, and
Argentina recognised the TSSA epitope common to lineages TcII/TcV/TcVI. Comparison with clinical information showed
that a higher proportion of Brazilian TSSApep-II/V/VI responders had ECG abnormalities than non-responders (38% vs 17%;
p,0.0001). Among northern chagasic sera 4/20 (20%) from Ecuador reacted with this peptide; 1/12 Venezuelan and 1/34
Colombian samples reacted with TSSApep-IV. In addition, a proposed TcI-specific epitope, described elsewhere, was
demonstrated here to be highly conserved across lineages and therefore not applicable to lineage-specific serology.
Conclusions/Significance: These results demonstrate the considerable potential for synthetic peptide serology to
investigate the infection history of individuals, geographical and clinical associations of T. cruzi lineages.
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Introduction
Chagas disease (South American trypanosomiasis) is still
considered to be the most important parasitic disease in Latin
America, despite notable success with control of household
infestation by the triatomine insect vectors. Up to 8 million
people are estimated to be chronically infected with the causative
agent Trypanosoma cruzi, of whom at least 30% are likely to develop
chagasic cardiomyopathy, in some cases with megasyndromes of
the intestinal tract [1,2]. Vector borne transmission is usually by
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contamination of mucous membranes or abraded skin with T. cruzi
infected triatomine faeces and sporadic oral outbreaks occur due
to triatomine contamination of food [3]. Infection can also be
propagated by congenital transmission and blood or organ
donation, and this may arise among migrant populations far
beyond the endemic regions in Latin America [4].
The species T. cruzi is remarkably diverse genetically and is
currently described as comprising six distinct lineages or discrete
typing units (DTUs, TcI-TcVI) [5]. The six lineages have complex
disparate but partially overlapping geographical and ecological
distributions and are circumstantially associated with different
epidemiological features [6,7]. TcI is the principal agent North of
the Amazon, in association with chagasic heart disease but where
megasyndromes are considered to be rare. TcII is one of three
principal agents of Chagas disease in the Southern Cone region of
South America, where chagasic cardiomyopathy, megaoesophagus
and megacolon are found. TcIII is seldom isolated from humans
but is widely distributed with the natural armadillo host Dasypus
novemcinctus. TcIV is a sporadic secondary agent of Chagas disease
in Venezuela [8]. TcV and TcVI, like TcII, are also agents of
Chagas in the Southern Cone region, and are known to be
relatively recent hybrids of TcII and TcIII [7,9].
Parasitological diagnosis in the acute phase of T. cruzi infection
is by microscopy of fresh blood films, thin blood films, thick blood
films or by haematocrit centrifugation and examination of the
buffy coat, the latter being recommended particularly for
congenital cases. In the chronic phase recovery of live organisms
may be attempted by multiple blood cultures or xenodiagnosis
with colony bred triatomine bugs but with limited sensitivities, or
parasite DNA may be detectable by amplification.
Serological diagnosis of T. cruzi infection is usually performed by
either indirect immunofluorescence (IFAT) or indirect haemaglu-
tination (IHA) or enzyme-linked immunosorbent assay (ELISA),
giving .94% sensitivity and specificity [2]. There are several
commercially available diagnostic kits, including rapid lateral flow
tests but sensitivities may not be equivalent, particularly when they
are used in regions where non-homologous genetic lineages of T.
cruzi are prevalent [8–10]. These serological methods give no
information on the genetic lineage or lineages that a patient
carries, and are not designed for that purpose.
A key objective of Chagas research therefore remains to follow
up in detail the circumstantial evidence of a relationship between
infecting T. cruzi lineage and the clinical outcome [6,7,11].
However, such analysis is complex and vulnerable to multiple
confounders, including diversity of host susceptibility. Even if T.
cruzi isolates can be recovered from the infected blood by
parasitological diagnosis or if DNA can be amplified from blood,
genotyping methods [12,13] do not provide an entire profile of the
infecting lineages in an individual patient, because distinct T. cruzi
lineages may be sequestered in the tissues [14]. An approach to
overcoming this limitation is to identify infecting T. cruzi lineage in
a more indirect way. One strategy to achieve this is by serological
detection of antibodies that are produced in response to lineage-
specific antigens.
Di Noia et al [15] described the trypomastigote small surface
antigen (TSSA), encoded by a member of the TcMUCIII mucin
gene family, expressed on the mammalian bloodstream trypomas-
tigote stage of the T. cruzi life cycle. The authors reported that
TSSA is dimorphic in sequence, with TSSA-I being present in
TcI, and TSSA-II found in TcII-TcVI. On the basis of this finding
the authors pioneered lineage-specific serology for Chagas disease
through application of a TSSA-II recombinant antigen to serology
with patients from the Southern Cone region of South America.
Chagasic patients were only TSSA-II seropositive, which led to the
suggestion that TcI could be benign. However, this suggestion was
in conflict with the geographical predominance of TcI North of
the Amazon and the acute and chronic clinical presentations of
known TcI infections [16,17]. In subsequent publications E. coli-
produced recombinant TSSA proteins have been used more
widely for serology with humans and animals [18–23].
We have previously analysed TSSA diversity among a panel of
T. cruzi isolates representing a broad geographical and ecological
range of lineages TcI-TcVI [24]. We found a greater lineage-
specific diversity than had previously been described. Lineages
TcII, TcV, and TcVI were shown to share a common TSSA
sequence. However, in both of the hybrid lineages TcV and TcVI
we found that two TSSA alleles were present at an heterozygous
locus within the polymorphic epitope: one haplotype was shared
with TcII and in the second haplotype a Thr was replaced by Ala
at position 44 of the protein. Lineage-specific TSSA sites were also
found in TcIII and TcIV strains [24]. Ca´nepa et al [25] suggested
a functional significance for this diversity in that the TcII/TcV/
TcVI form of TSSA, but not the TcI form, has the property of
binding surface receptor(s) and inducing signalling pathways in
host cells prior to parasite internalisation.
Recently, Mendes et al [26] used a bioinformatic analysis of the
reference genome of the TcVI strain CL Brener [27] to identify
candidate peptides for differential screening with sera from mice
experimentally infected with single, known T. cruzi lineages. A
resultant peptide, derived from a putative RNA-binding protein,
was reported to be applicable for TcI serology [26].
Here, we have used our expanded knowledge of the range of
TSSA diversity to design and synthesise lineage-specific peptides.
We assess the capacity of these peptides to provide antigens for
lineage-specific serology by ELISA and thus reveal which lineages
have infected individual patients during their lifetime. Further-
more, we examine the geographical and clinical distribution of
recognition of the synthetic peptide epitopes. In addition, we also
investigate the diversity of the gene coding for the peptide
described [26] as applicable for TcI-specific serology.
Author Summary
Chagas disease remains a significant public health issue in
Latin America. Caused by the single-celled parasite
Trypanosoma cruzi, the main route of infection is via
contact with contaminated faeces from blood-sucking
triatomine bugs, but following successful insecticide
spraying campaigns, congenital, food-borne, and transfu-
sion/transplantation routes of infection have become
more relevant. In the absence of successful chemotherapy,
T. cruzi usually persists in the body for life, and in
symptomatic cases may lead to death or debilitation by
heart failure and/or gastrointestinal megasyndromes. As a
species, T. cruzi displays great genetic diversity, and is
subdivided into lineages called TcI - TcVI. Associating T.
cruzi lineage with clinical symptoms is a key goal of Chagas
disease research. Direct isolation and typing of T. cruzi
from chronically infected patients is hampered by the
sequestration of the parasite in host tissues. Identifying
lineage-specific antibodies in serum provides an alterna-
tive approach to determining an individual’s history of
infection. Here, we performed lineage-specific serology
using samples from a range of South American countries.
We show that lineage-specific seropositivity is associated
with geographical distributions and clinical outcome.
These findings have wide implications for further diagnos-
tics development and improved understanding of the
epidemiology of Chagas disease.
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Materials and Methods
Ethics statement
Human sera were collected as part of routine diagnostic
examination, with local institutional ethical approvals, and in
accord with EC ethical standards established as part of the
ChagasEpiNet international collaboration. All human sera were
anonymised and coded by letters and numbers that did not reveal
patient identities. Production of mouse sera adhered to the
European 3Rs policy of Refinement, Reduction and Replacement
(99/167/EG: Council decision of 25/1/99), took place in
authorised animal facilities by licensed staff in agreement with
the European Directive 86/609/EEC, and with review and
approvals under UK Home office regulations [Animals (Scientific
Procedures) Act 1986; project licence number 70/6997 to the
London School of Hygiene and Tropical Medicine].
Mouse and human sera
Mouse sera were from mice previously inoculated intraperito-
neally with 106 organisms from stationary phase cultures
containing infective metacyclic trypomastigotes, of known biolog-
ical clones of T. cruzi representing the lineages. Sera were
separated from whole mouse blood by allowing clotting at room
temperature, overnight storage at 4uC, centrifugation at 120006g
for 10 mins and removal of the supernatant serum. Serum samples
were stored 1:1 with glycerol at 220uC.
Human sera were from chronic cases of Chagas disease,
confirmed by a combination of parasitological and serological
diagnosis. As shown in Table 1, 113 samples were from the
Southern Cone countries, Brazil, Bolivia and Argentina, and 66
samples were from countries North of the Amazon, Colombia,
Ecuador, Venezuela, where TcI has been considered to predom-
inate. Brazilian sera were from patients who had a positive
parasitological diagnosis at the time of serum collection, together
with a full clinical history, their geographical origin, age and sex.
Institutes providing sera were: Hospital das Clinicas, Goiaˆnia,
Brazil; Universidad Mayor de San Simon, Cochabamba, Bolivia;
Universidad Nacional de Salta, Argentina; Universidad Central de
Venezuela, Caracas, Venezuela; Universidad de los Andes,
Bogota´, Colombia; Pontificia Universidad Cato´lica del Ecuador,
Quito, Ecuador. Endemic healthy controls were from the Hospital
das Clinicas, Goiaˆnia, Brazil, and additional controls were 17 sera
from Colombia that were serologically negative to T. cruzi lysate.
Synthesis of lineage-specific peptides
The synthetic peptides were prepared with an amino terminal
biotin molecule linked via a polyethylene glycol-glycine spacer so
that they could be bound to avidin-coated ELISA plates.
Importantly, this method increased their rotation and ensured
that each amino acid side chain could freely interact with
antibodies, as opposed to being adsorbed onto the solid phase
where some amino acid side chains would be unavailable, as
discussed previously [28].
Design of the peptides was based on the T. cruzi TSSA lineage-
specific amino acid sequences previously described [24]; chimeric
peptides comprised by TSSA-I and TSSA-II sequences were also
designed and synthesised (Results; Figure 1). Synthetic peptides
were prepared at the 20 mM scale on 100–200 mesh-size Fmoc-
Cys(Trt) Wang resin (0.5 mmol/g) (856006: Novabiochem, UK)
using a Zinsser Analytic SMPS 350 (Zinsser Analytic, UK) or
Advanced Chemtech Apex 396 (Advanced Chemtech, USA)
robotic multiple peptide synthesizer. Aspartamide formation of
aspartic acid residues was reduced by the use of OMpe-protected
Fmoc-Asp(OMpe)-OH (852104: Novabiochem, UK). The
coupling steps were performed using 0.5 M Fmoc-protected
amino acids diluted in 6.76% (wt/vol) 1-hydroxybenzotriazole
(HOBt)/dimethylformamide (DMF) (Activotec, UK/Rathburn
Chemicals Ltd., UK) activated using 0.5 M N,N,N9,N9-tetra-
methyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate
(HBTU) (851006: Novabiochem, UK) with 1M N,N-diisopropy-
lethylamine (DIPEA) (Rathburn Chemicals Ltd., UK), while the
deprotection steps were performed using 20% (vol/vol) piperi-
dine/DMF (Rathburn Chemicals Ltd., UK). The carboxyl- and
amino- regions flanking the core epitope sequences contained
additional glycine (G) residues to increase rotation (high dihedral
(y against Q) angles) of their carboxyl-terminal cysteine (C) residue
and their amino-terminal spacer and molecular label. Their amino
termini were labelled via a polyethylene glycol (PEG) spacer
(Fig 1A) through sequential couplings with 0.5 M Fmoc-NH-
(PEG)2-COOH (13 atoms or 20 atoms) (851034 or 851031:
Novabiochem, UK) followed by 0.5 M biotin (B4501: Sigma
Aldrich, UK) using the more efficient coupling agent, 0.5 M
N,N,N9,N9-tetramethyl-O-(7-azabenzotriazol-1-yl)uranium hexa-
fluorophosphate (HATU) (851013: Novabiochem, UK) containing
1 M DIPEA. The final peptides were each washed 5 times with
dichloromethane and then methanol (Rathburn Chemicals Ltd.,
UK) before being dried in a freeze-drier (Edwards, UK). Peptide
cleavage was performed by reaction for 3–4 hours using 1% (wt/
vol) phenol, 2% H2O, 2.5% (vol/vol) triisopropyl silane (233781:
Sigma Aldrich, UK) and 2% (vol/vol) 2,29 (ethylenedioxy)
diethanethiol (3,6-dioxa-1,8-octanedithiol (DODT)) (465178: Sig-
ma Aldrich, UK) in trifluoroacetic acid (Rathburn Chemicals Ltd.,
UK) [29]. The cleaved peptides were then precipitated in cold
(0uC) peroxide-free diethyl ether (Rathburn Chemicals Ltd., UK),
centrifuged at 2,0006g; the supernatants were discarded and the
precipitation and centrifugation steps were repeated twice. The
peptides were then dried under a stream of anhydrous argon gas
(BOC, UK) before being stored at 280uC.
For purification each peptide was subsequently dissolved in
500 ml of 2,2,2, trifluoroethanol (T63002: Sigma Aldrich, USA),
made to 5.5 ml with 5% (vol/vol) far UV grade acetonitrile
(Rathburn Chemicals Ltd., UK) in H2O containing 0.1% (vol/vol)
trifluoroacetic acid, and then subjected to reversed-phase HPLC
using a 5 ml injection loop, a 5–95% acetonitrile gradient run at
9 ml/min over 30 min through an ACE C18–300 A˚
250621.2 mm preparative column (ACE-231-2520: Advanced
Chromatography Technologies, UK) in a Beckman Gold prepar-
ative HPLC system (Beckman, USA). The main peaks, detected at
a wavelength of 215 nm, were collected and freeze-dried before
storage at 280uC.
Additionally, peptides TSSApep-II/V/VI, chimera TSSApep-
I/-II, and MenTcI were also synthesised commercially (Geno-
sphere Biotechnologies, Paris, France).
Purified peptides were prepared as 1 mg/ml stock solutions in
PBS and the addition of biotin in the last coupling was assessed by
ELISA. For this assay, 10 mg/ml of each peptide was prepared in
16 carbonate-bicarbonate coating buffer (15 mM Na2CO3,
34 mM NaHCO3, pH 9.6) and added at 50 ml/well to 96-well
ELISA plates (735–0465: Immulon 4HBX, VWR, UK). Plates
were covered with an adhesive sheet and incubated overnight at
4uC. Following three washes with PBS containing 0.05% (vol/vol)
Tween 20 (P7949: Sigma Aldrich, UK) (PBS/T), 200 ml/well
blocking buffer (PBS/2% skimmed milk powder (Premier Inter-
national Foods, Spalding, UK) was added and incubated at 37uC
for 2 hrs. Following three washes, a 1:2000 dilution of peroxidase-
labeled streptavidin (S2438: Sigma Aldrich, UK) in PBS/T
containing 2% skimmed milk powder (PBS/T/M) was added at
50 ml/well, and incubated at 37uC for 1 hour. After washing six
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times with PBS/T, 50 mM phosphate/citrate buffer (pH 5.0)
containing 2 mM o-phenylenediamine HCl (P1526: Sigma
Aldrich, UK) and 0.005% (vol/vol) H2O2 (216763: Sigma Aldrich,
UK) was added at 50 ml/well and the plates were incubated in the
dark at room temperature for 10 minutes. The substrate reactions
were then stopped by the addition of 2M H2SO4 (25 ml/well) and
the absorbance values were determined at a wavelength of 490 nm
(MRX, Dynatech, USA).
Production of whole-cell lysate antigen
T. cruzi was cultured as previously described [30]. For
production of lysate antigen, mid-to-late log phase cultures of a
TcII strain (IINF/PY/00/Chaco23cl4) of T. cruzi were centrifuged
at 8006g for 10 mins at 4uC in an Allegra X-15R benchtop
centrifuge (Beckman Coulter, UK). After washing in PBS, cell
pellets were subjected to 3 cycles of flash-freezing in liquid
nitrogen and thawing in a cold water bath. Cell lysates were then
sonicated for 3630 sec, with intervals on ice, using a Soniprep 150
sonicator (MSE), at 12 m amplitude. Sonicated lysates were
centrifuged at 13000 rpm for 1 min, and the supernatant used
as antigen in ELISA. Protein concentration was determined using
the BCA Protein Assay kit (PN23227: Fisher Scientific, UK).
Lineage-specific peptide ELISA
Immulon 4HBX 96-well flat bottomed ELISA plates were
coated with 1 mg/100 ml/well of avidin (A9275: Sigma, UK)
diluted in 16 carbonate-bicarbonate coating buffer for binding to
lineage-specific peptide, and in separate wells coating was with
TcII T. cruzi lysate at 0.2 mg/100 ml/well to act as a serologically
positive control for each sample. Plates were covered with an
adhesive sheet and incubated overnight at 4uC. The following day,
unbound avidin and lysate were removed, the plate washed three
times with wash buffer PBS/T, then wells were blocked with
200 ml blocking buffer PBS/T/M at 37uC for 2 hrs. Following
three washes, 1 mg/100 ml/well TSSA lineage-specific peptide in
PBS/T/M was incubated with the avidin-coated wells at 37uC for
1 hr. Following three washes, 100 ml/well of a 1:200 dilution of
serum in PBS/T/M was added and incubated at 37uC for 1 hr.
Following six washes, 100 ml/well of donkey anti-human IgG (H+
L)-HRP (709-035–149: Jackson Immunoresearch, Pennsylvania,
USA), diluted 1:5,000 in PBS/T/M was added, and incubated at
37uC for 1 hr. Following six washes, plates were developed and
read as described above, except that the volumes were 100 ml for
substrate and 50 ml for 2M H2SO4. Replica plates were run in
duplicate simultaneously.
Statistical analysis
Cut-off values for ELISAs with human sera and peptides were
calculated from the mean plus 3 standard deviations compared to
the endemic healthy controls from Goiaˆnia, Brazil. Statistical
analysis (2-tailed unpaired t-test) on the Brazilian TSSApep-II/V/
VI seropositives and non-responders was performed using
GraphPad Prism version 4.02 for Windows (GraphPad Software,
San Diego, California, USA).
Analysing diversity of the putative TcI epitope
We designed PCR primers MenTcI FOR (59 ATGCCA-
CAATCGAAACCAAG 39) and MenTcI REV (59 TCACAA-
CAAACGTTTGGCTG 39) (synthesised by Eurofins MWG
Operon, Germany) to amplify the whole open reading frame
(ORF) of the putative RNA–binding protein (Tc00.1047
053511837.129) which was described as containing an epitope
and corresponding peptide applicable for TcI serology [26]. T.
cruzi strains, from which genomic DNA was used as amplification
template, are listed in Table 2. Amplification reactions were
performed in a total volume of 20 ml, and comprised of 16NH4
reaction buffer supplemented with 1.5 mM MgCl2 (Bioline, UK),
200 mM dNTPs (New England Biolabs, UK), 10 pmol of each
primer, and 1 U BioTaq DNA polymerase (Bioline). Amplification
conditions were: 1 cycle of 94uC, 3 mins; 25 cycles of 94uC for
30 secs, 55uC for 30 secs, 72uC for 30 secs; 1 cycle of 72uC for
10 mins. Five microliters of the PCR reaction were analysed by
electrophoresis on 1.5% agarose gels (Bioline); amplification
products were purified from the remaining reaction by precipita-
tion with an equal volume of isopropanol at room temperature,
followed by washing with 70% EtOH, air-drying and resuspension
in ddH2O. Bi-directional DNA sequencing, using each PCR
primer separately at 3.2 pmol, was achieved using a BigDye
Figure 1. TSSA provides potential epitopes that are T. cruzi lineage-specific. [A] Components of the peptides synthesised: N-terminal
biotinylation; PEG spacer; Gly; the lineage-specific sequence; C-terminal Cys. [B] Amino acid sequences of the T. cruzi lineage-specific TSSA potential
epitopes in the synthetic peptides (TSSApep-), with polymorphic residues underlined; for the two chimeric peptides the TSSA-II residues are shown in bold.
doi:10.1371/journal.pntd.0002892.g001
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Terminator v3.1 RR-100 kit (Applied Biosystems, UK) according
to standard protocols. Sequence alignment was performed using
BioEdit software [31]. In parallel, the coding region of the TSSA
gene containing lineage-specific sequences was also sequenced, as
described previously [24], to confirm lineage identity.
Linear B-epitope profiling
Computer analysis of the TSSA-I and the TSSA-II/V/VI
common epitope was performed using EpiQuest-B software (v
2.1.17, Matrix B7.1) from Aptum Biologics Ltd (Southampton,
Hampshire, UK). The algorithm of the program allows prediction
of potential linear B-epitopes and their immunogenicity. The data
were used in graphical format.
Accession numbers
Nucleotide sequences derived in this manuscript are available
under GenBank accession numbers KJ395471 - KJ395493.
Results
TSSA provides potential epitopes specific for each T. cruzi
lineage
The structures and sequences of the peptides synthesised,
indicating the lineage-specific amino acids, are shown in Figure 1,
as based on the comparisons of diversity previously described [24].
In addition to the peptides representing single lineages we
synthesised two chimeric peptides, one with TSSA-I residues at
the N terminus and TSSA-II residues at the C terminus, and the
second with TSSA-II at the N terminus and TSSA-I at the C
terminus (Figure 1B).
Consistent with the known extensive genomic divergence
between TcI and TcII, eight residues differed between their
TSSA potential epitopes. Five and six residues separated TSSA-II
from TSSA-III and TSSA-IV, respectively. Four residues distin-
guished TSSA-I from TSSA-III and two residues separated TSSA-
I from TSSA-IV, in accord with their somewhat greater affinity
with TcI. A single residue differed between the TSSA-II haplotype
shared by TcII, TcV and TcVI and the second haplotype present
at the heterozygous locus in the hybrids TcV and TcVI.
Synthetic peptides are recognised by serum antibodies
Sera from mice experimentally infected with biological clones of
TcII, TcV and TcVI strains recognised TSSApep-II/V/VI in
serology by ELISA, and sera from TcIII and TcIV murine
infections reacted with the corresponding TSSA peptides (Bhat-
tacharyya et al, in preparation), encouraging the evaluation
described here of the diagnostic potential of all the synthetic
peptides with sera from patients with chronic Chagas disease.
Figure 2 shows examples of ELISA plates with T. cruzi lysate
and lineage-specific synthetic peptides as antigens. Sera from
normal healthy endemic controls did not react with the T. cruzi
lysate or with any of the synthetic peptides. Without exception all
Table 2. T. cruzi strains used here for comparative analysis of the ORF containing the reported TcI-applicable peptide (GenBank
accession numbers refer to sequences determined here).
Lineage Strain Origin Host/vector Tc00.1047053511837.129 [26]
a
GenBank
E N S A N P P P P D R S L P T P
TcI MHOM/BR/78/Sylvio-X10/1 Bele´m, Brazil Homo sapiens . . . . . . . . . . . . . . . . KJ395471
MHOM/PE/00/SaxP18 Majes, Peru Homo sapiens . . . . . . . . . . . . . . . . KJ395472
MPHI/BO/00/SJM41 Beni, Bolivia Philander opossum . . . . . . . . . . . . . . . . KJ395473
MDID/BO/00/SMA2 Beni, Bolivia Didelphis marsupialis . . . . . . . . . . . . . . . . KJ395474
MDID/BO/00/SJM37 Beni, Bolivia Didelphis marsupialis . . . . . . . . . . . . . . . . KJ395475
MPHT/BO/00/COTMA47 Cotopachi, Bolivia Phyllotis ocilae . . . . . . . . . . . . . . . . KJ395476
TcII MHOM/CL/00/IVV Cuncumen, Chile Homo sapiens . . . . . . . . . . . . . . . . KJ395477
MHOM/BR/00/Y Sa˜o Paulo, Brazil Homo sapiens . . . . . . . . . . . . . . ST. KJ395478
MHOM/CL/00/CBB Region IV, Chile Homo sapiens . . . . . . . . . . . . . . ST. KJ395479
IINF/BO/00/Tu18 Tupiza, Bolivia Triatoma infestans . . . . . . . . . . . . . . . . KJ395480
IINF/PY/00/Chaco23 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395481
IINF/PY/00/T655 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395482
TcIV IINF/AR/00/LHVA Chaco, Argentina Triatoma infestans . . . . . . . . . . . . . . . . KJ395483
TcV IINF/CL/00/Vinch101 Limari, Chile Triatoma infestans . . . . . . . . . . . . . . . . KJ395484
MHOM/BO/00/92:80 Santa Cruz, Bolivia Homo sapiens . . . . . . . . . . . . . . . . KJ395485
IINF/BR/00/Bug2148 Rio Grande do Sul, Brazil Triatoma infestans . . . . . . . . . . . . . . . . KJ395486
IINF/PY/00/Para6 Paraguari, Paraguay Triatoma infestans . . . . . . . . . . . A . . A . KJ395487
TcVI MHOM/BR/00/CL Brener Rio Grande do Sul, Brazil Triatoma infestans . . . . . . . . . . . . . . . . KJ395488
MHOM/BO/00/P251 Cochabamba, Bolivia Homo sapiens . . . . . . . . . . . . . . . . KJ395489
IINF/PY/00/Chaco17 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395490
IINF/PY/00/Chaco9 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395491
IINF/AR/00/EPV20-1 Chaco, Argentina Triatoma infestans . . . . . . . . . . . . . . . . KJ395492
IINF/CL/00/VFRA Francia, Chile Triatoma infestans . . . . . . . . . . . . . . . . KJ395493
a. = no amino acid change.
doi:10.1371/journal.pntd.0002892.t002
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sera from patients with chronic Chagas disease recognised the T.
cruzi TcII lysate antigen preparation. Figure 2 also provides
examples of sera from Brazil, Argentina and Ecuador that
recognised TSSApep-II/V/VI, indicative of infection with
TcII,TcV or TcVI. A positive result for the epitope derived from
the TcV/VI specific haplotype indicates definite infection with
TcV or TcVI. Some of these sera (e.g. B6 & B10) reacted with
both TSSApep-II/V/VI and TSSApep-V/VI representing the
haplotype restricted to TcV and TcVI, indicating infection with a
hybrid strain, possibly in conjunction with a TcII infection.
Recognition of the TcV and TcVI restricted epitope was never
seen in the absence of recognition of the TSSApep-II/V/VI.
A Venezuelan serum (V4 in Figure 2) recognised TSSApep-IV,
consistent with the known presence of TcIV as a secondary agent
of Chagas disease in Venezuela [16]. However, this serum also
bound to TSSApep-III, which only differs by 2 of 16 residues.
An antibody response to TSSApep-I was exceptional, only two
sera were reactive from the entire set of samples (Table 1) of which
one weak reactor (Argentina A3) is shown in Figure 2.
Chimera TSSApep-I/-II and chimera TSSApep-II/-I were
designed to determine whether the antigenic epitope resided at
the N or C terminus of the peptides. Chimera TSSApep-II/-I was
recognised by 71/83 TSSApep-II/V/VI reactive sera, as demon-
strated for example by Argentine patients A1, A2 and A4 (Figure 2).
In comparison, only 11/83 recognised the chimera TSSApep-I/-II,
indicative that, although not precisely mapped, the dominant region
of the epitope lies towards the N terminus of the peptide and that in
some patients the N terminus is adequate to provide a detectable
epitope. A single TSSApep-IV/TSSApep-III positive serum also
recognised the chimera TSSApep-I/-II peptide.
Four of 186 samples responded to all wells containing peptides;
these were demonstrated to bind non-specifically to avidin in the
absence of peptide, but not to cross react with milk proteins (data
not shown).
Rare recognition of the TSSA-II/V/VI common peptide in
northern South America
The 186 sera from patients with chronic Chagas disease spanned
a geographical range from Argentina to Venezuela. Three Southern
Cone countries were included, where TcII, TcV and TcVI have
been reported to be endemic, and three countries from northern
South America, where TcI is considered to predominate. A
summary of the geographical distribution of the antibody responses
to all the lineage-specific synthetic peptides is shown in Table 1. Of
the sera recognizing TSSApep-II/V/VI, 79 out of 83 were from the
Southern Cone countries and four were from Ecuador. Of these 83
sera, 13 sera also recognised TSSApep-V/VI, 12 from Southern
Cone countries and one of the four sera from Ecuador, indicating
presence of TcV or TcVI, possibly with TcII co-infection.
Independently of the lineage-specific peptides, we also examined
the response to two different chimera peptides, each comprising
different combinations of sequences from TSSApep-I and TSSA-
pep-II/V/VI. Of the Bolivian, Ecuadorean and Argentine sera
which reacted with TSSApep-II/V/VI, all reacted with chimera
TSSApep-II/-I, but only two samples (Ecuadorean) also reacted
with chimera TSSApep-I/-II. In the case of Brazilian samples, of
the 67 that reacted with TSSApep-II/V/VI, 55 reacted with
chimera TSSApep-II/-I, and of these 55, 9 also reacted with
chimera TSSApep-I/-II. Only one sample (Venezuelan) reacted
with chimera TSSApep-I/-II but not with TSSApep-II/V/VI or
chimera TSSApep-II/-I. TSSApep-I failed to detect antibodies,
regardless of origin of the chagasic sera, with the exception of two
sera, one each from Brazil and Argentina. Four sera recognised both
TSSApep-IV and TSSApep-III, consistent with cross-reaction due
to the close similarity between these epitopes.
The country by country distribution of antibody recognition of
the peptides is given in Table 1. ELISA cut-offs and absorbance
values for each lineage-specific peptide are shown in Figure 3.
Each data point represents the mean A490 readout of duplicate
assays of the serum sample with the lineage specific peptides. In
Figure 3, the samples giving the highest reading for TSSApep-III
from Colombia and Venezuela are the same samples that
recognised TSSApep-IV.
Antibodies to the TcII/TcV/TcVI peptide are more
frequent among symptomatic Brazilian patients
60/63 of the Brazilian patients with chronic Chagas disease who
were seropositive against TSSApep-II/V/VI had detailed clinical
evaluation, and of these 60 patients, 23 (38%) had ECG
abnormalities typical of Chagas disease. 23/28 patients seroneg-
ative for TSSApep-II/V/VI also had detailed clinical evaluation,
but in contrast only 4 of these latter, different 23 patients had such
ECG abnormalities (p,0.0001).
Novel bioinformatic algorithms predict highly antigenic
residues
The sequences coding for the TSSA proteins containing the
TSSApep-I and TSSApep-II/V/VI epitopes were subjected to a
Figure 2. Chagasic sera recognise TSSA lineage-specific peptides. Lineage-specific peptides or lysate were added to rows of the ELISA plate
as indicated. ELISA plates showing: recognition of TSSApep-II/V/VI and TSSApep-V/VI, among Brazilian, Ecuadorean and Argentine sera; recognition of
TSSApep-I and TSSApep-IV by an Argentine serum and a Venezuelan serum; recognition of chimera TSSApep-II/I by Argentine sera. All patients were
seropositive with T. cruzi lysate. NEHC = non-endemic healthy control.
doi:10.1371/journal.pntd.0002892.g002
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novel bioinformatic analysis using EpiQuest-B program that builds
the immunogenicity profile for linear protein sequences and
predicts the location and potential immunogenicity of the linear B-
cell epitopes (Litvinov et al, in preparation) in order to give an
antigenicity score for the polymorphic region. The algorithm
predicted high scores within the TSSApep-II/V/VI epitope
region, but much lower for TSSApep-I, as shown in Figure 4.
The different antigenicity scores indicate that the N-terminal
TEN in TSSApep-II/V/VI is the dominant epitope, explaining
the frequent recognition of chimera TSSApep-II/-I (Figure 1)
despite the higher scoring C-terminal GEAPS, which provides a
secondary site of recognition for some (Brazilian) sera that respond
to chimera TSSApep-I/-II (Figure 1). Neither the TEN nor
GEAPS is present in TSSApep-I, explaining the rare recognition
of this epitope. The GEAPS, which is also present in TSSApep-III
and TSSApep-IV, gave much lower antigenicity scores in these
peptides, in the absence of the upstream TEN in these sequences
(data not shown).
Comparative diversity of the putative TcI-applicable
peptide reveals high conservation across lineages
Mendes et al [26] used heterozygous loci in the CL Brener
genome to identify candidate lineage-specific epitopes. One
conserved and three potentially lineage-specific peptides were
synthesised, described as deriving from hypothetical protein
Tc00.1047053510421.310 (conserved epitope peptide), putative
RNA-binding protein Tc00.1047053511837.129 (for TcI serolo-
gy), putative ADP-ribosylation factor GTPase activating protein
Tc00.1047053511589.70 (for TcII), and putative DNA-directed
RNA polymerase III subunit Tc00.1047053510359.320 (for TcVI)
that displayed some discriminatory power in ELISAs and affinity-
ELISAs based on differential range of absorbance values. The
putative TcI epitope was described as restricted to TcI and TcVI
and applicable to serological identification of a specific response to
TcI. We examined the diversity in the coding sequence for this
epitope, using a panel of T. cruzi strains across the lineages
(Table 2). A single amplicon of 381bp was produced by PCR from
all strains using primers MenTcI FOR and MenTcI REV.
Examples from TcI and TcII strains are shown in Figure 5.
However, in comparative sequencing across isolates represent-
ing the lineages we found this epitope to be highly conserved
(Table 2). This epitope had the same amino acid sequence across
all the strains and lineages analysed here with the exception of
strains Y and CBB (TcII) and Para 6 (TcV). In strains Y and CBB,
a heterozygous nucleotide (G/C) residue led to the presence of two
predicted amino acids, Ser or Thr.
The region homologous to the reported TcI-applicable epitope,
which was described as specific to a TcII strain, but given only as
amino acid sequence [26], was subject to BLAST against NCBI
and TriTrypDB databases. There were very low stringency
homologies returned by TriTryp BLAST to various T. cruzi
proteins (mainly around the PPP tripeptide), none of which was
described as RNA-binding proteins. On NCBI BLAST, highest-
scoring matches were to various bacteria and fungi, none to
trypanosomes. Furthermore, none of 55 sera from northern
countries of South America, where TcI is highly endemic, bound
to the TcI synthetic peptide reported in Mendes et al in our
ELISA assays (data not shown).
Discussion
Kong et al [32] developed lineage-specific serology for the
protozoan parasite Toxoplasma gondii, which is difficult to isolate
from chronically infected patients, and most isolates of which are
classified into clonal lineages type I, II, or III. Serology with
synthetic peptides based on diversity within the dense granule
proteins GRA6 and GRA7 was able to distinguish type II from
non-type II infections in humans. Using discriminatory serology, it
was possible to demonstrate that the T. gondii lineages had different
Figure 3. Recognition of TSSA lineage-specific peptides shows a disparate geographical distribution. Each data point represents the
mean A490 of the reaction of duplicates of each serum sample with the peptides. Means of each country data set are represented by solid horizontal
lines; cut-offs, derived from the mean +3SD for each peptide with the EHCs, are shown as dotted line on each graph. Circled and boxed values
indicate the same sera. Resolution for the Brazilian responses to TSSApep-II/V/VI is increased by smaller symbols.
doi:10.1371/journal.pntd.0002892.g003
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continental distributions [33], and that adult offspring of type I-
infected mothers had a significantly increased risk for the
development of psychoses [34].
Here we have used detailed comparative analysis of the genetic
diversity of the T. cruzi TSSA gene encoding the protein core of the
mucin TSSA, to design synthetic peptides for lineage-specific
serology of T. cruzi infection history. These epitopes were
presented on an avidin-coated solid phase via an amino terminal
biotin-label linked to a polyethylene glycol-glycine spacer to
increase rotation and ensure that each amino acid side chain could
freely interact with antibodies. We synthesised and tested these
lineage-specific peptides in ELISA with 186 human sera from six
countries, three in the Southern Cone region of South America
and three in northern South America. We have selected these
countries because typing of T. cruzi isolates with multilocus enzyme
electrophoresis (MLEE) [6], multilocus sequence typing (MLST)
[35] and multilocus microsatellite typing (MLMT) [17] has
repeatedly indicated the predominance of TcII, TcV and TcVI
as the agents of Chagas disease in Southern Cone countries yet the
contrasting high prevalence of TcI in patients North of the
Amazon [7,11]. Nevertheless, there have been some reports that
TcII, as identified by genotyping, can be found among isolates
from humans and domestic triatomine bugs in northern endemic
regions, for example in Colombia and Guatemala [36–38].
Lineage-specific serology is therefore of special interest for T.
cruzi, because of the disparate geographical distributions of both
the T. cruzi lineages and clinical manifestations of chronic Chagas
disease. Thus as long ago as 1981, Miles et al proposed that the
presence of chagasic cardiomyopathy with megaoesophagus and
megacolon in Southern Cone countries, yet apparent absence of
associated megasyndromes from Venezuela, may be related to the
comparative predominance of TcI as the agent of Chagas disease
in northern South America [6]. Nevertheless the evidence of a link
between infecting lineage of T. cruzi and prognosis of chronic
Chagas disease remains circumstantial. As with T. gondii, this is
partly due to the difficulty of isolating and genotyping T. cruzi from
chronic chagasic patients. Blood culture and xenodiagnosis have
limited sensitivity and may be selective for faster growing
biological clones. Furthermore, even if parasites or DNA can be
recovered from chronically infected patients, the resultant T. cruzi
isolates may not be representative of the genetic diversity in the
patient, because T. cruzi replicates intracellularly and lineage
genotypes may be sequestered in the tissues but not recoverable
from the circulating blood [14]. Serology with lineage-specific
antigens provides a means of profiling an individual’s history of T.
cruzi infection, to overcome inaccessibility of the parasite to direct
genotyping during chronic infections.
TSSA provides a good candidate for development of synthetic
peptide-based, lineage-specific serology, because no TSSA homo-
logue beyond the species T. cruzi has been detected by genomic
comparisons, and a lineage-specific candidate epitope can be
represented by a single synthetic peptide. Thus such peptides are
unlikely to generate false positive ELISA results with sera from
endemic healthy controls or from patients with other infectious or
autoimmune diseases. In the multiple ELISAs performed here
none of the healthy controls recognised any of the synthetic
peptides, and all were also serologically negative with the T. cruzi
lysate (Figure 2). However, sera from four of the chagasic patients
bound non-specifically to plates coated with avidin alone and thus
Figure 4. Computer-predicted antigenicity score is much
higher for TSSA-II/V/VI sequence than TSSA-I. Polymorphic
sequences of [A] TSSA-I and [B] TSSA-II/V/VI showing regions of high
antigenicity in red, and low antigenicity in blue. A few amino acid
replacements in TSSA-I lead to disappearance of the immunogenic
epitope that is present in TSSA-II/V/VI sequence.
doi:10.1371/journal.pntd.0002892.g004
Figure 5. PCR amplification of the ORF containing the reported TcI-applicable epitope. Only the amplicon of predicted size (381 bp) was
amplified by the reaction conditions. –ve = no template DNA control. Mk = Hyperladder IV (Bioline, UK).
doi:10.1371/journal.pntd.0002892.g005
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spuriously appeared to recognise all peptides; such artifactual
binding to avidin has been observed in other serological studies
[39].
Since the initial report of the sequence and antigenic
dimorphism of TSSA by Di Noia et al [15], E. coli-produced
recombinant TSSA proteins have been used as antigen with
human and animal sera, as summarised in Table 3. Recognition of
only TSSA-II by chronic chagasic sera from the Southern Cone
region was initially interpreted as suggesting that only TcII caused
chronic Chagas disease [15]. However there are many descriptions
of Chagas disease and chronic chagasic cardiomyopathy in TcI
endemic regions. Recognition of recombinant TSSA-I by human
chagasic sera has been reported by western blot but not by ELISA
[18,21]. One western blot study with recombinant TSSA-II and
TSSA-I has recorded an unexpected level of TcII in northern
South America and Mexico [21]. The recombinant TSSA proteins
used as antigens as described encompass up to 26 amino acids
flanking the polymorphic region [15,20,21], which are highly
conserved between TSSA-I and TSSA-II.
The lineage-specific peptide representing the epitope common
to TcII/TcV/TcVI was recognized by a large number of sera
from Brazil; a proportion of these sera also bound to TSSApep-V/
VI. All duplicate separate samples from the same patients gave
indistinguishable results. The Brazilian sera tested here originated
from the states of Goia´s and Minas Gerais, where TcII human
infections are known to be prevalent, TcV and TcVI are also
present and TcI is (relatively) uncommon [11,40,41], although TcI
is well represented among Brazilian sylvatic transmission cycles
[41,42]. However, a substantial minority of the Brazilian serum
samples (31/98 (31.6%)) did not react with TSSApep-II/V/VI.
Thus sensitivity of the TSSApep-II/V/VI ELISA does not appear
to be absolute for TcII/TcV/TcVI T. cruzi infections (Figure 2,
Table 1). It is possible that corresponding antibodies in the TcII/
TcV/TcVI seronegative patients were simply below the threshold
for detection in the ELISA, although this seems unlikely because
such patients remained equally seronegative against the peptides
even when re-tested at the higher serum concentration of 1:100
(data not shown). Alternatively, some patients may fail to generate
an immune response to the epitope or there may be as yet
undiscovered TSSA diversity in some T. cruzi TcII strains.
Elsewhere in the Southern Cone countries 12 of 15 sera from
Bolivia or Argentina were seropositive with TSSApep-II/V/VI, in
accord with the known high prevalence of these lineages in those
countries [23]. All sera from Bolivia, Argentina and Ecuador, and
the great majority of those from Brazil, that recognised TSSApep-
II/V/VI also reacted with chimera TSSApep-II/-I indicating that
crucial residues reside in the N-terminal part of the TSSA-II/V/
VI epitope.
We found that few serum samples from the three countries in
northern South America recognized TSSApep-II/V/VI or
TSSApep-V/VI. This is consistent with the literature on the
geographical distribution of T. cruzi lineages based on genotyping
of isolates from domestic and sylvatic transmission cycles. In fact
only 4 sera from Ecuador were seropositive with TSSApep-II/V/
VI out of 66 from these northern countries. At least 3 of these 4
Ecuadorian serum samples originated from the Loja region in
southern Ecuador, where TcI has been isolated [43], close to the
border with Peru. Risso et al [21] reported the identification of
TcII in Colombia, Venezuela, and Mexico using western blots
with TSSA-II recombinant antigen. However, when the same
Colombian sera samples were tested here using the lineage-specific
peptides we found no TSSApep-II/V/VI seropositive patients.
Thus with our data we are unable to confirm the presence of
TcII/TcV/TcVI in those Colombian patients.
Only four sera, including one from Venezuela where TcIV is
known to sporadically infect humans, recognised TSSApep-IV. All
four sera also recognised TSSApep-III, which shares 14 of 16
residues, presumably due to cross reaction, as we have observed
with experimental murine sera (Bhattacharyya et al, in prepara-
tion).
Apart from one Argentine and one Brazilian serum, no clear
specific reaction with TSSApep-I was observed, even with sera
from known TcI endemic regions in Venezuela, Colombia and
Ecuador. The few TSSApep-II/V/VI seropositive samples from
Brazil that also reacted with chimera TSSApep-I/-II did not react
with TSSApep-I. One possibility is that the TSSA-I protein, if
expressed at all in chagasic patients, is not sufficiently immuno-
genic to generate an antibody response, possibly due to post-
translational glycosylation of the core peptide sequence. Identifi-
cation of the disaccharide Gala(1,3)Galb as the immunodominant
glycotope present in the O-linked mucins, i.e., those glycosylated
on serine or threonine residues of the peptide chain, has been
reported recently [44,45], and both serine and threonine are
represented by one additional residue in TSSApep-I as compared
Table 3. Reports of TSSA recombinant proteins in serological assays.
Reference
rTSSA Tc
lineage Assay Sources of human sera Authors’ reports
[15] I, II ELISA, CL-ELISAa Argentina, Brazil, Chile TSSA dimorphism; chagasic sera only recognise rTSSA-II; TcI or TcII -infected animal sera
recognised the homologous rTSSA form, without cross-reactivity.
[18] I, II/V/VI Western blot Argentina TcII/V/VI and TcI co-infection in cases of chagasic cardiomyopathy; TcII/V/VI also in
indeterminate clinical form.
[19] II ELISA Argentina rTSSA-II recognised by chagasic but not non-chagasic or cutaneous leishmaniasis sera.
rTSSA-II recognised by canine sera from TcVI but not TcI or TcIII infections.
[20] IIb CL-ELISA a Brazil rTSSA-II 98% sensitive; no response to rTSSA-I; minimal cross-reactivity with Leishmania
sera.
[21] I, II Western blot Argentina, Colombia, Mexico,
Paraguay, Venezuela
Recognition of TSSA-II, TSSA-I and TSSA-II/I in northern South America and Mexico;
almost exclusively rTSSA-II in southern South America.
[22] I, II/V/VI Western blot,
ELISA
Argentina, Bolivia, Paraguay TcII/V/VI predominant in pregnant chagasic women; no recognition of TSSA-I reported.
[23] IIb ELISA Argentina TcII and/or TcV/TcVI in the north of Salta province.
aChemiluminescent ELISA; bcalled by authors TSSA VI, but the same as that first described as TSSA-II.
doi:10.1371/journal.pntd.0002892.t003
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with the TSSA-II epitope. However, equally likely, the TSSA I
epitope may be conformational, with a structure that is not
represented by the linear peptide. Also, alternative immunodomi-
nant epitopes elsewhere in TSSA-I may skew the humoral
response away from the sequence represented by TSSApep-I.
We were interested to see whether there was a difference in the
proportions of TSSApep-II/V/VI seropositive and seronegative
patients presenting with clinical symptoms of chronic Chagas
disease. Remarkably, there was a clear statistically significant
difference: 23/60 (38%) of the Brazilian TSSApep-II/V/VI
seropositives had ECG abnormalities typical of Chagas disease,
whereas such abnormalities only occurred in 4/23 (17%) of the
seronegatives (p,0.0001). One possible interpretation of these
data is that TSSApep-II/V/VI seronegative patients may not be
infected with these lineages but with some less pathogenic strains.
Alternatively, such seronegative patients may be infected with
TcII, TcV or TcVI but the absence of an immune response to the
TSSA-II/V/VI common epitope may be an indicator of a long
term better prognosis; however confirmation would require a
more extensive and longitudinal study. However, the frequencies
of megaoesophagus (43% vs 48%) and megacolon (10% vs 8.7%)
were not significantly different between the TSSApep-II/V/VI
seropositive and seronegative groups respectively.
Trypanosoma rangeli is non-pathogenic to humans, is found
sympatric with T. cruzi, particularly in northern South America,
and serological cross-reaction between these species has been
recognised [46]. The divergence of the TSSA epitopes in T. cruzi
and the lack of response to the peptides with sera from northern
South America, indicate that monospecific sera from patients
infected with T. rangeli alone will not recognise these synthetic
peptide epitopes.
A recent paper reported the identification of a TcI epitope for
lineage-specific serology [26]. However, upon analysing the
sequence diversity in the ORF coding for the parent protein
across T. cruzi lineages, in contrast we found a very high degree of
sequence conservation across the lineages. Thus, we were not able
to confirm any TcI-specificity of that peptide epitope.
We have demonstrated that synthetic peptides are able to
provide T. cruzi antigens for lineage-specific serological diagnosis
in chronic Chagas disease. Synthetic-peptide based lineage-specific
serology has also confirmed the disparate geographical distribution
of TcII/TcV/TcVI but found fewer TcII infections in northern
South America than reported with western blots and recombinant
TSSA-II. Further comparisons of recombinant TSSA antigens and
synthetic peptides are indicated. More attempts should be made to
design a TcI specific peptide, and by comparative genomics to seek
alternative antigens to TSSA that may be lineage-specific.
However, such in silico methods will need to incorporate structural
analysis, and if necessary devise linear peptides that represent
conformational epitopes. In a region of Brazil endemic for TcII we
find a higher rate of ECG abnormalities among patients with
TSSApep-II/V/VI seropositivity than among seronegative pa-
tients. Synthetic-peptide antigens clearly have substantial and
versatile potential in studying the relationship between a patient’s
history of infection and clinical status, and they may provide
clinical biomarkers for prognosis of Chagas disease.
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Key points, novel results and implications 
 In cases of suspected visceral leishmaniasis, the rapid diagnostic test (RDT) for the 
presence of anti-Leishmania antibodies is based on the antigen rK39, a fragment of a 
kinesin-like protein comprising 39 amino acid repeats, originally cloned from a 
Brazilian L. infantum (syn. L. chagasi) strain. However recent multi-centre trials have 
shown much lower sensitivities in East Africa than the South Asia, for unclear 
reasons. 
 Here, the molecular diversity of the rK39 homologous sequences among East African 
L. donovani strains was investigated as a possible factor for this differential 
sensitivity. Diversity of HASPB1 and HASPB2 gene repeat sequences, used to flank 
sequences of a kinesin homologue in the synthetic antigen rK28 designed to reduce 
variable RDT performance, was also investigated. 
 Coding sequences of rK39 homologues from East African L. donovani strains were 
amplified from genomic DNA, analysed for diversity from the rK39 sequence, and 
compared to South Asian sequences. East African sequences were revealed to 
display significant diversity from rK39. Most coding changes in the 5’ half of repeats 
were non-conservative, with multiple substitutions involving charge changes, 
whereas amino acid substitutions in the 3’ half of repeats were conservative. Specific 
polymorphisms were found between South Asian and East African strains. 
 Non-canonical combination repeat arrangements were revealed for HASPB1 and 
HASPB2 gene products in strains producing unpredicted size amplicons. 
 This work demonstrates that there is extensive kinesin and HASPB genetic diversity 
among strains in East Africa and between East Africa and South Asia, with ample 
scope for influencing performance of diagnostic assays based on these antigens. 
 
Candidate’s contribution: 
79 
 
The candidate designed all the PCR primers used in this publication, following an 
exhaustive search of the relevant literature and databases. The candidate performed most 
of the cell culture, and all the DNA extractions, PCRs, gel electrophoresis, DNA sequencing 
preparation, alignment and analysis of the kinesin and HASPB genes as described in this 
publication. The candidate prepared the first draft of the manuscript, which was accepted 
for publication by PLoS Negl Trop Dis in December 2012 following academic peer review.  
 
 
 
 
(Double-click on image to view embedded document) 
As another possible explanation of the reported differential sensitivity of the rK39 
RDT in East Africa and South Asia, the anti-Leishmania IgG levels of VL patients from 
endemic regions of Sudan and India were directly compared in ELISA against Leishmania 
lystaes originating from both regions. That work is described in the following section 
(ANNEX 4 Bhattacharyya et al., 2014). 
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Abstract
Background: Visceral leishmaniasis (VL), caused by infection with Leishmania donovani complex, remains a major public
health problem in endemic regions of South Asia, East Africa, and Brazil. If untreated, symptomatic VL is usually fatal. Rapid
field diagnosis relies principally on demonstration of anti-Leishmania antibodies in clinically suspect cases. The rK39
immunochromatographic rapid diagnostic test (RDT) is based on rK39, encoded by a fragment of a kinesin-related gene
derived from a Brazilian L. chagasi, now recognised as L. infantum, originating from Europe. Despite its reliability in South
Asia, the rK39 test is reported to have lower sensitivity in East Africa. A reason for this differential response may reside in the
molecular diversity of the rK39 homologous sequences among East African L. donovani strains.
Methodology/Principal Findings: Coding sequences of rK39 homologues from East African L. donovani strains were
amplified from genomic DNA, analysed for diversity from the rK39 sequence, and compared to South Asian sequences. East
African sequences were revealed to display significant diversity from rK39. Most coding changes in the 59 half of repeats
were non-conservative, with multiple substitutions involving charge changes, whereas amino acid substitutions in the 39
half of repeats were conservative. Specific polymorphisms were found between South Asian and East African strains.
Diversity of HASPB1 and HASPB2 gene repeat sequences, used to flank sequences of a kinesin homologue in the synthetic
antigen rK28 designed to reduce variable RDT performance, was also investigated. Non-canonical combination repeat
arrangements were revealed for HASPB1 and HASPB2 gene products in strains producing unpredicted size amplicons.
Conclusions/Significance: We demonstrate that there is extensive kinesin genetic diversity among strains in East Africa and
between East Africa and South Asia, with ample scope for influencing performance of rK39 diagnostic assays. We also show
the importance of targeted comparative genomics in guiding optimisation of recombinant/synthetic diagnostic antigens.
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Introduction
Visceral leishmaniasis (VL) remains a major public health
concern in many parts of the tropical world, with the great
majority of the estimated 200,000 to 400,000 annual new cases
found in South Asia, East Africa, and Brazil [1,2]. VL is caused by
kinetoplastid protozoa of the Leishmania donovani complex. These
are: L. donovani in South Asia and East Africa; L. infantum, mainly in
Europe, the wider Mediterranean region, and in Latin America,
where it was historically also known as L. chagasi but is now
demonstrated to be synonymous with L. infantum originating from
Europe [3].
Leishmania promastigotes, transmitted during bloodmeal feeding
by female sandflies (Phlebotomus and Lutzomyia spp., in the Old and
New World respectively), are internalised by local dermal
macrophages and dendritic cells. Within these host cells, flagella
are lost, and transformation into proliferative amastigote forms is
followed by cell lysis, re-invasion of other cells, and parasite
dissemination by the lymphatic and vascular systems, which can
lead to infiltration of bone marrow and hepatosplenomegaly. In
symptomatic cases, VL is fatal if untreated [4].
Parasitological diagnosis, by demonstration of amastigotes in
spleen aspirates, approximates to a gold standard for VL diagnosis
but is applied cautiously due to associated risk. Serological (anti-
Leishmania antibody) tests include enzyme-linked immunosorbent
assay (ELISA), indirect fluorescent antibody test (IFAT), and direct
agglutination test (DAT) [5]. However, after drug treatment and
cure current serological tests may still give positive results and
therefore cannot readily diagnose relapse. Furthermore, such tests
can also detect anti-leishmanial antibodies in asymptomatic
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individuals living in endemic areas, but with no VL history or
subsequent progression to VL [6].
Burns et al [7] identified a kinesin-related gene product, LcKin,
as a candidate diagnostic antigen by screening a Brazilian L.
infantum (L. chagasi) genomic library with serum of an L. donovani
patient. A part of the coding sequence, comprising a 46aa region
followed by 6.5639aa repeats, forms the recombinant diagnostic
protein rK39. In recent multicentre evaluations, the use of the
rK39 in a lateral-flow immunochromatographic, rapid test format
reported less success in East Africa than in the Indian subcontinent
for point-of-care diagnosis of VL [8,9]. Underlying explanatory
factors may reside in molecular divergence between East African
L. donovani kinesin gene homologues and the Brazilian L. infantum
(L. chagasi)-derived rK39 sequence, and/or may be due to
differential immunocompetence and antibody levels produced
among African and Asian human populations.
Studies on South Asian L. donovani strains using PCR primers
based on LcKin have identified rK39 homologous sequences [10–
12]. Gerald et al [13] reported the first East African (Sudanese) L.
donovani kinesin homologue, LdK39. The first two of the 39-aa
repeats of LdK39, flanked by sequences of the L. donovani antigens
HASPB1 and HASPB2 [14], comprise rK28, a novel recombinant
protein for diagnosis of VL, designed to be an improvement over
rK39 [15–16]. HASPB proteins are expressed on the surface of
infective promastigote and amastigote Leishmania life cycle stages
[14]. The first 3614aa repeats of HASPB1 are incorporated into
rK28, along with the complete ORF of HASPB2, which includes
three imperfect consecutive repeats, 2614aa and 1613aa.
HASPB1 and HASPB2 correspond with K26 and K9, respectively
[17], which were originally identified in L. infantum (L. chagasi) at
the same time as the HASPBs, but were given different
nomenclature. A recent comparison of rK26 and rK9 showed
significantly lower diagnostic efficacy than rK28 [15].
Here we investigate whether molecular divergence in rK39
kinesin sequence homologues of East African L. donovani may
contribute to lower rK39 diagnostic test success rates in East
Africa. We analyse the rK39 homologues in a panel of East
African L. donovani strains and compare their diversity against
published South Asian sequences. In addition, we compare
sequence diversity of HASPB1 and HASPB2 in East African
and South Asian strains.
Methods
L. donovani strains
Table 1 lists the East African L. donovani strains used in this
study. Strains were selected to represent genetic groups within the
L. donovani complex in East Africa (Baleela et al, unpublished data;
identified by multilocus sequence typing (MLST) and microsatel-
lite analysis (MLMT)). Strains were cultured in aMEM medium
supplemented by foetal calf serum (Sigma, UK), and genomic
DNA was extracted from uncloned cultures using Gentra Pure-
gene Tissue Core Kit A (Qiagen, UK). Uncloned cultures were
specifically used here because the intention was to capture the
diversity present within natural L. donovani populations. Table 2
lists the GenBank sequences derived in other studies [7,10–14,18–
19] and used here for comparisons.
Kinesin homologues
PCR primers LdonK39F (gagctcgcaaccgagt) and LdonK39R
(ctgrctcgccagctcc) were designed for this study based on a
comparison of LcKin and LdK39 coding sequences (Figure 1A),
and were targeted to amplify the 894 bp region of the L. donovani
kinesin gene that is incorporated into the diagnostic antigen rK39.
The level of conservation in the sequences encoding the 39-aa
repeats predicts that primer LdonK39R would be expected to
anneal to multiple sites within the kinesin gene template,
generating multiple amplicons. Amplification reactions were
performed in a total volume of 20 ul, and comprised of 16NH4
Reaction buffer supplemented with 1.5 mM MgCl2 (Bioline, UK),
200 mM dNTPs (New England Biolabs, UK), 10 pmol of each
primer, and 1 U BioTaq DNA polymerase (Bioline). Amplification
conditions were: 1 cycle of 94uC, 2 mins; 25 cycles of 94uC for
30 secs, 55uC for 30 secs, 72uC for 1 min; 1 cycle of 72uC for
5 mins. PCR products were separated by electrophoresis on 1.5%
agarose gels (Bioline). Amplicons corresponding to rK39 homo-
logues were excised and purified from gels using QIAquick Gel
Extraction Kit (Qiagen), cloned into pGEM-T easy vector
(Promega, UK), and transformed into XL1-blue E. coli on blue-
white selection. Primers Sp6/T7 and M13for/rev were used to
sequence from the vector (between 2–5 colonies per strain were
taken forward for sequencing, except UGX-MARROW and
SUDAN1, where due to difficulty in cloning the corresponding
inserts only one clone was sequenced); in addition, LdonK39int
(cgagcggctaaccagc), which binds to the 39 end of the non-repeat
region immediately upstream of the repeats, was used as an
internal sequencing primer (Figure 1A). Sequences were analysed
using BioEdit [20].
HASPB
PCR primers LdonHASPBfor (cataaaaccactgaggc) and Ldon-
HASPBrev (atcttcgttcttctcctg) were designed for this study to flank
the repeat regions of the HASPB1 ORF, amplifying a 1064 bp
product (Figure 1B). Due to the identity between HASPB1 and
HASPB2 at the primer binding sites, a 260 bp product would also
be predicted to be amplified from HASPB2 by these primers
(Figure 1C). Composition of PCR mix was as described above for
kinesin, except that 40 mM dNTPs were used. Amplification
conditions were: 1 cycle of 94uC, 2 mins; 25 cycles of 94uC for
30 secs, 50uC for 30 secs, 72uC for 1 min; 1 cycle of 72uC for
10 mins. PCR products were separated by electrophoresis on 1%
agarose gels (Bioline). Amplicons were excised and purified from
Author Summary
Visceral leishmaniasis (VL) is caused by infection with
parasites of the Leishmania donovani complex, spread by
the bite of blood-sucking sandflies, especially in South
Asia, East Africa, and Brazil. If untreated, symptomatic VL
leads to systemic pathologies and is usually fatal. Up to
approximately 400,000 new cases are estimated to occur
annually, and regional epidemics have been devastatingly
severe. Diagnosis of clinically suspect cases in the field, and
thus appropriate treatment, relies principally on a rapid
diagnostic test (RDT) based on detection of antibodies
against a Leishmania antigen known as rK39. Although this
test is reliable in South Asia, it has shown less success in
East Africa. One reason may reside in diversity of the rK39
homologue among East African L. donovani, with conse-
quent limitations in the binding of diagnostic antibodies.
Here, we investigate the sequences of rK39 homologues in
a panel of East African L. donovani strains, and show that
there is significant diversity compared to rK39 and to
South Asian sequences. Additionally, we examine diversity
in another diagnostic antigen known as HASPB1/2. Our
results indicate that an improved RDT may need to
encompass East-African-specific antigen diversity to pro-
vide high performance field diagnosis for this region.
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gels using QIAquick Gel Extraction Kit, and sequenced directly
using the amplification primers. Sequences were analysed using
BioEdit.
Accession numbers
Kinesin nucleotide sequences derived in this manuscript are
available under GenBank accession numbers KC342866-
KC342872. HASPB Nucleotide sequences derived in this manu-
script are available under GenBank accession numbers
KC342849- KC342865.
Results
East African L. donovani kinesin diversity
Multiple kinesin amplicons were produced using a combination
of primers LdonK39F, which binds to the non-repeat region and
LdonK39R, because the latter primer binds to nucleotide
sequence that is conserved across the repeats. An example is
shown in Figure 2. Sequencing of cloned amplicons containing the
rK39 homologous sequences into plasmid vectors revealed the
presence of nucleotide and predicted amino acid diversity among
East African L. donovani strains. Table 3 shows the amino acid
polymorphisms that were found among the East African strains,
together with their divergence from L. infantum (L. chagasi) derived
LcKin rK39, and alongside the GenBank sequence for L. donovani
derived kinesin LdK39 used in rK28. Substitutions between a non-
charged and a charged residue (D2, E2, H+, K+, R+) in
comparison with the LcKin rK39 sequence are shown underlined.
When the seven rK39 homologous repeats of all the East
African strains were compared with the LcKin rK39 amino acid
sequence, residues 2, 6, 10, 16 and 18 were each affected three or
four times by substitutions involving charge changes. In contrast,
although there were multiple substitutions in the latter half of the
East African rK39 tandem repeats, especially affecting residues 21,
Table 1. East African L. donovani strains for which sequences were determined, with GenBank accession numbers.
Strain Origin MON/LONa Kinesin HASPB amplicon
HASPB1 HASPB2 Unpredicted
MHOM/ET/67/HU3 (LV9) Ethiopia MON18/LON46 KC342866 KC342849 KC342855 -
MHOM/ET/00/HUSSEN Ethiopia MON31/LON42 KC342867 - - KC342861
MHOM/ET/72/GEBRE1 Ethiopia MON82/LON50 - KC342850 - -
MHOM/SD/87/UGX-MARROW Sudan MON31 KC342868 - - KC342862
MHOM/SD/82/GILANI Sudan MON30/LON48 KC342869 KC342851 KC342856 -
MHOM/SD/98/LEM3582 Sudan MON18 KC342870 KC342852 KC342857 -
MHOM/SD/XX/SUDAN1 Sudan MON18 KC342871 - KC342858 -
MCAN/SD/98/LEM3556 Sudan MON82 - KC342853 KC342859 -
MHOM/SD/97/LEM3458 Sudan MON18 - KC342854 KC342860 -
IMAR/KE/62/LRC-L57 Kenya MON37/LON44 KC342872 - - KC342863
MHOM/KE/67/MRC(L)3 Kenya MON37/LON44 - - - KC342864
MCAN/IQ/81/SUKKAR 2 Iraq LON43 - - - KC342865
aMON and LON reference numbers refer to multilocus sequence enzyme electrophoresis (MLEE) profiles.
doi:10.1371/journal.pntd.0002057.t001
Table 2. GenBank sequences used in comparisons.
Strain Origin Gene product GenBank Reference
MHOM/BR/82/BA-2,C1 Brazil Kinesin LcKin/rK39 L07879 [7]
MHOM/IN/KE16/1998 India Kinesin/Ld-rKE16 AY615886 [10]
Morenaa India Kinesin DQ648599 [11]
MHOM/IN/80/DD8 b Kinesin/rKRP42 AB256033 [12]
MHOM/SD/62/1S-CL2D Sudan Kinesin/LdK39 DQ831678 [13]
MCAN/ES/98/LLM-877 (JPCM5)c Spain Kinesin XM_00146426e [18]
MHOM/NP/2003/BPK282/0cl4d Nepal Kinesin FR799601e [19]
MHOM/ET/67/L28 (LV9) Ethiopia HASPB1 AJ011810 [14]
MHOM/ET/67/L28 (LV9) Ethiopia HASPB2 AJ011809 [14]
MHOM/NP/2003/BPK282/0cl4d Nepal HASPB FR799601e [19]
aDescribed in [11] as clinical isolate, not laboratory strain, so WHO code not given here.
bDescribed in [12] as isolated from a Bangladeshi patient, but MHOM/IN/80/DD8 is also reported as being from India [6].
cL. infantum reference genome.
dL. donovani reference genome.
eGenBank numbers refer to locations on the entire chromosome 23 sequence, to which both the kinesin and HASPB BLAST searches map.
doi:10.1371/journal.pntd.0002057.t002
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23, 27 and 39, none of these substitutions involved charge changes.
Two tracts of the rK39 repeat, residues 11 to 15 and 28 to 34 were
perfectly conserved between LcKin39 across all the East African
strains examined and across all seven rK39 repeats within those
strains.
Sequencing of multiple plasmid clones revealed the presence of
alternative residues at single sites within single strains. This was
notably widespread for the two strains Gilani and Hussen, in the
case of Gilani, including several alternatives within the first and
second repeats.
Comparison of L. donovani kinesin diversity between East
Africa and South Asia
Figure 3 depicts the composite L. donovani kinesin polymor-
phisms for East Africa and South Asia and the divergence between
the two geographic regions, in comparison with the LcKin rK39
derived from L. infantum (L. chagasi). The East African polymor-
phisms in Figure 3 incorporate the data obtained here together
with the published LdKin (rK28) sequence. Substitutions between
non-charged and charged residues (D2, E2, H+, K+, R+)
compared to the LcKin rK39 sequence are shown underlined.
East Africa-specific polymorphisms are boxed; South Asia-specific
polymorphisms are circled.
In the 46aa non-repeat region the only divergence from L.
infantum (L. chagasi) diagnostic LcKin rK39 was CysRSer41, found
among both South Asian and East African strains (Table 3).
Throughout the 6.5639aa repeats, there were polymorphisms
divergent from the diagnostic LcKin rK39 that were unique to
each region and other polymorphisms that were common to East
Africa and South Asia. For example, GluRGly2 (Repeats 4, 5, 7)
and ArgRHis11 (Repeats 1, 2, 4) are found only in East Africa and
South Asia respectively, whereas in Repeat 1, AlaRSer21,
AlaRThr23, SerRMet27, ThrRAla39, which are all conservative
changes found in the latter half of the repeats, were found in both
regions. Indeed, as for the East African strains (Table 3) all such
polymorphisms identified in the latter half of the repeats among
South Asian strains are conservative, i.e., a non-charged residue is
replaced by another non-charged residue; conversely, non-
conservative substitutions between non-charged and charged
residues are found in the first half of the repeats. Among the
published South Asian sequences charges diverged from those in
Figure 1. Leishmania rK39 and HASPB antigen repeats and the PCR primer target sequences. Repetitive coding regions depicted as filled
boxes, PCR primers underlined, and 59 and 39 binding positions with amplicons are indicated by dashed lines. [A] Kinesin gene comparison for primer
design (* = non-conserved nucleotide). [B] HASPB1 GenBank sequence displays 226perfect 14aa repeats. [C] HASPB2 GenBank sequence displays 3
imperfect repeats.
doi:10.1371/journal.pntd.0002057.g001
Figure 2. Multiple amplicons corresponding to kinesin tandem
repeats are produced by PCR primers LdonK39F and
LdonK39R. Amplifications from strains HU3 (LV9), Hussen, and UGX-
MARROW, are depicted. Major amplicon sizes differ by 117 bp, the size
of the nucleotide sequence encoding the 39aa repeat in the kinesin
gene; mk=Hyperladder I (Bioline).
doi:10.1371/journal.pntd.0002057.g002
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diagnostic LcKin rK39 at residue 4 (GlnRArg; Repeats 2, 3, 4)
and at residues 16, 17 and 18, for example uncharged to positive
at these three sites in repeat 1 (Figure 3).
Comparison with L. donovani complex reference
genomes
After the sequencing of the L. infantum reference genome [18],
Downing et al [19] sequenced the Nepalese L. donovani strain
BPK282/0cl4 as the reference genome for L. donovani. The
sequence coding for the non-repeat 46-aa region of rK39 was
submitted to NCBI BLAST against the reference genomes. For the
L. infantum reference genome (Spanish, canine-isolated), there were
no differences across the entire rK39 sequence, in accordance with
this being the postulated source of L. infantum (L. chagasi) in South
America [3]. For the genome sequence of BPK282, due to the
repeat nature of the downstream region, only sequences of the first
two repeats could be unequivocally aligned and these were
incorporated into Figure 3 for comparisons with the individual
repeat sequences generated here. From the unequivocal BLAST
alignment information, BPK282 repeat 1 is the same as for rK39
except ThrRAla39; in BPK repeat 2, where only the first 6
residues are unambiguously assembled, GlnRArg4 is present.
L. donovani HASPB
PCR primers LdonHASPBfor and LdonHASPBrev were
designed to bind unique sequences flanking the 22614aa-repeat
coding region of HASPB1 to produce a 1064 bp amplicon.
However, with some of the strains studied here in addition to the
1064 bp product the smaller 260 bp amplicon corresponding to
HASPB2 (Figure 1C) could also be seen: an example is shown for
HU3 (LV9) in Figure 4. However, these primers unexpectedly
gave amplicons of ,400–500 bp for some of the strains (Hussen,
UGX-marrow, LRC-L57, MRC(L)3, SUKKAR 2) (Figure 4).
Comparisons with rK28 HASPB sequences
Strains HU3 (LV9), Gebre1, Gilani, LEM3582, LEM3556, and
LEM3458, which gave 1064 bp-amplicons, had identical sequenc-
es in their first 3614aa repeats as the HASPB1 used in diagnostic
rK28. However, subsequent repeats, not incorporated into rK28,
were imperfect with polymorphic residues at certain sites, such as
HisRArg6 (repeats 15, 18, 22) and GlyRAla14 (repeats 5, 14, 17)
for strains LEM3582, LEM3556, and LV9.
For those strains producing the predicted 260 bp amplicon of
the HASPB2 homologue, (Figure 1) a comparison with the rK28
sequence identified a Gly residue inserted between Ala32 and Val33
preceding the imperfectly repeated 14/13aa region and a
ProRGln96 substitution present after the 14/13aa region. The
only polymorphism within the imperfectly repeated 14/13aa
region, compared to rK28, was LysRGlu49, at the third residue of
first 14aa region, with a consequent charge change.
Interestingly, the strains producing unexpected ,400–500 bp
amplicons (Hussen, UGX-marrow, LRC-57, SUKKAR 2,
MRC(L)3) revealed on sequence analysis a HASPB1/HASPB2-
like combination composition across their repeats, due to the
presence of the central motifs that were HASPB1-like (HTQKN)
or HASPB2-like (HAH-N). The HTQKN and HAH-N motifs
were not consistently present in the same repeat numbers across
these five strains and the HASPB1-like and HASPB2-like sections
of the tandem repeat were not necessarily aggregated (Table 4). In
the case of LRC/L57, both the 1064 bp (predicted HASPB1-
homologue) and ,500 bp amplicons contained the HASPB2-like
motif HAH-N. The LysRGlu49 substitution at the third residue ofT
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the first 14aa region, described above, was also present in those
strains giving the ,400–500 bp amplicons.
Comparison with L. donovani reference genome
The sequence coding for the pre-repeat region of HASPB1 (not
used in rK28, Figure 1A) was submitted to NCBI BLAST against
the Nepalese L. donovani reference genome, to facilitate correct
alignment. Due to the repeat nature of the downstream region,
only the first two repeats of the reference genome could be
unequivocally aligned for comparisons with the individual
sequences generated here. The first two repeats of the reference
genome showed the combination composition of central motifs
HTQKN in repeat 1 (HASPB1-like) and HAH-N in repeat 2
(HASPB2-like). Thus, the South Asian reference genome has a
HASPB1/2 combination structure like the four East African
strains Hussen, UGX-marrow, LRC-57, MRC(L)3, and the Iraqi
SUKKAR 2, and with the same organisation of repeats 1 and 2
seen in the Kenyan strains LRC-57 and MRC(L)3.
Figure 3. Polymorphisms among seven rK39 repeats of East African and South Asian strains show region-specific substitutions.
Changes between charged and non-charged residues are underlined. No residue entered at a particular site indicates conservation of that residue
with the corresponding residue of diagnostic rK39. Where two alternative residues are indicated in smaller text these are not necessarily always within
the same strain, for clarification compare with Table 3. Region-specific polymorphisms in each repeat are boxed (East Africa) or circled (South Asia).
doi:10.1371/journal.pntd.0002057.g003
Figure 4. Predicted (1064 bp, 260 bp) amplicons and unpre-
dicted (,400–500 bp) amplicons with HASPB PCR primers
LdonHASPBfor and LdonHASPBrev. Amplifications from strains
HU3 (LV9), Hussen, UGX-MARROW, and LRC-L57, are depicted;
mk=Hyperladder I.
doi:10.1371/journal.pntd.0002057.g004
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Discussion
For VL there is a particular need for rapid diagnostic tests
(RDTs) that can be unequivocally applied in endemic regions at
primary care level and with only basic technical training. Of the
available options for serological diagnosis of VL only the
immunochromatographic rK39 assay can be considered a point
of care test for field application. The IFAT requires a fluorescence
microscope. Use of the DAT is constrained by the readout delay,
the relative sophistication of the procedure and limited access to
lyophilised antigen. In agreement with other studies, Boelaert et al
[8] recommend the use of rK39 in South Asia, but report less
satisfactory results from East Africa. One factor influencing
regional differences in diagnostic performance may be divergence
in kinesin gene homologues in East African L. donovani from the L.
infantum (L. chagasi)-derived LcKin rK39 sequence. In an attempt to
overcome the geographical limitations of the rK39 test a modified
recombinant antigen, rK28, has been devised, incorporating
segments of the HASPB antigen.
Analyses of L. donovani complex isolates with multiple molecular
markers have revealed extensive genetic diversity with at least six
distinct lineages, and both inter- and intra-lineage diversity.
Furthermore, genotyping of isolates from endemic regions has
shown an association between genotype and geographical origin
[21–22]. Kuhls et al [22] used multilocus microsatellite typing
(MLMT) for high resolution comparison of the six global L.
donovani genetic lineages, and showed that allelic diversity in Africa
was greater than in India; a subsequent MLMT study also
described comparative homogeneity among South Asian L.
donovani [23]. Thus, the relative homogeneity of South Asian L.
donovani and greater diversity in East Africa, if mirrored in diversity
of the kinesin gene, is one potential explanation of the more
limited efficacy of diagnostic rK39 in East Africa.
Here we determined across a panel of East African strains the
diversity of the kinesin repeat region homologous to that used in
both the rK39 diagnostic antigen (repeats 1 to 6.5) and the rK28
recombinant antigen (repeats 1 and 2). We then compared this
diversity to that among predetermined South Asian sequences.
Surprisingly, in view of the proven value of the rK39 RDT in
South Asia, there is considerable amino acid diversity among
kinesin repeats 1 to 7 of South Asian strains as well as those from
East Africa (Figure 3). Alternative residues at multiple sites
suggested that Gilani and Hussen are heterozygous, although
sequences were not obtained from DNA clones and therefore
multiclonality rather than heterozygosity cannot be excluded.
Across all strains the diversity was particularly notable in the first
half of each rK39 repeat, because it involved charge changes at
residues 2, 6, 10, 16, and 18, with only a short stretch of
consistently conserved residues (11 to 15). Such charge changes
among the South Asian strains are very likely to disrupt antigenic
epitopes, if present. As far as we are aware epitopes within or
across adjacent rK39 repeats have not yet been precisely mapped.
However, we would predict that the diagnostic epitopes lie in the
latter half of the rK39 repeat, where, although there is extensive
diversity, the changes are conservative, none involving charge, and
there is one stretch of residues (28 to 34) that is entirely conserved
across all isolates and across all seven repeats. This is consistent
with the recent work of Costa et al [24] in which antigen
prediction software led to the synthesis of a 22mer peptide
(ESTTAAKMSAEQDRESTRATLE) encompassing the region of
rK39 from residue 20 of repeat 3 to residue of 2 of repeat 4, a
sequence which is also found in the next two repeats. In that study,
the peptide was recognised in ELISA by Brazilian sera from
symptomatic and asymptomatic canine VL and symptomatic
human VL. However, our study shows that at least 5 of the
residues within that 22mer are polymorphic in East Africa.
Kinesin repeat divergence from the rK39 diagnostic recombi-
nant is complex, and some divergence is common to both South
Asia and East Africa, for example at residues 7, 10, 21, 23
(Figure 3). Nevertheless, there were polymorphisms unique to each
region, for example at residues 4, 16, and 18, consistent with the
expectation that differential sensitivities of rK39 assays may be
partially attributable to positional and physiochemical polymor-
phisms of the kinesin gene. The identification and confirmation of
region-specific polymorphisms may be limited by the amount of
sequence data so far available. Also diversity beyond the seven
sequenced repeats of the kinesin tandem array may present a
wider range of epitopes for immunological recognition.
The differential immunocompetence and antibody titres of East
African and South Asian human populations in the context of VL
remains to be thoroughly explored, as a major alternative or
contributing explanation of variable rK39 test sensitivities.
Interestingly a recent WHO/TDR evaluation [9] of a rapid
diagnostic test based on rKE16 antigen, a LcKin homologue
derived from an Indian L. donovani [10], reported markedly lower
sensitivities against Brazilian and East African sera, compared to
South Asian. The same evaluation [9] also reported a lower
sensitivity of rK39-based tests with Brazilian sera. However, the
Table 4. Repeat sequences of unexpected amplicons.
HUSSEN UGX-Marrow LRC-L57 MRC(L)3 SUKKAR 2
Rpt 1 LKEDGHTQKNDGDG LKEDGHTQKNDGDG PKEDGHTQKNDGDG PKEDGHTQKNDGGG LKEDGHTQKNDGDG
Rpt 2 PKEDGHTQKNDGGA PKEDGHTQKNDGGA PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDGHTQKNDGDG
Rpt 3 PKEDGHTQKNDGDG PKEDGHTQKNDGDG PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDDHAH-NDGDG
Rpt 4 PKEDDHAH-NDGDG PKEDDHAH-NDGDG PKEDGHTQKNDGDG PKEDGHTQKNDGDG PKEDDHAH-NDGDG
Rpt 5 PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDDHAH-NDGGG
Rpt 6 PKEDDHAH-NDGGA PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDDHAH-NDGGG PKEDDHAH-NDGGG
Rpt 7 PKEDDHAH-NDGGG PKEDGHTQKNDGGV
Rpt 8 PKEDGHTQKNDGGV
Central motifs:
HTQKN=HASPB1-like.
HAH-N =HASPB2 like.
doi:10.1371/journal.pntd.0002057.t004
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rK39 antigen is derived from a Brazilian L. infantum (L. chagasi)
strain [7], which originated from Iberia in Europe and is
considered to be relatively homogeneous, based on microsatellite
typing [3]. Thus, kinesin diversity among Brazilian L. infantum
should be explored further and comparative immune response
levels among Brazilian and South American populations.
In the rK28 recombinant diagnostic antigen, designed to
improve on performance of the rK39 test, highly conserved
HASPB repetitive amino acid sequences flank the first two repeats
of Ldk39, derived from an East African strain. Alce et al [14],
following the work of McKean et al [25], amplified two
homologues of the L. major Gene B protein from L. donovani,
naming the ORF of the larger HASPB1 and that of the smaller
HASPB2. Recombinant HASPB1 has been used in animal vaccine
models [26–27], and HASPB has a role in L. major differentiation
within the sandfly vector P. papatasi [28]. The PCR primers used in
the current study, like those used by Alce et al [14], anneal to
regions flanking HASPB repeat regions and generate two PCR
products of predicted size corresponding to HASPB1 and
HASPB2, compatible with the presence of two distinct HASPB1
and HASPB2 loci in the genome, as concluded for the L. major
genome [29]. However, several strains produced unexpected sized
amplicons with a mix of HASPB1 and HASPB2 motifs within
these PCR products, indicating a structural reorganisation of
HASPB in these strains. Similarly, Haralambous et al [30] in K26,
a homologue of HASPB, also found unexpected amplicons for the
Hussen strain as compared to Gebre1 and Gilani. Nevertheless,
despite this structural reorganisation, there was limited HASPB
amino acid diversity across the strains. There was only one
polymorphism compared to rK28 that involved a charge change,
LysRGlu49 in HASPB2, potentially affecting antigenicity. A
recent study [31] reports HASPB repeat sequence diversity in
Indian L. donovani strains; a comparison with sequences derived
here shows that among those East African strains producing
unexpected sized amplicons (Table 4), there is the presence of
repeat sequence types that are also predominant among Indian
strains (PKEDDHAHNDGGG, PKEDGHTQKNDGDG,
PKEDDHAHNDGDG). In addition we find repeat types not
reported from Indian strains, for example repeats beginning with
Lys in place of Pro (Hussen, UGX-Marrow, SUKKAR 2), or
ending in Val (LRC-L57, MRC(L)3).
We did not have patient samples from which to attempt direct
amplification of kinesin and HASPB and confirm diversity in situ.
Nevertheless the polymorphisms described here do not occur
stochastically across strains but at sites of reported kinesin
diversity, or in the case of the HASPB2, are consistent among
strains (Ala32-Gly-Val33 or ProRGln96). Furthermore, the strains
were cryopreserved, not subjected to prolonged passage in vitro,
and sequences were determined bi-directionally and/or repeated
to confirm their validity.
We have undertaken the most comprehensive analysis of
diagnostic kinesin and HASPB antigen diversity in East African
strains to date. We show that there is extensive kinesin genetic
diversity among strains and between East Africa and South Asia,
with ample scope for influencing performance of rK39 diagnostic
assays. Future research should both widen and focus the genomic
comparisons between strains and also compare immune compe-
tence profiles among East African, Brazilian and South Asian
populations as an alternative or contributory factor to variable
RDT performance. There are broader implications from these
findings. Firstly, we see the crucial importance of sustaining
accessible collections of Leishmania strains representative of genetic
lineages and global diversity. Secondly, due to present limitations
in the capacity of whole genome sequencing to assemble complex
antigen gene families, especially those comprised of repeated
sequences, targeted analysis of individual strains is also necessary
for these comparisons of genetic diversity. Thirdly, it is evident
that comparative genomics has a vital role in guiding the
optimisation of recombinant or synthetic diagnostic antigens.
Not only are even better diagnostic tests needed for diagnosis of
VL but biomarkers are urgently required to distinguish symptom-
atic cases, asymptomatic infections at risk or not of progression to
VL, and post-treatment outcome (relapse versus cure).
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Ahmed O, Boelaert M, Miles MA (2014). Significantly lower anti-Leishmania IgG responses in 
Sudanese versus Indian visceral leishmaniasis. PLoS Negl Trop Dis 8 e2675 
Key points, novel results and implications 
 As described in ANNEX 4 Bhattacharyya et al., 2013 recent multi-centre trials of the 
rK39 RDT have shown much lower sensitivities in East Africa than the South Asia, and 
the extent and nature of Leishmania antigen diversity was examined as a possible 
cause.  
 Here, the relevance of the human immunoglobulin response by patients from 
endemic regions in Sudan and India is examined by comparative serology against 
Leishmania lysates originating from both regions. 
 ELISA plates were coated with whole cell lysates of Sudanese and Indian L. donovani 
strains, such that each strain was coated on half of each plate. VL patient plasma 
from the different endemic areas of Bihar (India) and Gedaref (Sudan) were then 
titrated aginst the lystaes, for comparasion of anti-Leishmania response. 
 Composite results for each cohort (India n=36, Sudan n=36) were analysed by 
plotting 1/log plasma dilution of the serial titration against ELISA readout. A striking 
finding was that the Sudanese cohort produced much lower IgG titres than the 
Indian, as measured by 50% end titres. This was observed regardless of antigen 
source, patient age or sex (p<0.0001). 
 This work shows that a possible reason for the lower sensitivity of the rK39 RDT in 
East Africa is the lower IgG response generated, which may be due to genetic/ethnic, 
nutritional or environmental factors. 
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To further serological studies on VL, and in the context of the existing literature, the 
relationship between IgG subclass responses in VL patients of different clinical status was an 
additional area of interest. That work is described in the following section (ANNEX 5 
Bhattacharyya et al., 2014). 
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Abstract
Background: Visceral leishmaniasis (VL), a widely distributed systemic disease caused by infection with the Leishmania
donovani complex (L. donovani and L. infantum), is almost always fatal if symptomatic and untreated. A rapid point-of-care
diagnostic test for anti-Leishmania antibodies, the rK39-immunochromatographic test (rK39-ICT), has high sensitivity and
specificity in South Asia but is less sensitive in East Africa. One of the underlying reasons may be continent-specific
molecular diversity in the rK39 antigen within the L. donovani complex. However, a second reason may be differences in
specific IgG anti-Leishmania levels in patients from different geographical regions, either due to variable antigenicity or
immunological response.
Methodology/Principal Findings:We determined IgG titres of Indian and Sudanese VL patients against whole cell lysates of
Indian and Sudanese L. donovani strains. Indian VL patients had significantly higher IgG titres against both L. donovani
strains compared to Sudanese VL patients (p,0.0001). Mean reciprocal log10 50% end-point titres (1/log10t50) were i) 3.80
and 3.88 for Indian plasma and ii) 2.13 and 2.09 for Sudanese plasma against Indian and Sudanese antigen respectively (p,
0.0001). Overall, the Indian VL patients therefore showed a 46.8–61.7 -fold higher mean ELISA titre than the Sudanese VL
patients. The higher IgG titres occurred in children (,16 years old) and adults of either sex from India (mean 1/log10t50:
3.60–4.15) versus Sudan (mean 1/log10t50: 1.88–2.54). The greatest difference in IgG responses was between male Indian and
Sudanese VL patients of $ 16 years old (mean 1/log10t50: 4.15 versus 1.99 = 144-fold (p,0.0001).
Conclusions/Significance: Anti-Leishmania IgG responses among VL patients in Sudan were significantly lower than in
India; this may be due to chronic malnutrition with Zn2+ deficiency, or variable antigenicity and capacity to generate IgG
responses to Leishmania antigens. Such differential anti-Leishmania IgG levels may contribute to lower sensitivity of the
rK39-ICT in East Africa.
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Introduction
The great majority of the estimated 200,000 to 400,000 annual
new cases of visceral leishmaniasis (VL) occurs in six countries,
with India having the highest estimated incidence in the world
(146,700 to 282,800/year), Sudan having the highest in Africa
(15,700 to 30,300/year) and Brazil having the highest in the
Americas (4,200 to 6,300/year) [1]. In South Asia and East Africa,
VL is caused by the kinetoplastid protozoan Leishmania donovani,
transmitted by the sandfly vectors Phlebotomus argentipes in South
Asia and P. orientalis and P. martini in East Africa. Following
inoculation into the human host, the parasite disseminates through
the lymphatic and vascular systems. Some infected individuals
remain asymptomatic, but full-blown symptomatic VL with bone
marrow infiltration and hepatosplenomegaly is almost always fatal
if untreated [2].
The demonstration of L. donovani amastigotes in lymph node,
spleen or bone marrow tissue smears is the definitive diagnostic
method for infection, however due to the invasive nature and the
operational difficulties associated with these procedures, serolog-
ical assays have been developed. Serological (anti-Leishmania
antibody) tests include the enzyme-linked immunosorbent assay
(ELISA), indirect fluorescent antibody test (IFAT) and the direct
agglutination test (DAT) [3,4]. However, these antibody detection
tests remain positive for several months to years after drug
treatment and cure and therefore cannot readily diagnose relapse;
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such tests can also be positive in asymptomatic individuals living in
endemic areas and exposed to L. donovani infection yet with no
history of VL or subsequent progression to VL.
The lateral-flow rapid diagnostic ‘point-of-care’ immunochro-
matographic test (ICT) format based on the rK39 antigen derived
from a Brazilian isolate of Leishmania infantum (historically known as
L. chagasi) [5] has demonstrated high levels of sensitivity in South
Asia but is less effective in East Africa for diagnosis of VL [6,7]. A
new ICT, based on the synthetic gene rK28, has recently been
developed to overcome these limitations [8,9], and is currently
under evaluation. Underlying explanatory factors for the different
levels of rK39 diagnostic success observed across geographical
regions may be molecular divergence between East African L.
donovani kinesin gene homologues and the Brazilian L. infantum (L.
chagasi)-derived rK39 sequence [10], and/or may be due to
quantitative differences in the IgG titres generated against the
rK39 antigen between South Asian and East African VL-endemic
populations. Here, we compare anti-L. donovani IgG titres in cases
of active VL in children and adults of each sex from India and
Sudan against whole cell lysates of L. donovani strains from both
countries. We find striking differences between the anti-Leishmania
IgG titres of the two human populations.
Methods
Ethics statement
In India, comparative serology was approved by the Ethics
Committee of the Banaras Hindu University, Varanasi, India. In
Sudan the protocols were approved by the Ethical Research
Committee, Faculty of Medicine, University of Khartoum and the
National Health Research Ethics Committee, Federal Ministry of
Health. Written informed consent was obtained from all adult
subjects included in the study, or from the parents or guardians of
individuals less than 18 years of age. This research was also
covered by the London School of Hygiene and Tropical Medicine
Ethics Committee approval of the EC NIDIAG project.
Study populations
Sudan: plasma samples were obtained upon clinical presenta-
tion from active cases of VL in the Gedaref region in eastern
Sudan between July and September 2011. Patients were diagnosed
as positive for VL by a combination of bone marrow aspiration,
lymph node aspiration, or serology. India: plasma samples were
obtained upon clinical presentation from active cases of VL in
Bihar state, north-eastern India after 2009. Active VL patients
were diagnosed by identification of parasitologically-positive
splenic aspirates. All samples in Sudan were transported by
continuous cold chain with samples maintained at 4uC, to the
research laboratory at Suba University Hospital and there stored
at 280uC; similarly all samples in India were cold chain
transported at 4uC to the laboratory at Banaras Hindu University
and stored at 280uC.
Antigen preparation
Strains of L. donovani originating from Sudan (MHOM/SD/97/
LEM3458) and India (MHOM/IN/80/DD8) were cultured in
aMEM (Sigma, UK) supplemented as described [11]. Mid-to-late
log phase cultures were washed three times in phosphate-buffered
saline (PBS), followed by three cycles of flash-freezing in liquid
nitrogen and thawing in a cold water bath. Subsequently, cells
were subjected to three 30 sec 12-micron sonication cycles on ice
at 30 second intervals using a Soniprep 150 sonicator (MSE, UK).
Sonicates were centrifuged at 120006g for 1 min, and the
supernatant used as antigen. Protein concentrations in these
lysates were determined using the BCA Protein Assay kit (Fisher
Scientific, Loughborough, UK).
Anti-Leishmania donovani ELISA
The indirect L. donovani ELISA was performed using relatively
low antigen concentrations (0.2 mg/well) established by prior
ELISA checkerboard titrations (not shown), with the intention of
increasing ability to discriminate between patients generating high
and low IgG antibody responses. Lysates of the L. donovani DD8
(Indian) and LEM3458 (Sudanese) strains, diluted to 2 mg/ml in
35 mM NaHCO3/15 mM NaCO3 buffer (pH 9.6), were sepa-
rately added at 100 ml/well to 48 wells (A to H 1–6 or A to H
7–12) (see Figure 1) of Immulon 4HB ELISA plates (VWR,
Lutterworth, UK) and incubated overnight at 4uC. After washing
the plates three times using PBS containing 0.05% (vol/vol)
Tween 20 (Sigma, Gillingham, UK) (PBST), they were blocked
using 200 ml/well PBST containing 2% skimmed milk powder
(Premier International Foods, Spalding, UK) (PBSTM) at 37uC for
2 hr. After washing three times with PBST, serial four-fold 1:400
to 1:25,600 dilutions of VL plasma samples (Table 1, Figure 1)
(100 ml/well) in PBSTM were added to the plates and incubated at
37uC for 1 hr. Plasma samples from the two endemic countries
were assayed on the same plate against antigens of both Indian
and Sudanese strains and were matched for sex and age groups as
shown in Figure 1. Following six PBST washes, a 1:5,000 dilution
of peroxidase-labelled goat anti-human IgG (H+L) (Jackson
ImmunoResearch, West Grove, USA) prepared in PBSTM was
added at 100 ml/well and the plates incubated at 37uC for 1 hr.
Following six PBST washes, 50 mM phosphate/citrate buffer
(pH 5.0) containing 2 mM o-phenylenediamine HCl and 0.007%
(vol/vol) H2O2 (Sigma, UK) was added at 100 ml/well and
incubated in the dark at room temperature for 15 minutes. The
substrate reactions were then stopped by the addition of 2 M
H2SO4 (50 ml/well) and the ELISA plates were read at 490 nm
(Spectra Max 190, Molecular Devices, Sunnyvale, USA). Coeffi-
cients of variation (mean positive control readings (n = 4)/standard
deviation of positive control x 100) at dilutions of 1/400 and
1/1600 were calculated from simultaneous duplicate plates for
both Indian and Sudanese sera (most coefficients of variation were
less than 1%). Reference positive plasma controls were also used
on every plate (Figure 1). Samples that gave coefficients of
Author Summary
Visceral leishmaniasis (VL) is a systemic disease with
highest prevalence in South Asia, East Africa, and Brazil.
VL is caused by protozoan parasites of the Leishmania
donovani complex, transmitted to humans when an
infected sandfly takes a bloodmeal. Within the human
host, the parasites replicate within cells, particularly of
bone marrow and spleen. Without effective treatment,
symptomatic VL is usually fatal. Correct treatment depends
on accurate diagnosis, which is by detection of parasites or
specific antibodies. The rK39 rapid diagnostic test for
antibody is highly sensitive in South Asia but less so in East
Africa, for poorly understood reasons. Here, we have
directly compared the anti-Leishmania antibody response
in groups of VL patients from India and Sudan. We found a
strikingly higher anti-Leishmania antibody response in
Indian compared to Sudanese patients, which was also
seen when further analysed by age and sex of the patients.
Thus in addition to parasite factors, we have shown that
difference in antibody levels may contribute to the lower
sensitivity of antibody-based diagnosis for VL in Sudan.
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variation above 20% were repeated. Representative plasma
samples from Indian and Sudanese endemic healthy controls
and from cases of active VL were used as inter-assay controls.
These plasma samples were chosen in preliminary assays as having
median responses against the lysate obtained from the L. donovani
strain isolated from the corresponding region (data not shown). To
Figure 1. Design of assay for comparative ELISA serology. Serial four-fold dilutions of plasma samples from Indian and Sudanese VL patients
were reacted with whole cell lysates of L. donovani strains isolated from each country. Identically formatted plates were run in all cases. Unlabelled
wells were not used.
doi:10.1371/journal.pntd.0002675.g001
Table 1. Indian and Sudanese plasma study populations used in comparative serology against Leishmania donovani antigens.
Endemic region Sex Age (years) n Mean age in years (range; standard deviation)
India (n = 36) Male $16 10 33.4 (16–70; 17.45)
,16 8 12.8 (10–15; 1.67)
Female $16 8 30.5 (17–52; 12.22)
,16 10 12.8 (9–15; 2.20)
Sudan (n = 36) Male $16 10 22.2 (16–43; 9.17)
,16 8 9.8 (4–15; 4.1)
Female $16 7 35.6 (25–60; 12.35)
,16 11 8.1 (1–15; 4.55)
Total n = 72
doi:10.1371/journal.pntd.0002675.t001
Lower IgG Responses in Sudanese versus Indian VL
PLOS Neglected Tropical Diseases | www.plosntds.org 3 February 2014 | Volume 8 | Issue 2 | e2675
maximize the chances of identifying differences in the IgG
responses against the two different L. donovani strains (Figure 2)
and between Indian and Sudanese VL patients of each sex and age
group ($ or,16 years old), the highest mean absorbance (Absmax)
value was determined for each data set, from which the Absmax/2
was determined for calculating the mean reciprocal log10 50%
end-point (1/log10t50) ELISA titres. This methodology has been
recommended for comparisons between high, low and non-
classical IgG responses of acute and convalescent phase samples
from both individuals and patient groups infected with another
pathogen [12,13]. This approach is more accurate than deter-
mining ELISA titres as either: i) single end-point values located on
the very trailing slope of the ELISA sigmoid curve (e.g. values that
are 2 standard deviations above the mean obtained using negative
control sera) or ii) the mean absorbance values obtained using
single serum dilutions (e.g. 1/100) [12]. In the latter case, the
limited use of absorbance values results in a low dynamic range of
data for comparisons [12].
Statistical analyses
Two sided independent sample t-tests were used to analyse the
data (SPSS INC. Armonk, NY: IBM Corp). Normality was
assessed using a three tiered approach. Shapiro-Wilk tests were
conducted first with subsequent evaluation of the data through
visual assessment and by calculating a z-score for skewness
(ZSkewness = Skewness-0/SE Skewness) as proposed by Ghasemi and
Zahediasl [14]. In the event of a violation of the assumption of
homogeneity of variance (homscedasticity), SPSS calculated a
corrected p value. Significance was set at the 5% level.
Results
Table 1 summarises the age and sex compositions of the Indian
and Sudanese VL patients who provided plasma for comparisons
of serological responses between the two endemic regions.
Comparison of Indian and Sudanese IgG isotype
responses
The mean overall Sudanese (n = 36) and Indian (n= 36) active
VL patients’ IgG responses, at each plasma dilution, against lysates
of L. donovani strains isolated from each endemic area, with 95%
confidence intervals (CIs) are shown in Figure 2. In a few
instances, the unforeseen low Sudanese titres required minor
extrapolation of curves to determine specific 1/log1050% end-
point titres but since homoscedasticity was obtained in each case a
correction factor was not required. Similar high mean maximum
absorbance (Absmax) values were obtained for the Indian VL
patients against both the Indian and Sudanese L. donovani strains.
However the Indian VL patients showed significantly higher IgG
titres against both the Sudanese (mean 1/log10t50: 3.88) and
Indian (mean 1/log10t50: 3.80) L. donovani strains than the
Sudanese VL patients (mean 1/log10t50: 2.09 and 2.13 respective-
ly) (Figure 2A and B, Table 2; two-sided independent sample
t-tests for both L. donovani strains: p,0.0001). Thus, overall the
Indian VL patients generated 46.8–61.7-fold higher IgG titres
than the Sudanese patients against the L. donovani strains (Table 2).
We further assessed whether there were differences in anti-L.
donovani IgG titres generated by the male and female Indian and
Sudanese VL patients of less than or greater than 16 years old
against both L. donovani strains. We again used the mean highest
absorbance (Absmax) value for each data set (Figure 3A to D) to
maximize the identification of differences in the mean IgG
responses, from which the Absmax/2 value was determined for
interpolating the mean 1/log10t50 IgG ELISA titres. We observed
that the male VL patients of $16 years old from India showed
higher Absmax values against both the Sudanese (Absmax 3.34) and
Indian (Absmax 3.33) antigens than the female Indian VL patients
of the same age group (Absmax 3.11 and 2.99, respectively)
(Figure 3C and D). This difference was less in the male and female
Indian VL patients of ,16 years old (Figure 3A and B).
Importantly, the Sudanese male and female children (,16 years
Figure 2. IgG anti-Leishmania responses are higher in Indian than Sudanese VL patients. The mean IgG responses are shown with 95% CI,
for 36 Indian (purple line with nodes) and 36 Sudanese (green line) patients with active VL, against lysates of L. donovani strains isolated from [A] India
or [B] Sudan. Comparative mean 1/log10t50 IgG titres and fold-differences are shown in Table 2. Statistical p values of,0.0001 were obtained for both
the Indian and Sudanese antigens.
doi:10.1371/journal.pntd.0002675.g002
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old) and adults all generated lower mean IgG ELISA titres against
both L. donovani strains than the corresponding Indian VL patient
sex/age groups (Figure 3A to D). These differences ranged from
11.5 to 144-fold (Table 2).
The Sudanese male VL patients less than 16 years old showed
the lowest fold-differences compared to the Indian male VL
patients of the same age group (12.9-fold and 11.5-fold against
Sudanese and Indian antigen respectively). In contrast, the
Sudanese male VL patients older than 16 years showed the
highest fold-difference with the Indian male patients of the same
age group (144-fold).
Discussion
According to a recent report from the World Health Organi-
sation, among the research priorities for human diseases caused by
infection with kinetoplastid protozoa is research on diagnostics for
case detection and characterisation [15]. For many years, the
rK39 antigen has been the only rapid diagnostic ICT in a lateral
flow system that is readily applicable for field diagnosis of VL and
that can be used with minimal training with no other equipment
or reagent. Despite high levels of sensitivity in South Asia, the
rK39 ICT has shown lower efficacy in East Africa, for reasons that
are not fully understood. The recent rK28 ICT, based on 2639
amino acid repeats of a Sudanese L. donovani-derived kinesin
homologue of rK39, flanked by HASPB sequences, has been
developed in an attempt to overcome the differential sensitivity of
rK39. Reduced efficacy in East Africa has also been reported for a
diagnostic test using another L. donovani antigen, rKE16 [7].
Different sensitivities of the rK39 ICT in South Asia and East
Africa may be explained by molecular divergence in diagnostic
antigen sequences of geographically disparate L. donovani strains
and/or reflect the different levels of overall IgG anti-Leishmania
response between human populations in VL endemic areas. We
have assessed the first of these factors, and demonstrated
substantial and regional specific antigen diversity [10], an
observation subsequently reported by others [16].
Differential serological responses among different ethnic groups
within the same geographical region have been reported
previously, for both bacterial and protozoal pathogens, although
generally without understanding of the genetic/biological expla-
nations. Higher responses were found against: Helicobacter pylori in
non-Japanese Brazilians than Japanese Brazilians [17]; Streptococcus
pyogenes superantigen in Polynesian than New Zealand Europeans
[18]; Plasmodium falciparum in Fulani than sympatric ethnic groups
in Burkina Faso [19]; P. falciparum in Austro-Asiatic than Tibeto-
Burman groups in north-east India [20]. Jensen et al [21] reported
comparatively higher anti-Plasmodium titres in subjects from Flores
(Indonesia) than in counterparts from southern Sudan. In the UK,
higher IgG levels were found in South Asian patients compared to
European counterparts in the context of cardiovascular disease
[22].
Here, we used comparative analysis of serological responses, as
applied elsewhere [12,13] to assess accurately differences in IgG
titres between VL patient cohorts from Bihar (India) and Gedaref
(Sudan). We have clearly shown that active VL patients from India
generated significantly higher anti-L. donovani IgG responses
against whole cell lysates of both Indian and Sudanese parasite
strains than active VL patients from Sudan. This may contribute
to the reduced sensitivity of the commercial rK39 ICT assay with
Sudanese versus Indian VL patients. We used soluble antigens
from Leishmania whole cell lysates in the comparative ELISAs. On
western blots human VL serum antibodies recognise multiple
antigens in such lysate preparations (data not shown). It is
therefore likely that Sudanese patients with active VL had reduced
IgG titres against several L. donovani promastigote antigens; we
have not yet determined whether the response to particular
antigens is depleted. Thus, it may be challenging to identify L.
donovani antigens that provide adequately high sensitivity and
specificity for East Africa. Whilst it would be of interest to extend
these comparisons to include IFAT, results from ELISA and IFAT
generally accord, and we therefore anticipate that the two tests will
give compatible data [23]. Detection of antigens in urine may
provide an alternative, non invasive approach, possibly giving
prognostic information [24,25]. In the same multi-centre trial
comparing rK39 dipstick sensitivity and specificity across South
Asia and East Africa, Boelaert et al. [6] also compared the KAtexH
test, which detects a Leishmania carbohydrate antigen in urine
Table 2. Mean reciprocal ELISA titres and fold differences of Indian and Sudanese VL patients by age, sex and antigen source.
Mean reciprocal 50% end-point titre
(1/log10t50) interpolated
from Absmax/2
Figure Sex Age
Antigen
source
Indian
plasma
Sudanese
plasma Fold difference p value (95% CI) p value (95% CI)
(Indian-Sudanese) Sex: M or F Both Sexes
2A Both All Sudan 3.88 2.09 61.7 - p,0.0001 (1.35–2.24)
2B Both All India 3.80 2.13 46.8 - p,0.0001 (1.29–2.06)
3A M ,16 Sudan 3.63 2.52 12.9 p,0.007 (0.356–1.87) p,0.0001 (0.929–2.21)
F ,16 Sudan 3.78 1.88 79.4 p,0.001 (0.898–2.91)
3B M ,16 India 3.60 2.54 11.5 p,0.004 (0.385–1.73) p,0.0001 (0.90–2.03)
F ,16 India 3.69 1.92 58.9 p,0.001 (0.883–2.66)
3C M $16 Sudan 4.15 1.99 144 p,0.0001 (1.45–2.87) p,0.0001 (1.38–2.67)
F $16 Sudan 3.95 2.09 72.4 p,0.02 (0.388–3.33)
3D M $16 India 4.03 2.02 102 p,0.0001 (1.53–2.48) p,0.0001 (1.36–2.40)
F $16 India 3.84 2.13 51.3 p,0.008 (0.539–2.89)
doi:10.1371/journal.pntd.0002675.t002
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[26,27]. Sensitivities in both regions were described as moderate to
very low, with the lowest in India and Nepal, although higher
sensitivities have been recently reported from Bangladeshi studies
[28–30].
We have not yet assessed antibody levels in patients with post-
kala azar dermal leishmaniasis (PKDL). This is of interest because
PKDL is a sequela of VL that displays markedly different
epidemiological features between regions, in Sudan occurring at
a higher frequency (.50%) and much sooner after VL than in
India (,10%) [31]. In Sudan and India the plasma was collected
at time of clinical presentation of VL and no obvious differences in
symptoms between the two cohorts were observed; further
comparisons would benefit from more precise grading of clinical
severity.
Whilst the active VL patient numbers used in our analysis were
relatively low, Indian males $16 years old with active VL
generated higher IgG responses than females of the same age
group, whereas Sudanese male VL patients $16 years old
generated lower IgG responses than females of the same age
group. These trends were not apparent in Indian or Sudanese
patients,16 years old. Differences in infection between males and
females in late teenage years and in adults may be attributable to
increased susceptibility of young and adult men [32]; testosterone
increases L. donovani infection in macrophages [33]. In Sudan VL is
a disease of extreme poverty with high incidence associated with
chronic malnutrition, displacement of populations and lack of
health care [1,34–39]. Particular ethnic groups, possibly with
greater genetic susceptibility, may be more affected within the
ethnically mixed Sudanese population [40,41].
Malnutrition is known to reduce both human innate and
acquired immune responses against parasitic diseases such as VL
[42,43]. Experimental models of protein, zinc and iron malnutri-
tion have shown reduced immune responses in L. infantum infected
mice and increased early visceralisation [44,45]. Of these, even
mild zinc deficiency has been extensively reported to: i) reduce T-
and B -cells in the blood and lymphoid tissues of humans, non-
human primates and other animals, ii) dramatically reduce both
T- and B- cell numbers in the bone marrow by .75%, iii)
dramatically reduced B-cell IgG production, particularly to T-
dependent antigens, by 90% and iv) reduce both T- and B- cell
proliferation, resulting in depletion through apoptosis [46]. More
specifically, zinc deficiency in mice was shown to block the
Figure 3. IgG anti-Leishmania responses are higher in Indian VL regardless of age, sex or antigen source. The mean IgG responses and
95% CI are shown for Indian (purple and orange lines) and Sudanese (blue and green lines) active VL patients against lysates of L. donovani strains
isolated from Sudan [A & C] or India [B & D]. Comparative mean 1/log10t50 IgG titres and fold-differences are given in Table 2.
doi:10.1371/journal.pntd.0002675.g003
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development of bone-marrow pre-B and immature B-cells,
resulting in reduced B lymphocytes in the spleen; pre-natal zinc
deficiency in monkeys and mice reduced lymphocyte numbers and
IgG concentrations and produced long-term suppression of IgM,
IgA and IgG. Zinc deficiency in mice also resulted in reduced B-
cell responses to recall antigens with which they had previously
been inoculated, thereby suggesting that T- and B- cell depletion
resulted in impaired immunological memory [46]. Thus, malnu-
trition with zinc deficiency, even if relatively mild and previously
encountered may play an important role in the significantly lower
IgG titres of the Sudanese patients.
Human interleukin-2 (IL-2) and signalling through its receptor
(IL-2R) play a critical role in both T- and B-cell proliferation and
induce the expression of the IL-2Ra gene in B cells, thereby
increasing B-cell responses to IL-2, antibody heavy and light chain
expression and antibody secretion [47]. Thus, single nucleotide
polymorphisms in the genes encoding IL-2 and its receptor (IL-
2Ra or IL-2Rb) chains significantly affect human IgG titres in
response to both inactivated and live attenuated vaccines (e.g. the
live attenuated measles-mumps-rubella (MMR) vaccine) [48,49].
While there have not been similar studies performed on Sudanese
populations, VL patients in eastern Sudan had a significant
association with two SNPs in the IL-2Rb gene, one of which
encoded a non-conserved amino acid substitution (G245R) in the
proximal membrane domain that was very likely to affect IL-2
signalling [50]. Thus, these SNPs and others located in the genes
that affect IL-2 expression, function and responses may have
contributed to the reduced IgG responses of Sudanese VL patients
observed in our study.
Human leukocyte antigen (HLA) polymorphisms in the genes
encoding the MHC class II (HLA-DR, -DP and -DQ) molecules
are known to have significant effects on IgG responses to vaccines
[48], infectious diseases, cancer, asthma and autoimmune diseases
[51–53]. Early studies did not however find a significant
association of HLA class II polymorphisms in VL patients in
either Tunisia or Brazil [54,55]. By contrast, in a more recent
study performed using VL patients’ samples from Brazil and India,
HLA-DRB1 and HLA-DQA1 were the only genes associated with
VL risk in both populations [56] but comparisons of anti-
L. donovani IgG titres between these groups or the control groups
were not performed. Since no similar HLA studies have been
performed on Sudanese VL patients, it is presently not yet known
whether polymorphisms in these genes may have contributed to
the significantly lower IgG titres observed in the Sudanese versus
Indian VL patients found in our study.
Thus, the significant differences in the anti-L. donovani IgG titres
found here between the Indian and Sudanese VL patients in this
study may result from a combination of environmental and genetic
factors, in which malnutrition with Zn2+ deficiency, differences in
IL-2 responses due to polymorphisms in IL-2 and its receptor
(IL-2Ra and IL-2Rb) genes and possibly HLA-DRB1 and HLA-
DQA1 genes are to date the most likely candidates.
We have presented here a direct ELISA comparison of
serological responses between VL patients from different endemic
regions (Sudan and India), and have shown a clear difference in
the levels of IgG anti-Leishmania antibodies. Comparative serolog-
ical responses could also be extended to samples from Brazilian
cases of VL to investigate their contribution to reported lower
sensitivity with rK39-based ICTs [7], despite this diagnostic
antigen being derived from a Brazilian L. infantum (L. chagasi),
dispersed from Iberian Europe [57]. Our data suggest that the
relative levels of ability to mount a humoral response against
Leishmania antigen between the different human populations may
be a significant contributory factor in the differing levels of
sensitivity reported for rapid diagnostic tests applied in both
regions, and argue for the design and development of a test more
suited to East Africa, guided by comparative genomics [10].
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Bowes DE, Thunissen C, Singh OP , Kumar R, Ahmed O, Eisa O, Saad A, Pereira SS, Boelaert 
M, Mertens P, Miles MA. IgG1 as a potential biomarker of post-chemotherapeutic relapse in 
visceral leishmaniasis, and adaptation to a rapid diagnostic test. PLoS Negl Trop Dis 8 e3273 
Key points, novel results and implications 
 Current definitions of successful cure following chemotherapy for visceral 
leishmaniasis are based on clinical definitions. The identification of biomarkers which 
can indicate therapeutic outcome (cure or relapse), especially in the form of a point-
of-care rapid assay, has been listed by WHO as a knowledge gap and research 
priority (WHO, 2012)  
 Here, the association of IgG subclass with clinical status in VL was investigated by 
ELISA using Indian and Sudanese samples, initally from unpaired samples from pre-
treatment patients, those deemed cured after therapy, and those deemed relapsed. 
Levels of IgG1 (and to a lesser degree IgG3) were elevated in the pre-treatment and 
relapsed groups, compared to cured (p<0.0001). 
 When using paired pre- and post-treatment samples from patients considered cured, 
the decrease in IgG1 was not significant in the immediate few weeks following 
treatment, but was greatly diminished in the 6-month post treatment samples in 
cohorts compared to day 0 (p = 0.0032) or day 15 (p<0.0001). 
 Two prototype lateral flow immunochromatographic RDTs were developed to detect 
IgG1 levels following VL treatment: more than 80% of the relapsed VL patients were 
IgG1 positive; at least 80% of the cured VL patients were IgG1 negative (p <0.0001). 
 Thus this work demonstrated that six months after treatment of active VL, elevated 
levels of specific IgG1 were associated with treatment failure and relapse, whereas 
no IgG1 or low levels were detected in cured VL patients. A lateral flow RDT was 
successfully developed to detect anti-VL IgG1 levels as a potential biomarker of post-
chemotherapeutic relapse. 
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Abstract
Background: Visceral leishmaniasis (VL), caused by protozoa of the Leishmania donovani complex, is a widespread parasitic
disease of great public health importance; without effective chemotherapy symptomatic VL is usually fatal. Distinction of
asymptomatic carriage from progressive disease and the prediction of relapse following treatment are hampered by the
lack of prognostic biomarkers for use at point of care.
Methodology/Principal Findings: All IgG subclass and IgG isotype antibody levels were determined using unpaired serum
samples from Indian and Sudanese patients with differing clinical status of VL, which included pre-treatment active VL, post-
treatment cured, post-treatment relapsed, and post kala-azar dermal leishmaniasis (PKDL), as well as seropositive (DAT and/
or rK39) endemic healthy controls (EHCs) and seronegative EHCs. L. donovani antigen-specific IgG1 levels were significantly
elevated in relapsed versus cured VL patients (p,0.0001). Using paired Indian VL sera, consistent with the known IgG1 half-
life, IgG1 levels had not decreased significantly at day 30 after the start of treatment (p = 0.8304), but were dramatically
decreased by 6 months compared to day 0 (p = 0.0032) or day 15 (p,0.0001) after start of treatment. Similarly, Sudanese
sera taken soon after treatment did not show a significant change in the IgG1 levels (p = 0.3939). Two prototype lateral flow
immunochromatographic rapid diagnostic tests (RDTs) were developed to detect IgG1 levels following VL treatment: more
than 80% of the relapsed VL patients were IgG1 positive; at least 80% of the cured VL patients were IgG1 negative (p,
0.0001).
Conclusions/Significance: Six months after treatment of active VL, elevated levels of specific IgG1 were associated with
treatment failure and relapse, whereas no IgG1 or low levels were detected in cured VL patients. A lateral flow RDT was
successfully developed to detect anti-Leishmania IgG1 as a potential biomarker of post-chemotherapeutic relapse.
Citation: Bhattacharyya T, Ayandeh A, Falconar AK, Sundar S, El-Safi S, et al. (2014) IgG1 as a Potential Biomarker of Post-chemotherapeutic Relapse in Visceral
Leishmaniasis, and Adaptation to a Rapid Diagnostic Test. PLoS Negl Trop Dis 8(10): e3273. doi:10.1371/journal.pntd.0003273
Editor: Albert Picado, Barcelona Centre for International Health Research (CRESIB), Spain
Received June 29, 2014; Accepted September 14, 2014; Published October 23, 2014
Copyright:  2014 Bhattacharyya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work is part of the NIDIAG network research partnership supported by the European Commission under the Health Cooperation Work Programme
of the 7th Framework Programme (Grant agreement no. 260260, http://cordis.europa.eu/fp7/home_en.html). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: The design of the lateral flow
rapid diagnostic tests was performed as a research collaboration with Pascal Mertens and Caroline Thunissen of the company Coris BioConcept, Belgium, without
payment; none of the authors have any financial, non-financial, professional or personal conflicting interests. This collaboration does not alter our adherence to all
PLOS NTDs policies on shared data and materials.
* Email: Tapan.Bhattacharyya@lshtm.ac.uk
Introduction
The leishmaniases are widespread neglected infectious diseases
of major public health importance, caused by protozoan parasites
of the Leishmania (Leishmania) and Leishmania (Viannia)
subgenera. There are two principal symptomatic clinical presen-
tations of leishmaniasis: a) visceral (kala-azar, VL) caused by the
Leishmania donovani complex, with circa 400,000 cases per year
[1], which without appropriate chemotherapy is usually fatal, and
b) cutaneous (CL) caused by diverse Leishmania species, some of
which may give rise to diffuse cutaneous leishmaniasis (DCL) or
metastatic mucocutaneous disease (MCL), the latter with devas-
tating destruction of the nasopharynx [2]. The effective clinical
management, chemotherapy and control of transmission of VL are
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largely dependent on early and unequivocal diagnosis. Given that
many VL patients live below the poverty threshold in remote areas
poorly serviced by the health system, the diagnostic tools should be
ASSURED (Affordable, Sensitive, Specific, User Friendly, Rapid,
Equipment free and Deliverable where needed) [3]. The most
sensitive and specific method to detect the causative agent of VL is
microscopic examination of (invasive) spleen aspirates; bone
marrow and lymph node aspirates provide similar high specificity
but lesser sensitivity. More user-friendly point-of-care (POC)
diagnostics have been developed based on antibody detection
against rK39 and these provide high diagnostic accuracy in
suspected first-time episodes of VL when combined with a clinical
case definition [4–6]. However, these rapid diagnostic tests based
on antibody detection are unable by themselves to distinguish
asymptomatic carriers from those who will progress to acute fatal
disease, and following chemotherapy they remain positive for
many months precluding the detection of any relapse. To resolve
the limitations of current diagnostic tools higher resolution, non-
invasive, rapid and affordable POC tests are thus needed that
define clinical status and indicate prognosis.
Current serological tests for VL include the enzyme linked
immunosorbent assay (ELISA) with either crude or purified
Leishmania promastigote antigens, the direct agglutination test
(DAT) or indirect immunofluorescence test (IFAT) [7,8]. Each of
these tests has disadvantages: the ELISA requires laboratory
facilities and technical training; the DAT test has limited
commercial access and involves several hours or overnight
incubation before reading the results, and the IFAT uses a costly
fluorescence microscope.
The recombinant repetitive antigen rK39, a product of the
Leishmania kinesin-like gene, which was first cloned from
Brazilian Leishmania infantum (synonym L. chagasi) [9] has been
adapted to an immunochromatographic, lateral flow format and
applied extensively as a rapid diagnostic test (RDT) for VL.
However, in multicentre trials rK39 had much higher sensitivity in
South Asia than in East Africa [10,11]. This could be due to the
geographical diversity in the 6.5 repeats within the rK39 antigen
sequence [12] and/or regional differences in anti-Leishmania IgG
titres between the different human populations [13]. A modified
recombinant derivative of rK39, designated rK28, which incor-
porated the first two rK39 repeats of a Sudanese kinesin flanked by
HASPB1 and HAPB2 repeats, improved serological sensitivity for
East African VL patients [14]. The ELISA, DAT, IFAT, rK39
and rK28 serological tests all rely on the detection of anti-L.
donovani complex IgG. In human VL the IgG is produced
secondarily, after IgM. IgG is divided into IgG1, IgG2, IgG3, and
IgG4 subclasses, according to their ranked relative abundance in
normal serum [15]. In general, human IgG1 and IgG3 are
generated in response to protein antigens, whilst IgG2 and IgG4
are instead predominantly produced in response to polysaccharide
antigens [15]. Previous studies on the humoral responses during
active VL and after treatment, and on post kala-azar dermal
leishmaniasis (PKDL), have been performed using samples from
multiple endemic regions and a variety of serological tests [16–31].
Several of these studies, almost all of which used ELISAs, assessed
anti-L. donovani complex titres of IgG, its subclasses and other Ig
isotypes. In terms of IgG subclasses, increased IgG1 titres were
identified in active disease (VL or PKDL) compared to healthy
controls, and reduced IgG1 titres were reported after successful
VL treatment. This published work suggested that the dynamics
between proportionate IgG subclass responses and the clinical
status of patients warranted further investigation to search for
prognostic VL biomarkers.
A recent WHO report [8] designated the development of new
diagnostics to determine cure as a research priority for VL, and
there is an additional need for biomarkers to distinguish
asymptomatic non-progressors from early progressive VL. Here
we explore the potential of differential IgG subclass profiles to
provide a biomarker for patients who relapsed after chemotherapy
and therefore require urgent follow-up and life-saving additional
or alternative chemotherapy. We show that the dynamics and
levels of specific IgG1 responses can be indicative of relapse, and
can be assessed using a simple, lateral flow immunochromato-
graphic RDT format.
Methods
Ethics statement
In India, research on comparative serology and the collection of
all serum or plasma samples was approved by the Ethics
Committee of the Banaras Hindu University, Varanasi. Similarly,
in Sudan research and collection of serum samples was approved
by the Ethical Research Committee, Faculty of Medicine,
University of Khartoum and the National Health Research Ethics
Committee, Federal Ministry of Health. Written informed consent
was obtained from all adult subjects included in the study or from
the parents or guardians of individuals less than 18 years of age.
This research was also approved, as part of the NIDIAG project,
by the London School of Hygiene and Tropical Medicine Ethics
Committee.
Sources of sera/plasma
Indian plasma samples were collected after 2007 from active
VL, cured, relapsed, PKDL and asymptomatic groups from the
endemic region of Muzaffarpur, Bihar state, north-eastern India,
and control subjects from a region where VL is not endemic. In
India active cases of VL were diagnosed parasitologically by
microscopy of splenic aspirates. Sudanese serum samples were
collected in 2011 and 2013, from active VL, treated, relapsed,
PKDL, and endemic controls in the Gedaref region in eastern
Sudan. All patients were HIV negative. Active cases of VL were
diagnosed by a combination of microscopy of bone marrow or
Author Summary
Visceral leishmaniasis (VL) is a systemic disease with
highest prevalence in South Asia, East Africa, and Brazil.
VL is caused by protozoan (unicellular) parasites of the
Leishmania donovani complex, transmitted to humans
when an infected sandfly takes a bloodmeal. Within the
human host, the parasites replicate within cells, particularly
of bone marrow and spleen. Without effective treatment,
symptomatic VL is usually fatal. As outlined in a recent
World Health Organisation report, the development of
new diagnostic tools to test for successful cure after
chemotherapy is a research priority. In this work we
investigated the association of clinical status of VL patients
(active pre-treatment, and those deemed cured or
relapsed post-treatment) with subclasses of the IgG
antibody response made to L. donovani infection. We
show that high levels of subclass IgG1 are found in pre-
treatment and relapsed patients, but are very much lower
in patients deemed to be cured. We further show that the
decrease in IgG1 is detectable in patients 6 months after
successful treatment, and that this detection method can
be adapted to a rapid diagnostic test format requiring
minimal technical expertise. Thus we believe that IgG1
levels are potentially a biomarker of post-chemotherapeu-
tic monitoring.
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lymph node aspirates in conjunction with serological assays. We
have previously observed that serum and plasma derived from the
same sample show no difference in titre in ELISA against L.
donovani lysate (unpublished observations).
Unpaired samples. Table 1 shows the numbers of samples
used in unpaired comparisons of IgG subclass responses and
clinical status. For the Indian samples, two sets of comparisons
were performed using these unpaired samples. There was an initial
pilot study (Trial 1), followed by an expanded investigation (Trial
2), using different samples in each case. For the Sudanese sera,
only one study was performed, after the Indian pilot serology.
Paired samples and multiple sequential samples. The
comparative dynamics of IgG subclass response were studied using
paired serum samples or, in the case of PKDL patients, several
sequential samples from individual patients. Sera had been
collected prospectively and the intervals between collections are
shown in Table 2. For the Indian patients samples were available
prior to treatment of active VL (day 0), paired with days 15, 30, or
approximately 180 after start of treatment, depending on the
patient. For Indian PKDL multiple sequential serum samples from
the same patient were available at days 0, 30, 60, and 180 or 360
(Table 2). Paired sera from Sudanese patients were taken prior to
treatment (day 0) and at the end of treatment lasting 11 days
(ambisome), 17 days (sodium stibogluconate (SSG)+paromomycin)
or 30 days (SSG alone).
Antigen preparation
L. donovani strain MHOM/IN/80/DD8 isolated from India,
and MHOM/SD/97/LEM3458 isolated from Sudan, were
cultured in aMEM (Sigma, UK) supplemented as described
[32]. Mid-to-late log phase promastigote cultures were washed
three times in phosphate-buffered saline (PBS), followed by three
cycles of flash-freezing in liquid nitrogen and thawing in a 26uC
water bath. Subsequently, these cells were subjected to three
30 seconds, 12-micron, sonication cycles on ice at 30 second
intervals using a Soniprep 150 sonicator (MSE, UK). Sonicates
were centrifuged at 120006 g for 1 minute at 4uC, and the
supernatants were used as antigen. Protein concentrations in these
lysates were determined using the BCA Protein Assay kit (Fisher
Scientific, Loughborough, UK).
ELISA
Lysates of L. donovani DD8 (for Indian samples) or LEM3458
(for Sudanese samples), diluted to 2 mg/ml in 35 mM NaHCO3/
15 mM NaCO3 buffer (pH 9.6), were added at 100 ml/well to
Immulon 4HBX ELISA plates (VWR, Lutterworth, UK) and
incubated overnight at 4uC. After washing the plates three times
using PBS containing 0.05% (vol/vol) Tween 20 (Sigma,
Gillingham, UK) (PBST), they were blocked using 200 ml/well
PBST containing 2% skimmed milk powder (Premier Interna-
tional Foods, Spalding, UK) (PBSTM) at 37uC for 2 hr. Following
three PBST washes, the human sera were added at 1:400 dilution
for the Indian sera or 1:100 dilution for the Sudanese sera, in
PBSTM, and the plates were incubated at 37uC for 1 hr. The
different sample concentrations were used due to the significantly
lower anti-Leishmania IgG response generated by the Sudanese
VL patients, as recently described [13]. Following six PBST
washes, 100 ml of horseradish peroxidase-conjugated subclass-
specific mouse monoclonal antibodies specific for human IgG1
(ab99774), IgG2 (ab99784), IgG3 (ab99829) or IgG4 (ab99817)
(Abcam, UK), diluted 1:5000 for the Indian sera or 1:1000 for the
Sudanese sera, in PBSTM, were added and plates were incubated
at 37uC for 1 hr.
T
a
b
le
1
.
Si
n
g
le
(u
n
p
ai
re
d
)
sa
m
p
le
s
u
se
d
in
Ig
G
su
b
cl
as
s
co
m
p
ar
is
o
n
s,
an
d
cl
in
ic
al
st
at
u
s
o
f
th
e
In
d
ia
n
an
d
Su
d
an
e
se
p
at
ie
n
t
g
ro
u
p
s.
V
L
p
a
ti
e
n
t
st
a
tu
s
C
o
n
tr
o
ls
U
n
p
a
ir
e
d
g
ro
u
p
A
ct
iv
e
C
u
re
d
R
e
la
p
se
d
T
re
a
te
d
a
P
K
D
L
O
th
e
r
d
is
e
a
se
s
E
H
C
(s
e
ro
p
o
si
ti
v
e
)
E
H
C
(s
e
ro
n
e
g
a
ti
v
e
)
T
ri
al
1
In
d
ia
2
0
2
1
1
9
-
-
2
0
-
2
0
T
ri
al
2
(E
xp
an
d
e
d
)
In
d
ia
4
6
2
8
3
5
-
2
4
2
8
2
8
3
2
T
ri
al
Su
d
an
4
7
-
-
2
2
2
3
-
3
0
1
2
EH
C
=
e
n
d
e
m
ic
h
e
al
th
y
co
n
tr
o
l;
P
K
D
L
=
p
o
st
ka
la
-a
za
r
d
e
rm
al
le
is
h
m
an
ia
si
s.
a
tr
e
at
e
d
,
n
o
t
in
re
ce
n
t
p
as
t,
b
u
t
ti
m
e
o
f
tr
e
at
m
e
n
t
u
n
kn
o
w
n
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
n
td
.0
0
0
3
2
7
3
.t
0
0
1
IgG1 as a Biomarker in VL
PLOS Neglected Tropical Diseases | www.plosntds.org 3 October 2014 | Volume 8 | Issue 10 | e3273
Human IgG isotype responses were determined using 100 ml/
well of a 1:5000 dilution for the Indian sera or 1:2500 dilution for
the Sudanese sera, of horseradish peroxidase–conjugated donkey
anti-human IgG secondary antibody (709-035-149: Jackson
ImmunoResearch, West Grove, USA) with incubation at 37uC
for 1 hr.
Following six PBST washes, 50 mM phosphate/citrate buffer
(pH 5.0) containing 2 mM o-phenylenediamine HCl and 0.007%
(vol/vol) H2O2 (Sigma, UK) was added at 100 ml/well and
incubated in the dark at room temperature for 15 minutes. The
substrate reactions were then stopped by the addition of 2M
H2SO4 (50 ml/well) and the ELISA plates were read at 490 nm
(Spectra Max 190, Molecular Devices, Sunnyvale, USA, or MRX
II, Dynex Technologies, Chantilly, USA). These assays were
performed on duplicate plates, simultaneously.
Statistical analyses
ELISAs cut-offs were determined by the mean values plus three
standard deviations obtained from the seronegative endemic
healthy control serum samples. Statistical analysis on ELISA data
(2-tailed unpaired t-test for unpaired samples, and paired t-test for
paired/sequential samples, with 95% confidence interval in both
cases) was performed using GraphPad Prism version 4.02 for
Windows (GraphPad Software, San Diego, California, USA).
Prototype L. donovani antigen-specific IgG1
immunochromatographic RDTs
The prototype lateral flow immunochromatographic tests
consisted of a cassette with a nitrocellulose membrane, a sample
pad, a conjugate pad and an absorbent pad, backed with a plastic
strip. The nitrocellulose membranes were sensitized with crude L.
donovani (strain LEM3458) antigen lysate produced as described
above and anti-human IgG1-specific antibody labelled with
colloidal gold was dried on the conjugate pad. This strip was
housed in a plastic cassette with two windows: the application well
and the test/reading window. Two prototypes of this assay were
developed and tested. For prototype 1, 2 ml of serum and 2 ml of
buffer were added to the nitrocellulose strip and then 90 ml of
buffer was added to the application well. In prototype 2, the
application of 2 ml of serum on the strip was followed by the
addition of 75 ml of buffer in the application well. The human IgG
that migrated over the nitrocellulose membrane reacted with the
immobilized target antigens. The anti-human IgG1-specific
conjugated MAbs rehydrated by the buffer recognised the
antigen-bound human IgG1 in the sample, thereby resulting in a
red-purple coloured band. A control line ensured that the human
IgG and conjugated anti-human IgG1 migration had occurred
successfully. The prototype tests were used with sets of post-
chemotherapeutic sera from Indian patients considered to have
relapsed VL (n= 30 for prototype 1, of which 22 were also used
with prototype 2) or cured VL (n = 21 for prototype 1, of which 5
were also used with prototype 2). Fisher’s exact 2-tailed test was
used for testing the difference between proportions.
Results
The IgG1 subclass responses gave discrete separations between
cured versus active VL and relapsed VL (Figure 1A and 1B). This
potential human IgG1 subclass association with clinical VL status
was therefore investigated further, in particular to determine
whether it could be suitable for development as a rapid (lateral
flow) diagnostic test (RDT) to detect relapsed VL patients at point
of care (POC). IgG isotype responses showed a similar trend to
IgG1; however as illustrated in Figure 2 (see below, paired
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samples) and already noted in the literature [33–37] this was less
apparent and was inconsistent.
In Indian VL IgG1 levels were high pre-treatment and in
relapse but were negative or substantially diminished in
cured VL patients
Figure 1A and Table S1 show the results of the initial pilot study
of IgG subclass in unpaired Indian VL patients with different
clinical status. There was marked elevation of IgG1 levels in active
(untreated) VL patients; IgG1 levels were dramatically reduced in
patients who were treated and considered to be cured by clinical
and parasitological assessments. Thus, 90.0% (18/20) pre-treat-
ment active VL patients were serologically positive, above the cut-
off value, whereas only 33.3% (7/22) patients considered to be
cured remained positive, all of whom had low IgG1 titres (p,
0.0001, cured VL versus active or relapsed VL; Figure 1A).
However, the IgG1 levels in the patients who were unsuccessfully
treated were high and at levels comparable to the group of patients
with active VL prior to treatment (p = 0.485; Figure 1A; Table
S1). This trend for IgG1 levels was partially mirrored by IgG3.
The IgG3 levels were however lower in the active VL patients
(IgG1: 90.0% positive: IgG3: 75.0% positive) and the relapsed VL
patients (IgG1: 84.2% positive: IgG3: 52.6% positive) patients and
47.4% (9/19) of these relapsed VL patients were IgG3 negative
(Figure 1A; Table S1). In comparison IgG2 profiles were very
weak (active VL: 5.0% positive; relapsed VL: 15.8% positive;
cured VL: 0.0% positive) and IgG4 levels were negative or at the
cut off boundary, except for one cured patient and one in the other
disease group (a meningitis patient) (Figure 1A).
An expanded study of Indian VL confirmed that elevated
IgG1 levels were a feature of relapse
Based on the initial study showing that elevated IgG levels were
a potential biomarker of Indian VL treatment failure and relapse,
a larger number of unpaired samples from Indian VL patients
were analysed, together with those from a post kala-azar dermal
leishmaniasis (PKDL) group, and from a group of patients who
were VL asymptomatic but all of whom had positive DAT and/or
rK39 serology. Since this second larger cohort was investigated
after the initial study (Trial 1), the results are presented separately
in Figure 1B, but were also incorporated into Table S1. In Trial 2
similar results were obtained to those in Trial 1, with 67.4%,
71.4% and 3.6% of the active VL, relapsed VL and cured VL
Figure 1. Specific IgG1 ELISA levels were high in active and relapsed VL but negative or substantially decreased in cured VL using
unpaired serum samples. [A] Indian VL pilot study (Trial 1). [B] Indian VL expanded study (Trial 2). [C] Sudanese VL. Mean and 95% CI are shown for
each data set (solid black lines); note the different Y axis scales. In each study set, the means plus three standard deviations obtained using DAT-
seronegative endemic healthy control (EHC) samples was used to calculate the cut-off value (dotted line) and p values of,0.05 were considered
significant.
doi:10.1371/journal.pntd.0003273.g001
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patients, respectively, being IgG1 positive (Figure 1B, Table S1). A
lower percentage of the cured VL patients were IgG1 positive in
Trial 2 compared to Trial 1 (Trial 1: 33.3% positive; Trial 2: 3.6%
positive), although the absolute readings for Trial 1 cured were low
and adjacent to cut-off borderline. IgG1 detection showed a much
greater sensitivity and specificity than IgG3. Thus amongst the
four IgG subclasses IgG1 was indicated for potentially identifying
VL Indian patients with relapse versus cure after chemotherapy.
Sudanese VL patients had reduced IgG1 levels after
treatment
Comparisons of Sudanese VL IgG subclass responses were
performed with unpaired sera from active VL, treated VL and
PKDL patients, as well as DAT-positive and DAT–negative
endemic healthy controls (Table S1), at 1:100 dilution to allow for
the overall lower IgG titres of Sudanese VL sera compared to
Indian sera [13]. A slightly lower percentage of the Sudanese
active VL patients (57.4%) had positive specific IgG1 levels
compared to the Indian patients (Trial 1: 90.0%; Trial 2: 67.4%),
but the treated Sudanese VL patients had low positive IgG1 levels
(4.6%) similar to the cured VL patients in the Indian Trial 2
(3.6%). Thus the IgG1 levels in Sudanese active VL and Sudanese
treated VL were significantly different (p,0.0001; Figure 1C,
Table S1).
Anti-L. donovani IgG1 levels were raised in Indian PKDL
IgG1 levels were elevated in Indian PKDL compared to cured
patients. Positivity rate was higher in Indian PKDL (Trial 2,
45.8%) than in Sudanese PKDL (4.3%), (Figures 1B and 1C,
Table S1), although overall antibody levels in Sudanese VL were
also lower, as we have reported previously [13].
In Indian VL, anti-L. donovani specific IgG1 levels
decreased in paired samples approximately 6 months
after successful treatment
Having determined that specific IgG1 levels were elevated in
single serum samples from cases of VL treatment failure but were
decreased in cured VL patients, we compared, for single
individuals, paired serum samples obtained prior to or at start of
Figure 2. IgG1 decrease following cured VL became more significant with time. [A] Indian paired samples group 1, day 0 and 30. [B] Indian
paired samples group 2, day 0 and 180. [C] Indian paired samples group 3, day 15 and 180. [D] Sudanese paired samples, day 0 and after treatment
lasting 11, 17 or 30 days. Empty and filled columns represent the earlier and later samples of each pair respectively. Comparison of column heights
allows the change in IgG1 level to be seen for each individual patient pre- and post–chemotherapy. For each data set represented in [A]–[D], paired
samples from individual patients are presented in the main graph, and in the insets the mean and 95% CI compiled from all patients in that data set
are shown for both IgG1 and IgG isotype. Mean plus three standard deviations of the results obtained using the seronegative endemic healthy
control samples was used to calculate each cut-off value (dotted line) and p values of,0.05 were considered significant (subclasses IgG2–4 were also
assayed but were not informative).
doi:10.1371/journal.pntd.0003273.g002
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treatment and again at subsequent particular times. As shown in
Table 2, for Indian VL paired samples from three Indian VL
groups were analysed: group 1: day 0 and 30, group 2: day 0 and
180 and group 3: day 15 and 180. L. donovani antigen-specific
IgG1 levels were not significantly reduced at 30 days after start of
treatment (group 1: p = 0.8304; Figure 2A) but were significantly
decreased at approximately 180 days after the start of therapy
(group 2: p = 0.0032; group 3: p,0.0001; Figures 2B and 2C,
respectively). In contrast, in Indian PKDL patients, a significant
decrease in specific IgG1 levels was not observed using the
sequential (day 0 to 30, 60, 180 or 360) samples (Table 2: groups
4–7).
In Sudanese VL specific IgG1 levels did not fall
immediately after the start of treatment
Assay of IgG1 levels with paired samples from treated Sudanese
VL patients (day 0 and 11, 17 or 30) showed that IgG1 subclass
responses do not fall precipitously immediately after start of
treatment (Figure 2D), as with Indian VL patients, which also
showed no rapid fall in IgG1 level shortly after start of treatment
(Figure 2A). However, with one exception, in which titre increased
(patient 16, Figure 2D) all Sudanese VL patients showed a non-
significant trend for titre to decrease slightly.
Prototype immunochromatographic rapid diagnostic
tests could detect specific IgG1 levels indicative of
relapsed VL
Two prototype immunochromatographic (lateral flow) RDTs
were designed (see Methods) and tested to determine whether they
could be used to discriminate between relapsed and cured VL
patients by the detection of L. donovani antigen-specific IgG1
levels. The results for some of these patients are shown in Figure 3.
As summarised in Table 3, most of the serum samples provided
clear positive IgG1 results for the relapsed VL patients. Thus with
prototype 1, 25 of 30 (83.3%) relapsed VL patients were positive
but only 4 of 21 (19.0%) cured VL patients. Similarly, with
prototype 2, 19 of 23 (82.6%) relapsed VL patients were positive
but only 1 of 5 (20%) cured patients (p,0.0001 for the prototypes
1 and 2 cumulative results, Fisher’s exact 2-tailed test). None of
these 5 cured patients tested with either prototype 1 or 2 gave
strong positive IgG1 signals. One of patients with malaria and no
diagnosed VL had detectable IgG1. Thus, these prototype L.
donovani antigen-specific IgG1 lateral flow assays could clearly
discriminate between most of the relapsed and cured VL patients.
Discussion
Diagnosis of VL is not straightforward: clinical symptoms may
overlap with other infectious diseases associated with fever
syndrome; parasitological methods of diagnosis are invasive and
have limited sensitivities. The currently recommended rK39-based
rapid diagnostic tests have their limitations as they cannot
distinguish systematically and reliably between the different
clinical phases of VL. A large Indian/Nepalese population study
reported an association between higher DAT and/or rK39 titres
and risk of progression from asymptomatic to symptomatic VL
[38]. Recent papers have studied asymptomatic (seropositive)
populations in Bangladesh [39] and elsewhere [40–42]. In
Bangladesh when assessing a patient cohort at 24 months follow-
up for VL disease development, discrepancies were found between
the molecular and serological tests [39]. In one long-term follow-
up of 55 rK39 seropositive asymptomatic cases in India 69%
developed VL and 31% remained asymptomatic [43]. However,
the proportion of L. donovani complex seropositive asymptomatic
individuals that progresses to symptomatic VL can be minor, and
varies between endemic regions, for example between 1: 2.4 in
Sudan [44], 4:1 in Kenya [45], 8:1 in Brazil [46], 4:1 in
Bangladesh [47], 8.9:1 in India and Nepal [48], and 50:1 in Spain
[49]. There is no rapid diagnostic test that determines which
asymptomatic carriers will progress to active VL. Nor is there a
rapid diagnostic test that is a biomarker of treatment failure and
relapse as opposed to cure after chemotherapy. Thus development
of such point of care tests has been identified by WHO as a
research priority [8].
We are by no means the first to investigate the dynamics of
antibody response in the different clinical phases and evolution of
VL. The persistence of detectable anti-Leishmania IgG years after
treatment, mainly using DAT and rK39, has been reported from
India [33,34], Brazil [35], and Sudan [36,37]. We are not the first
to mention that IgG subclass profiles may be associated with
clinical status. The evaluation of IgG subclasses has been applied
in other parasitic infections including echinococcosis [50–52],
toxoplasmosis [53,54], and malaria [55–57]. Table 4 summarises
Figure 3. RDT IgG1 prototypes show the ability to distinguish relapsed VL from cured VL. C=migration control line; T = test line. Black
dots indicate places where samples should be deposited: 2 ml serum in front of upper dot for prototype 1 or single dot in prototype 2, and 2 ml of
buffer in front of lower dot in prototype 1.
doi:10.1371/journal.pntd.0003273.g003
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previous published studies on IgG subclasses and clinical status of
VL.
Here, using comparative plate ELISAs and in the context of
previous literature, we have specifically examined the capacity of
anti-L. donovani IgG subclass antibodies to act as a biomarker of
therapeutic failure and relapse as opposed to cure. Furthermore,
and most importantly, we have shown that the biomarker can be
adapted to a lateral flow rapid diagnostic test suitable for use at
point of care.
We analysed the IgG subclass profiles of patients in India with
active VL and treated VL in comparison with asymptomatic
seropositives, PKDL cases, other infectious diseases and endemic
healthy controls. Future work could include a wider range of other
diseases, including fungal infections. In a pilot study, we saw a
remarkable decline in IgG1 levels in samples from unpaired Indian
patients who were treated six months previously and were
considered to be cured, so much so that the IgG1 titres for almost
all of the individual patients fell below the ELISA cut off value for
seropositivity (Figure 1A). IgG1 is produced in response to protein
antigens and its decline with cure is thus presumably due to
disappearance of the antigenic stimulus. A similar profile was to
some extent also seen with IgG3, although IgG3 was not
consistently raised above the cut-off in active VL. IgG2 levels
were low across all groups (Figure 1). The results were similar for
Sudan, in that there was a significantly lower level of IgG1 in non-
recently treated patients, in almost all cases to below ELISA cut-
off, compared to pre-treatment patients (p,0.0001; Figure 1C),
although overall IgG and subclass titres were much lower for
Sudanese active VL than Indian, as reported previously [13].
Other authors have referred to high IgG1 levels in active VL
compared to healthy controls, and a decrease in IgG1 following
successful therapy, as assessed by ELISA [17,21,23,29] or in one
case by flow cytometry [30].
To explore the timing of the decline in IgG1 levels following
successful chemotherapy of Indian VL we compared IgG1 ELISA
titres prior to treatment, shortly after the start of treatment or
approximately 180 days later, using paired Indian samples (groups
1–3, Table 2). At day 30 after start of treatment (group 1, Table 2)
decline in IgG1 was minimal and not significant (p = 0.8304;
Figure 2A), which is not surprising as the half life of human IgG1
is estimated to be around 21 days [58]. The slow decline in IgG1
shortly after treatment was confirmed with paired sera from
treated Sudanese patients who had active VL (p= 0.3939;
Table 2, Figure 2D).
We have not performed a western blot analysis with sera taken
at different time points after treatment to determine whether the
decrease in IgG1 titres relates to response to particular L.
donovani antigens. However, one published study comparing
western blot profiles using subclass specific conjugates and sera
taken before and after treatment reported a general decline in
band recognition and not the selective disappearance of bands
[26]. Here we have used antigen derived from cultured
promastigotes. However, in human VL the stage of the
Leishmania life cycle is the amastigote, and given access to
sufficient quantity of amastigote antigens it would be worthwhile to
repeat such a comparative western blot study with amastigotes and
subclass specific conjugates. In this way it might be possible to
identify and subsequently isolate a specific amastigote antigen(s)
applicable to determination of cure.
Recently decreases in IgG1 and IgG3 after cure [59] or post-
active disease scarring [60] have also been reported for Brazilian
cutaneous leishmaniasis (CL), and higher levels of these IgG
subclasses in Turkish patients with active CL compared to
endemic controls [61].
IgG subclass responses have been reported for experimental
murine models of Leishmania infection and for canine infections
with L. infantum, based on FccR binding [62]. For canine
leishmaniasis there are conflicting interpretations of IgG subclass
profiles, (reviewed in [63]), reportedly due to confusion in subclass
nomenclature of the commercial polyclonals used [63,64]. A
recent study has proposed improvement of comparative studies by
categorising canine IgG subclasses against function of their human
analogues [65].
The detection of VL relapse following unsuccessful chemother-
apy is of special importance because without effective treatment
symptomatic VL is considered to be almost invariably fatal. Thus,
if relapse is not recognized and followed up with repeated or
alternative treatment, patients, who are often relatively isolated in
rural endemic regions, will succumb to the disease. We were
therefore interested to examine the IgG subclass profiles in
unsuccessful treatment and relapse. Notably, IgG1 levels were
raised in patients who failed to respond to chemotherapy and were
considered to have relapsed 6 months after start of treatment. As
in active VL the majority of relapsed patients had IgG1 titres
clearly above the ELISA cut-off (Figures 1A and 1B). Such
elevation of IgG1 in patients not responding to treatment has been
mentioned rarely in the literature [21,23]. Accordingly, to provide
an RDT for point of care application we devised two lateral flow
Table 3. Summary of results from IgG1 rapid diagnostic tests (RDT) prototypes.
RDT results
Patient Groups n RDT Used Positive Negative
Relapsed VLa 30 Prototype 1 83.3% (25/30) 16.7% (5/30)
23b Prototype 2 82.6% (19/23) 17.4% (4/23)c
Cured VL 21 Prototype 1 19.0% (4/21) 81.0% (17/21)
5d Prototype 2 20.0% (1/5) 80.0% (4/5)c
Other diseasese 7 Prototype 1 14.3% (1/7) 85.7% (6/7)
aTherapy: sodium antimony gluconate n = 8; miltefosine n = 10; amphotericin B n = 3; combination therapy n= 2.
b22 of these samples were also used with prototype 1.
cthese samples were also negative with prototype 1.
dthese 5 samples were also used with prototype 1.
emalaria n = 3; hepatitis n = 1; TB n = 2; dengue n = 1.
doi:10.1371/journal.pntd.0003273.t003
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prototypes, with which we assessed IgG1 seropositivity in
treatment failure and relapse. Although we had already demon-
strated that IgG1 levels were drastically reduced in cure, 6 months
after treatment, for comparison we included a set of serum samples
from such cured patients. Strikingly, the majority of patients
considered to have relapsed were strongly positive in the IgG1
specific RDT, whereas none of the cured patients were strongly
positive and the vast majority were entirely negative (Table 3,
Figure 3). Further validation is indicated with a one year
longitudinal study (since some patients may relapse between 6
months and one year after treatment [66]) and a larger cohort of
patients, ideally with baseline application of the RDT prior to
treatment, since despite successful treatment, extent of decline of
IgG1 might be influenced by the pre-treatment titre. All relapse
patients might be screened/rescreened for HIV infection to assess
whether relapse may be associated with immunocompromised
status. Thus, with optimisation and standardisation of reagents,
and preferably with higher discriminative sensitivity, this RDT
may provide an important and life-saving epidemiological tool to
detect relapse of VL.
We have shown the potential of IgG1 to be a simple indicator of
VL clinical status in terms of relapse. Symptomatic VL is treated at
an acute phase of infection, which may favour the decline of IgG1
seropositivity in cure; it remains to be seen whether such markers
are equally applicable to the treatment of prolonged chronic
infections. As PKDL is a long-established chronic infection, this
may explain why IgG1 does not decline with time after
chemotherapy. A recent study has proposed that a high
seropositivity in asymptomatic people may be associated with
greater risk of progression to symptomatic VL [38]. Further work
Table 4. IgG subclass serology in VL and PKDL: Published studies.
Reference Origin of samples Antigen (assay) Authors’ reports
[16] Sudan Intact promastigote (ELISA) Elevated IgG1 and IgG3 in VL, not IgG2 or IgG4 (n = 15).
[17] Sudan Crude promastigote sonicate (ELISA) Overall decrease in IgG1 and IgG3 (n = 28) 1 month post
treatment of VL with sodium stibo-gluconate (Pentostam)
[18] India Crude promastigote sonicated lysate
(ELISA); whole promastigote (immunoblotting)
IgG1.G2.G3.G4 in VL (n = 10) and PKDL (n = 6). IgG3
recognition of antigens by immunoblot persisted 24 weeks
after successful chemotherapy, whereas IgG1 decreased in VL
24 weeks post chemotherapy.
[19] Venezuela Promastigote soluble extract (ELISA) IgG1 predominant subclass; IgG4 also detectable (n = 10).
[20] Somalia Crude promastigote lysate (ELISA & western blot) Elevated IgG1, IgG3, IgG4 in VL (n = 22).
[21] India Crude promastigote lysate (ELISA) IgG1.IgG2.IgG3 = IgG4 before sodium antimony gluconate
treatment in responders (n = 10) and non-responders (n = 10).
4–6 weeks post treatment, responders decreased all subclasses;
non-responders no significant decrease.
[22] India Leishmanial membrane antigens (ELISA) IgG1 predominant subclass, and IgG3 is useful diagnostic
marker, in VL (n = 25).
[23] India Leishmanial membrane antigens (ELISA) IgG1 increase in non-responders to sodium stibogluconate,
reduced after subsequent cure by amphotericin B therapy
(n = 5); all IgG subclasses decrease in sodium stibogluconate
responders (n = 10)
[24] Brazil, Colombia,
Venezuela
Recombinant kinetoplastid membrane protein-1
(ELISA)
IgG1..IgG3.IgG2.IgG4 in pre-treatment in VL (n = 12)
[25] Ethiopia Sonicated promastigote antigen (ELISA) High IgG1 in VL (n = 10) compared to subclinical DAT positive
(n = 18) and successfully treated (n = 20). IgG2 non-
discriminating.
[26] India Leishmanial membrane antigens (western blot) IgG1 50 days after sodium antimony gluconate therapy VL
patients (n = 7) gave similar but less intense western blotting
banding patterns.
[27] India Leishmanial membrane antigens (ELISA) IgG1 elevated in PKDL (n = 23). IgG4 elevated in active VL
(n = 10) but not in PKDL (n = 23). IgG1, IgG2, IgG3 overall higher
in PKDL (n = 23) than in cured VL (n = 10)
[28] India Crude promastigote lysate (ELISA) IgG1 elevated in VL (n = 38) compared to PKDL (n = 27); IgG2,
IgG4 higher in PKDL than VL. IgG3 and IgG4 higher in paediatric
(n = 16) than adult VL (n = 22). All IgG subclass levels
comparable in paediatric (n = 7) and adult PKDL (n = 20)
[29] India Crude promastigote lysate (ELISA) IgG1 and IgG3 decreased in VL 1 month post amphotericin B
treatment (n = 6). Less IgG1 and IgG3 in macular (n = 5) than
polymorphic PKDL (n = 11)
[30] Brazil Fixed L. infantum (syn. L. chagasi)promastigote
(immunofluorescent flow cytometry)
IgG1.IgG3 in untreated VL (n = 21); absence of IgG2 and IgG4.
IgG1 100% sensitive and specific for discriminating pre- and 12
month post-amphotericin B treatment paired sera of patients
considered cured.
[31] India Crude promastigote lysate (ELISA) IgG3..IgG1..IgG4.IgG2 in polymorphic PKDL (n = 3).
IgG3..IgG1.IgG2$IgG4 in macular PKDL (n = 11) IgG1 and
IgG3 decreased post treatment of polymorphic PKDL (n = 15)
doi:10.1371/journal.pntd.0003273.t004
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could investigate whether high anti-L. donovani IgG1 titre in
asymptomatic patients is a potential biomarker for progression to
active VL.
Seroepidemiological comparisons with more detailed and
sophisticated technological analysis of patient profiles is clearly a
promising approach to defining precise, robust and widely
applicable biomarkers.
Based on analysis and interpretation of our results, in
conjunction with review of the relevant literature, we conclude
that:
1. Retention of high anti-L. donovani IgG1 titre (or presumably
rising titre) 6 months after chemotherapy (but not immediately
after chemotherapy) is an indicator of treatment failure and
relapse (however this is not likely to hold true for immuno-
compromised HIV co-infected patients, in whom antibody
responses may be impeded). Patients with such a serological
profile require follow-up and alternative treatment or will
almost certainly succumb to fatal VL.
2. Most importantly we have shown that high anti-L. donovani
IgG1 levels 6 months after treatment, and in comparison with
preceding pre- or shortly post-treatment levels, are amenable to
detection with a simple lateral flow POC applicable RDT.
Nevertheless, such RDTs should not be applied at the
exclusion of concomitant clinical evaluation.
Further investigation of seroepidemiological indicators is clearly
justified to find even better alternative biomarkers of clinical status,
in particular to identify asymptomatic progressors to VL, as well as
to distinguish cure from treatment failure and relapse.
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Table S1. Single (unpaired) samples used in ELISA IgG subclass comparisons and clinical status of the Indian and Sudanese patient groups. 
Patient group  n  IgG1  IgG2  IgG3  IgG4 
Trial 1  India    % positive    Mean A490 (95% CI)  % positive   Mean A490 (95% CI)  % positive   Mean A490 (95% CI)  % positive   Mean A490 (95% CI) 
Active VL  20  90.0 (18/20)  1.47 (0.90 ‐2.03)  5.0 (1/20)  0.10 (0.08‐0.12)  75.0 (15/20)  0.23 (0.16‐0.31)  0.0 (0/20)  0.09 (0.07‐0.10) 
Cured VL  21  33.3 (7/21)  0.28 (0.15 – 0.40)  0.0 (0/21)  0.09 (0.08‐0.10)  14.3 (3/21)  0.10 (0.06‐0.14)  4.8 (1/21)  0.10 (0.7‐0.13) 
Relapsed VL  19  84.2 (16/19)  1.74 (1.17‐2.31)  15.8 (3/19)  0.11 (0.09‐0.14)  52.6 (10/19)  0.21 (0.14‐0.29)  5.3 (1/19)  0.10 (0.08‐0.12) 
Other diseases  20  0.0 (0/20)  0.10 (0.08‐0.11)  0.0 (0/20)  0.09 (0.08‐0.11)  5.0 (1/20)  0.08 (0.07‐0.09)  5.0 (1/20)  0.09 (0.06‐0.13) 
Endemic healthy control (seronegative)  20  5.0 (1/20)  0.09 (0.08‐0.11)  0.0 (0/20)  0.10 (0.08‐0.11)  5.0 (1/20)  0.08 (0.07‐0.09)  0.0 (0/20)  0.10 (0.08‐0.11) 
Trial 2 (Expanded) India 
Active VL  46  67.4 (31/46)  0.61 (0.47‐0.75)  4.3 (2/46)  0.11 (0.10‐0.12)  28.3 (13/46)  0.13 (0.12‐0.15)  40.0 (8/20)  0.12 (0.11‐0.14) 
Cured VL  28  3.6 (1/28)  0.15 (0.10‐0.20)  7.1 (2/28)  0.11 (0.09‐0.12)  3.6 (1/28)  0.10 (0.08‐0.11)  35.7 (10/28)  0.14 (0.11‐0.16) 
Relapsed VL  35  71.4 (25/35)  0.70 (0.49‐0.92)  0.0 (0/35)  0.09 (0.08‐0.10)  25.7 (9/35)  0.12 (0.10‐0.15)  2.9 (1/35)  0.09 (0.08‐0.10) 
post kala‐azar dermal leishmaniasis  24  45.8 (11/24)  0.49 (0.34‐0.64)  20.8 (5/24)  0.15 (0.12‐0.17)  8.3 (2/24)  0.12 (0.10‐0.14)  0.0 (0/24)  0.10 (0.09‐0.11) 
Asymptomatic (seropositive)  28  14.3 (4/28)  0.24 (0.17‐0.31)  35.7 (10/28)  0.15 (0.12‐0.17)  53.6 (15/28)  0.16 (0.13‐0.19)  75.0 (21/28)  0.18 (0.14‐0.22) 
Other diseases  28  0.0 (0/28)  0.12 (0.10‐0.14)  0.0 (0/28)  0.11 (0.10‐0.12)  14.3 (4/28)  0.10 (0.09‐0.12)  3.6 (1/28)  0.09 (0.08‐0.10) 
Endemic healthy control (seronegative)  32  3.1 (1/32)  0.12 (0.09‐0.15)  3.1 (1/32)  0.09 (0.08‐0.10)  3.1 (1/32)  0.08 (0.07‐0.09)  3.1 (1/32)  0.09 (0.08‐0.09) 
Trial 1 Sudan 
Active VL  47  57.4 (27/47)  0.76 (0.60‐0.92)  6.4 (3/47)  0.10 (0.08‐0.11)  48.9 (23/47)  0.23 (0.19‐0.28)  6.4 (3/47)  0.08 (0.08‐0.09) 
Treated VLa  22  4.6 (1/22)  0.19 (0.13‐0.25)  0.0 (0/22)  0.07 (0.06‐0.08)  4.6 (1/22)  0.09 (0.07‐0.11)  0.0 (0/22)  0.07 (0.06‐0.07) 
post kala‐azar dermal leishmaniasis  23  4.3 (1/23)  0.18 (0.11‐0.25)  0.0 (0/23)  0.07 (0.06‐0.08)  0.0 (0/23  0.09 (0.08‐0.09)  0.0 (0/23)  0.07 (0.07‐0.08) 
DAT positive  30  3.3 (1/30)  0.15 (0.11‐0.19)  0.0 (0/30)  0.09 (0.08‐0.10)  0.0 (0/30)  0.09 (0.08‐0.10)  3.3 (1/30)  0.08 (0.08‐0.090 
Endemic healthy control (seronegative)  12  0.0 (0/12)  0.20 (0.13‐0.26)  0.0 (0/12)  0.08 (0.07‐0.10)  0.0 (0/12)  0.08 (0.06‐0.11)   0.0 (0/12)  0.07 (0.06‐0.08) 
a treated, not in recent past, but time of treatment unknown 
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6. GENERAL DISCUSSION: RECAPITULATION AND FUTURE PERSPECTIVES 
6.1 Trypanosoma cruzi and Chagas disease 
From the first demonstration of the diversity of T. cruzi in naturally occurring cycles 
(Miles et al., 1977), the relevance to differing clinical and geographical presentations has 
been the subject of enquiry (Miles et al., 1981).  Lineage identification, which was initially 
based on MLEE and then genotyping, requires that the parasite is first isolated. This is 
challenging in the post-acute phase of disease, due to the low parasitaemia, and 
confounded by the tissue tropisms of different lineages. Thus, the indirect approach of 
indentifying serologically antibodies produced against lineage-specific antigens has been 
applied here. 
In this project, the T. cruzi surface mucin TSSA, previously described as being 
expressed on the bloodstream form of the parasite and exhibit sequence dimorphism (Di 
Noia et al., 2002), has been further investigated (ANNEX 1). By sequencing the part of the 
TSSA coding region containing the previously-described amino acid diversity from genomic 
DNA of isolates representing TcI-TcVI and spanning the geographical and ecological range of 
T. cruzi, a greater degree of TSSA diversity was identified. Specifically, the sequence 
reported as being restricted to isolates described grossly as ‘TcII’ (now called TcII-TcVI in 
subsequently revised nomenclature) was found only in TcII, TcV, and TcVI. In addition, TcV 
and TcVI also contained an alternate haplotype which differs by the substitution of an 
alanine residue in place of threonine. TcIII and TcIV were also both discovered to have their 
own lineage-specific sequences, not previousy identified. The TSSA sequence of TcI was 
found to be as previously reported (ANNEX 1: Figure 3). 
Peptides based on these lineage-specific sequences were synthesised and used in this 
project in ELISA with serum from chagasic patients from a range of endemic countries in 
order to identify lineage-specific serological reactions (ANNEX 2). The use of recombinant, E. 
coli produced TSSA fusion proteins has been reported before (ANNEX 2: Table 3). In those 
studies, the TSSA sequences of the proteins contained not only the polymorphic region 
(residues 39-51), but also up to 26 of the flanking amino acids, which are highly conserved 
between T. cruzi lineages; however, this project is the first report of the use of synthetic 
peptides in this way. Here, recognition of the TSSApep-II/V/VI common peptide and 
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TSSApep-V/VI was very commonly found in serum originating from the Southern Cone 
countries (Brazil, Bolivia, Argentina), in agreement with their prevalence in this region based 
on MLEE/genotyping of parasite isolates. An unexpected finding was that 4/20 sera from 
Ecuador also reacted with TSSApep-II/V/VI, as these lineages had not previously been 
reported from that country. Another novel finding was the serological identification of 
TSSApep-IV, by one sample each from Colombia and Venezuela. However TSSApep-I, despite 
the broad geographical distribution of this lineage, was recognised only very rarely by the 
sera (ANNEX 2: Table 1 & Figure 3). The Colombian samples used here were the same as 
those used by Risso et al. (2011), in which western blotting of recombinant TSSA-II identified 
an unexpectedly high level of reactivity against this lineage north of the Amazon, including 
Colombia; however in this study, no such reactions were seen against the corresponding 
peptide TSSApep-II/V/VI. 
Associations between peptide recognition and clinical symptoms were also 
investigated. Among the Brazilian patients, a much higher proportion of TSSApep-II/V/VI 
responders had ECG abnormailities than non-responders (38% vs. 17%, p<0.0001). 
A novel bioinformatic analysis of the TSSA sequences from which these peptides 
derive predicted that TSSApep-II/V/VI and TSSApep-V/VI contain sequences of high 
antigenicity, whereas the TSSApep-I sequence predicts low antigenicity (ANNEX 2: Figure 4). 
Thus this project has demonstrated that the greater polymorphism of the TSSA gene 
can be exploited in ELISA by using synthetic peptides based on this diversity, to identify an 
individual’s history of lineage infection, association with cinical presentation, and 
geographical distribution of lineages.  
 
Future perspectives & ongoing work: 
Identification of a TcI-specific peptide: For unknown reasons, the TSSA peptide 
specific for TcI serology has not been successful in this project, even with those samples 
previously genotyped as containing TcI isolates, or presumed to do so due to geographical 
origin. Thus, identification of a robust TcI-specific peptide remains a crucial goal in sero-
epidemiological studies of Chagas disease. The approaches to achieve this include using in 
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silico bioinformatic analyses on reference genomes to identify candidate proteins displaying 
desirable antigenic properties, and the use of genomic or synthetic peptide libraries in 
differential screening of TcI and TcII sera (natural or experimental).  
Expanded studies of lineage identification and clinical symptoms: The link between 
infecting T. cruzi lineage(s) with the broad range of clinical symptoms remains largely 
circumstantial, with a paucity of candidate parasite or human factors identified. The 
application of lineage-specific serology to identify an individual’s history of lineage infection 
would be a great aid in associating lineage to symptoms, and also potentially to act as a 
prognostic tool. This would require an expanded study of the type presented here (ANNEX 
2), using samples from clinically well-characterised patients. 
Adaptation to a lateral flow rapid test: TSSApep-II/V/VI, and to a lesser extent 
TSSApep-V/VI, have been shown here to be well recognised in the ELISA format for lineage-
specific serology. A future and novel direction could be the incorporation of peptide(s) to a 
lateral flow, immunochromatographic, rapid diagnostic cassette, as described in Figures 13 
and 32. This could be designed for use at point-of-care or in a research context, and also 
relevant for immunological surveillance of reservoir hosts (see following point). 
Application to silvatic mammalian hosts: T. cruzi lineages circulate in the silvatic cycle 
by triatomine bugs feeding on mammal hosts. As with humans, lineage identification relies 
on parasite isolation and genotyping. The application of the lineage-specific serology 
described in this project would therefore have enormous potential in more fully 
understanding the ecology of lineages, particularly those which have been most associated 
with human disease. The use of TSSA (and future identified) lineage peptides, along with 
suitable host species-specific secondary antibodies, is envisaged to pursue this research 
direction. 
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6.2 Leishmania donovani and visceral leishmaniasis 
Full-blown systemic, symptomatic VL is a gravely serious disease, which is almost 
always fatal without treatment. Accurate and timely diagnosis of infection with L. donovani 
complex is therefore of crucial importance in disease management. As shown in Tables 5 & 
6, a significant difference in the sensitivity of the rK39 RDT between South Asia and East 
Africa had been previously identified. In this project, reasons potentially underlying this 
differential sensitivity were identified. These were parasite factors, namely the nature and 
extent of antigen diversity in the region coding for the 6.5 x 39 aa repeats used in rK39, and 
also human factors, namely the difference in overall anti-Leishmania IgG levels between VL 
patients from different endemic areas. Additionally, the nature of the IgG subclass response 
in VL patients of different status was analysed here. 
This region coding for the 6.5 x 39 aa repeats used in rK39 was amplified and 
sequenced from a panel of East African L. donovani strains, and compared to published 
sequences (ANNEX 3). As expected from the fact that one of the PCR primers binds within a 
repeat region, multiple amplicons 117 bp apart were produced (ANNEX 3: Figure 2). On 
sequencing of the amplicon corresponding to 6.5 x 39 aa repeats from these strains, a wide 
range of polymorphism was found, including non-conservative charge changes, with the 
capacity to affect epitope structure and nature. In comparison with the sequence of rK39 
and other published sequences mainly from South Asia, continent-specific polymorphisms 
were also identified (ANNEX 3: Figure 3). A similar approach to the proposed diagnostic 
antigen HASPB also revealed non-canonical combinations of repeat arrangements (ANNEX 3: 
Table 4). 
As an alternative explanation for the lower sensitivity of rK39 RDT in East Africa, this 
project also analysed the role of anti-Leishmania IgG levels in VL patients from different 
endemic regions. These were Gedaref in Sudan and Bihar in India. Plasma samples from VL 
patients from both regions were reacted on the same ELISA plate coated with lysate antigen 
from both Indian and Sudanese L. donovani strains (ANNEX 4: Figure 1). Results were 
striking, with a significantly lower IgG response seen among Sudanese than Indian VL 
patients (p<0.0001). This was observed regardless of antigen source, age or gender of 
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patient (ANNEX 4: Figures 2&3). The lower IgG responses in the Sudanese cohort may be 
due to genetic, nutritional, or other factors. 
In a WHO/TDR document (WHO, 2010e), case definitions for treatment outcome for 
VL patients were based on clinical and parasitological signs (Table 8), with another recent 
WHO publication listing an established marker of cure in VL as a knowledge gap and 
research priority (WHO, 2012). In this project, the discriminatory potential of IgG subclass 
responses in VL patients of differing clinical status by ELISA was evaluated (ANNEX 5). The 
clearest finding was the stark contrast in IgG1 levels comparing active (pre-treatment 
samples) plus those deemed to be therapeutically relapsed, versus those deemed to be 
therapeutically cured. The former group had displayed significantly elevated IgG1 levels 
compared to the latter (p<0.0001 for all cohorts of unpaired Indian and Sudanese samples; 
ANNEX 4: Figure 1). In accordance with the findings from the comparison of Sudanese and 
Indian overall anti-Leishmania IgG responses (Annex 4), the absolute values for the 
Sudanese IgG1 reactors were lower than for Indian. When performing the IgG1 ELISA on 
paired samples from the same patient before and either soon after or approximately 6 
months after start of successful therapy, the IgG1 decrease in cured patients was manifest 
at the later time point when compared to the paired baseline samples (ANNEX 5: Figure 2). 
Following these findings, prototype immunochromatographic rapid tests to specifically 
detect IgG1 responses in VL patients were developed in collaboration with Coris BioConcept. 
Early results encourage the further, expanded evaluation of this test (ANNEX 5: Table 3 & 
Figure 3).  
 
Future perspectives & ongoing work: 
An expanded survey of the use of the IgG1 RDT: Following the encouraging early 
results on the utility of the prototype IgG1 RDT, it is envisaged to expand this to a larger set 
of samples, particularly paired samples of pre- and post therapy, those deemed to be either 
cured or relapsed. The RDT is also envisaged to be applied to asymptomatic patients who 
later progressed to symptomatic VL or remained as non-progressors, to investigate the 
utility of the IgG1 RDT as a tool for predicting disease progression, or more speculatively, on 
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the role of asymptomatc people in transmission to sandflies. The identification of further 
serological biomarkers is also encouraged by these results. 
Identification of a Leishmania antigen indicative of current infection: Currently, non-
parasitological diagnosis of VL depends on detection of anti-Leishmania IgG produced by the 
patient. The identification of Leishmania antigen(s) produced and excreted in the urine 
would be a non-invasive alternative for diagnosing active infection. An approach to this, as 
initiated by T Marlais, LSHTM, would involve the isolation of experimentally-derived anti-
Leishmania IgG from immunised animals, and the subsequent generation of an anti-
Leishmania IgG affinity column. After immunodepletion to remove common human urinary 
proteins from VL patients, any ligands which bound to the column would be eluted for 
analysis by mass spectroscopy to identify Leishmania protein fragments. Synthetic pepides 
or recombinant proteins derived from the parent molecules could then provide a basis for 
developing new serological or antigen capture assays.  
 
6.3 Summary of overarching themes 
This project has sought to analyse parasite diversity and improve serology for Chagas 
disease and visceral leishmaniasis. Both diseases are caused by protozoa of the order 
Kinetoplastida, family Trypanosomatidae, which share a number of morphological and 
molecular biological characteristics, but disparate modes of transmission and clinical 
disease. Consequently, they have been considered separately. Nevertheless, there are 
cetain common themes. 
Molecular analysis of antigen diversity: Exploitation of T. cruzi TSSA diversity allows a 
deeper investigation of an individual's history of lineage infection, association with clinical 
symptoms, and geographical distribution. A similar approach to the Leishmania kinesin-like 
protein, a fragment of which is used as the rapid diagnostic antigen rK39, also revealed a 
great degree of diversity. However for VL, this diversity is predicted to disrupt the efficacy of 
serology using this antigen. 
Diagnostic serology: In both Chagas disease and VL, a key research need identified by 
WHO is the development of biomarkers for disease status, as prognostic indicators or for 
monitoring treatment outcome. The research here has shown that elevated IgG1 levels in VL 
are associated with active disease or post-therapy relapse; subsequently, a similar 
serological survey of IgG subclass levels in Chagas disease was initiated. Early results, which 
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have not been included here, indicate that further investigations of these biomarkers in 
chagasic sera are also warranted. 
 
Overall, for both T. cruzi and L. donovani, and for the serological reactions generated 
in their infected hosts, these results have shown the potential of deeper analyses to yield 
novel data and refined high resolution diagnostic and prognostic RDTs. 
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7. SUMMARY OF KEY FINDINGS 
Trypanosoma cruzi and Chagas disease 
 Greater genetic and amino acid diversity in the Trypanosoma cruzi surface mucin 
TSSA was revealed than had previously been reported, leading to the identification 
of lineage-specific epitopes [ANNEX 1 Bhattacharyya et al., 2010]. 
 Synthetic peptides based on TSSA diversity have been used to identify lineage-
specific serological responses in chagasic patient sera, and for associating lineage-
specifc reactions with geographical distributions and clinical symptoms [ANNEX 2 
Bhattacharyya et al., 2014]. 
Leishmania donovani and visceral leishmaniasis 
 A greater diversity in the Leishmania donovani diagnostic antigens rk39 and HASPB 
sequences has been demonstrated, with ample scope for affecting their diagnostic 
antigenicity. [ANNEX 3 Bhattacharyya et al., 2013]. 
 Comparative serology has shown that a Sudanese VL patient cohort generated a 
significantly weaker anti-Leishmania IgG response than a corresponding Indian 
cohort, revealing a possible cause of the differential RDT sensitivity in different 
geographical regions [ANNEX 4 Bhattacharyya et al., 2014]. 
 IgG1 levels were found to be elevated in active and relapsed VL patients, but 
substantially diminished in cured patients, over the course of several months post-
therapy, and identification of this biomarker can be achieved by a novel prototype 
RDT [ANNEX 5 Bhattacharyya et al., 2014]. 
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APPENDIX  
A.1 ChagasEpiNet Extracted from www.ki.se/chagasepinet/  
“ChagasEpiNet is a European Union Seventh Framework Program funded project whose aim 
is to elucidate the epidemiology of the genetic lineages of Trypanosoma cruzi for improved 
understanding and prevention of Chagas disease.This project unites compatible research 
skills across 15 partner institutions in Europe and South America to study the disease in 
different endemic areas.  
 Improve and standardise techniques for genotyping T. cruzi. 
 Improve our understanding of the population genetics of T. cruzi 
 Sequence the genome of T. cruzi lineage I. 
 Develop lineage specific immunological diagnosis. 
 Pilot studies to evaluate T. cruzi lineage specific associations with 1) Clinical 
outcome; 2) Congenital infection; 3) Cellular infectivity; & 4) Susceptibility to 
trypanocidal drugs.” 
INSTITUTE LOCATION 
LSHTM London, UK 
Universidad Mayor de San Simon Cochabamba, BOLIVIA 
Universidad Central de Venezuela Caracas, VENEZUELA 
Instituut voor Tropische Geneeskunde Antwerpen, BELGIUM 
Universidad Nacional de Salta Salta, ARGENTINA 
Université Libre de Bruxelles  Brussels, BELGIUM 
Fundação Oswaldo Cruz  Rio de Janeiro, BRAZIL 
GEMI-IDR Montpellier, FRANCE 
Universidade Federal de Goiás Goiania, BRAZIL 
Karolinska Institutet  Stockholm, SWEDEN 
Universidad de los Andes Bogota, COLOMBIA 
University of East Anglia Norwich, UK 
Universidad de Chile  Santiago, CHILE 
Universidad Autónoma de Madrid  Madrid, SPAIN 
Pontificia Universidad Católica del Ecuador  Quito, ECUADOR 
 
 
A.2 NIDIAG  Extracted from www.nidiag.org 
“NIDIAG is a European research network (Collaborative Project) coordinated by the Institute 
of Tropical Medicine. Our consortium brings together 13 complementary partners, including 
2 private companies and 11 laboratories, from 4 European Member States and Associated 
Countries, 4 countries in Asia and 3 countries in Africa. The project is supported by the 
European Commission under the Health Priority of the 7th Framework Programme. The aim 
of the NIDIAG project is improve the quality of NID care at primary health care level in 
resource-poor settings. The major objectives of the NIDIAG consortium are: to develop and 
validate an integrated syndromic approach based on diagnosis treatment algorithms for 
three NID-related clinical syndromes frequently encountered in primary care settings, 
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namely the persistent fever syndrome (at least 2 week duration), the neurological 
syndrome, and the intestinal syndrome; to develop novel diagnostic platforms/assays 
tailored to specific epidemiological contexts at primary care level in NID-endemic settings”  
INSTITUTE LOCATION 
Instituut voor Tropische Geneeskunde Antwerpen, BELGIUM 
LSHTM London, UK 
Inserm-Transfert Paris, FRANCE 
Université de Genève Geneva, SWITZERLAND 
Institut National de Recherches Biomédicales Kinshasa, DR CONGO 
Gadjah Mada University Yogyakarta, INDONESIA 
Institut National de Recherche en Santé Publique Bamako, MALI 
Swiss Tropical Institute Basel, SWITZERLAND 
Banaras Hindu University Varanasi, INDIA 
B.P. Koirala Institute of Health Sciences Dharan, NEPAL 
University of Khartoum Khartoum, SUDAN 
Sihanouk Hospital Center of HOPE Phnom Penh, CAMBODIA 
Coris BioConcept Gembloux, BELGIUM 
 
A.3 Public websites and online databases  
GenBank  http://www.ncbi.nlm.nih.gov/genbank/ 
NCBI BLAST  http://blast.ncbi.nlm.nih.gov/Blast.cgi 
TriTrypDB  http://tritrypdb.org/tritrypdb/ 
 
A.4 Molecular biology reagents 
1 x NEBuffer 2 (NEB): 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM 
dithothreitol (pH 7.9 @ 25°C).  
1 x NH4 buffer (Bioline):  16 mM (NH4)2SO4, 67 mM Tris-HCl (pH 8.8 @ 25°C), 0.01% 
stabilizer.  
1 x TAE buffer:  40 mM Tris, 1 mM EDTA, 20 mM glacial acetic acid (prepare 
50x stock). 
DNA loading buffer (‘home-made’): 1 x TAE buffer, 40% (v/v) glycerol, bromophenol blue, 
in ddH2O 
 
 
 
 
109 
 
Reagent/consumable/apparatus Supplier Cat. No. 
0.2 ml strip tubes & caps VWR 732-0551 
Agarose Bioline BIO-41025 
Ampicillin Sigma A0166 
Big Dye Terminator v3.1 Applied Biosystems 433 7455 
BioTaq DNA polymerase Bioline BIO-21040 
Bromophenol blue Sigma 114405 
Dilution buffer (DNA sequencing) Applied Biosystems 4336697 
DNA loading buffer (commercial) Bioline BIO-37045 
DNEasy Blood & Tissue kit Qiagen 69504 
dNTPs (10mM mix) NEB N0447S 
EDTA Sigma E5134 
EtBr VWR 443022U 
EtOH, absolute Fisher E/0650DF/17 
Glacial acetic acid VWR 100015N 
Hyperladder I Bioline BIO-33025 
Hyperladder IV Bioline BIO-33029 
Hyperladder V Bioline BIO-33031 
IPTG Bioline BIO-37036 
isopropanol VWR 20842.323 
NEBuffer 2 NEB B7002S 
NH4 buffer Bioline BIO-37025 
PTC-100 & -200 Thermal cycler machines MJ Research  
Puregene Tissue Core Kit Cell lysis solution, 
*Proteinase K, *RNaseA, Protein precipitation 
solution, DNA hydration buffer. 
 * = available separately: 
                     Proteinase K - 158918 
                     RNAseA – 158922 
Qiagen 158667 
 
 
 
PvuII Promega R6331 
QIAquick Gel Extraction Kit Qiagen 28704 
QIAquick PCR Purification Kit Qiagen 28104 
QIAGEN Spin miniprep kit Qiagen 27106 
SureClean reagent Bioline BIO-37042 
Tris (TRIZMA base) Sigma T6066 
UV transilluminator UVP 95-0216-02  
X-gal Bioline BIO-37035 
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A.5 GenBank submissions  
 T. cruzi 
WHO CODE OF STRAIN Lineage TSSA  
(ANNEX 1) 
RNA binding protein 
(ANNEX 2) 
MDID/US/00/92101601P cl1 TcI GU059926  
MPRC/US/00/92122102R TcIV GU075672  
MHOM/BO/00/92:80 TcV  KJ395485 
IINF/BR/00/Bug2148 cl1 TcV GU059934 KJ395486 
MHOM/BR/00/CanIII cl1  TcIV GU075671  
MHOM/CL/00/CBB cl3 TcII GU059929 KJ395479 
IINF/PY/00/Chaco9 TcVI  KJ395491 
IINF/PY/00/Chaco17 TcVI  KJ395490 
IINF/PY/00/Chaco23 TcII  KJ395481 
MINF/BR/00/CL Brener TcVI GU075678 KJ395488 
MDAS/CO/00/CM17 TcIII GU075674  
MPHT/BO/00/COTMA47 TcI  KJ395476 
MDAS/BR/00/Cutia cl1 TcI GU059922  
MCAN/US/00/Dog Theis TcIV GU059927  
IINF/AR/00/EPV20-1 TcVI  KJ395492 
MHOM/BR/00/Esm cl3 TcII GU075675  
MHOM/CL/00/IVV cl4 TcII GU059931 KJ395477 
IINF/AR/00/LHVA TcIV  KJ395483 
MDAS/BR/00/M5631 cl5 TcIII GU075673  
MHOM/BR/00/M6241 cl6 TcIII GU059932  
MHOM/BR/00/MAS cl1 TcII GU059930  
MHOM/CL/00/MN cl2 TcV GU075677  
MHOM/VE/00/OPS21 cl11 TcI GU059925  
MHOM/BO/00/P209 cl93 TcI GU059924  
MHOM/BO/00/P251 TcVI  KJ395489 
IINF/PY/00/P63 cl1 TcVI GU059936  
IINF/PY/00/Para6 TcV  KJ395487 
MHOM/PE/00/SaxP18 TcI  KJ395472 
IINF/BO/00/SC43 cl1 TcV GU075676  
MHOM/BR/78/Sylvio-X10/1 TcI GU059921 KJ395471 
MDID/BO/2004/SJM37 TcI  KJ395475 
MPHI/BO/2004/SJM41 TcI  KJ395473 
MDID/BO/00/SMA2 TcI  KJ395474 
IINF/BO/00/SO3 cl5 TcV GU059935  
IINF/CL/00/Sp104 cl1 TcI GU059923  
IINF/PY/00/T655 TcII  KJ395482 
IINF/BO/00/Tu18 cl93 TcII GU059928 KJ395480 
MHOM/CL.00/Tula cl2 TcVI GU059937  
IINF/CL/00/VFRA TcVI  KJ395493 
IINF/CL/00/Vinch101 TcV  KJ395484 
MCAN/PY/00/X109/2 TcIII GU059933  
MHOM/BR/00/Y TcII  KJ395478 
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a WHO code: MHOM/BR/78/Sylvio-X/10 
   Elements:  1    2       3    4        5 
 
[1] Type of host or vector from which isolated: M =Mammalia; I = Insecta. [2] Generic name of host 
or vector: AKO = Akodon boliviensis; CAN = Canis familiaris; DAS = Dasypus sp.; DID = Dideplhis spp.; 
HOM = Homo sapiens; INF = Triatoma infestans; PHI = Philander sp.; PHT = Phylottis sp.; PRC = 
Procyon sp. [3] Country of isolation, in accordance with International Organisation for 
Standardization: AR = Argentina; BO = Bolivia; BR = Brazil; CL = Chile; CO = Colombia; PE = Peru; PY = 
Paraguay; US = United States of America; VE = Venezuela. [4] Year of isolation: Last two digits of year 
starting 19__ ; all four digits of years starting 20__ ; 00 = unknown. [5] Laboratory designation. 
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L. donovani ANNEX 3 
  HASPB 
WHO CODE OF STRAIN a kinesin HASPB1 HASPB2 unpredicted 
MHOM/ET/72/GEBRE 1  KC342850   
MHOM/SD/82/GILANI KC342869 KC342851 KC342856  
MHOM/ET/67/HU3 (LV9) KC342866 KC342849 KC342855  
MHOM/ET/00/HUSSEN KC342867   KC342861 
MHOM/SD/97/LEM3458  KC342854 KC342860  
MCAN/SD/98/LEM3556  KC342853 KC342859  
MHOM/SD/98/LEM3582 KC342870 KC342852 KC342857  
IMAR/KE/62/LRC-L57 KC342872   KC342863 
MHOM/KE/67/MRC(L)3    KC342864 
MHOM/SD/00/SUDAN1 KC342871  KC342858  
MCAN/IQ/81/SUKKAR 2    KC342865 
MHOM/SD/87/UGX-marrow KC342868   KC342862 
 
a WHO code: MHOM/ET/72/GEBRE 1 
   Elements:  1    2       3    4        5 
 
[1] Type of host or vector from which isolated: M =Mammalia; I = Insecta; [2] Generic name of host 
or vector: CAN = Canis familiaris; HOM = Homo sapiens; MAR = Phlebotomus martini; [3] Country of 
isolation, in accordance with International Organisation for Standardization: ET = Ethiopia; IQ = Iraq; 
KE = Kenya; SD = Sudan; [4] Year of isolation: Last two digits of year starting 19__ ; 00 = unknown; [5] 
Laboratory designation. 
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A.6 ELISA reagents 
1 x Coating buffer: 15 mM Na2CO3, 34 mM NaHCO3. (prepare 10x stock, store 4°C). 
1x PBS (pH7.4):  137 mM NaCl, 8 mM Na2HPO4 (anhydrous), 2.7 mM KCl, 1.5 mM 
KH2PO4 
Wash buffer: PBS, 0.05% Tween-20.  
Blocking buffer: PBS, 2% Skimmed milk powder, 0.05% Tween-20. 
Substrate solution (prepared immediately before use):   
10ml phosphate citrate buffer pH5.5 
   (approx. 1:1 ratio of 100 mM Citric acid : 100 mM Na2HPO4) 
4 mg O-phenylenediamine HCl ([C6H8N2.2HCl]; 2 mM final) 
   3ul   30% H2O2 
Stop solution:  2M H2SO4  
 
Reagent/consumable Supplier Cat. No. 
Adhesive plate seals Sigma A5596 or G676001 
Avidin (resuspended to 1mg/ml in PBS) Sigma A9275 
BCA Protein assay kit Fisher PN23227 
Citric acid monohydrate VWR 
Sigma 
10081 
C1909 
H2O2 VWR 
Sigma 
23615.261 
216763 
H2SO4 VWR 20700.265 
Immulon 4HBX 96w flat bottomed plate VWR 735-0465 
KCl VWR 101984L 
KH2PO4 VWR 102032W 
NaCl Sigma S7653 
Na2CO3 Sigma S6139 
NaHCO3 Sigma S5761 
Na2HPO4 anhydrous VWR 301584L 
Na2HPO4.12H2O VWR 102484A 
O-phenylenediamine HCl Sigma P1526 
PBS (tablets)  Sigma 
VWR 
Fisher 
P4417 
524 650-1 
10209252 
Reagent reservoir VWR 613-1176 
Skimmed milk powder  - Brand ‘Marvel’ 
Streptavidin-HRP conjugate Sigma S2438 
Spectrophotometer Helios Epsilon Fisher SPR-200-150B 
Tween-20 Sigma P7949 
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A.7 HRP-conjugated secondary antibodies (anti-human) 
Target Raised in pAb/mAb Supplier Cat. No. 
IgG (H+L) donkey polyclonal Stratech 709-035-149 
IgG1 (γ chain) mouse monoclonal Abcam ab99774 
IgG2 (γ chain) mouse monoclonal Abcam ab99784 
IgG3 (hinge H Chain) mouse monoclonal Abcam ab99829 
IgG4 γ chain mouse monoclonal Abcam ab99817 
 
A.8 Cell culture reagents 
A.8.1 T. cruzi  
Stock solutions  
1M HEPES  23.8g/100 ml H2O, pH 7.2 
Tryptone/trypticase 17.5g/100 ml H2O 
Haemin   250mg/100 ml 0.01M NaOH 
PGAB    Final  100x stock 
Na Glutamate   2 mM  3.4g/100 ml 
Na Pyruvate  2 mM  2.2g/ 100 ml 
Gentamycin  50 μg/ml 500 mg/ml 
To 500ml RPMI 1640, add 50ml heat-inactivated FBS. 
Combine in a 50ml tube the stock solutions:  10 ml HEPES  
       14 ml Tryptone 
       4 ml Haemin 
       6 ml PGAB 
Filter this mix through a 0.2 μm filter directly into the RPMI/FBS. Store at 4°C. 
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A.8.2 Leishmania  
αMEM 
i) To 800ml ddH2O in a 1 L bottle or beaker, dissolve: 
(final) 
aMEM powder 1bottle   (1x) 
NaHCO3  2.2g    (26.2 mM) 
L-glutamine  0.59g    (4 mM) 
D-glucose  3g    (16.7 mM) 
HEPES   10g    (42 mM) 
Adjust pH to ~7.5. Add ddH2O to 860 ml. 
ii) Prepare: 
 Haemin 5mg /50 μl 1N NaOH/ 9.95 ml dH2O  (0.008 mM) 
 Adenine 40 mg /500 μl 1N NaOH /9.50 ml dH2O  (0.3 mM) 
 Folic acid 5mg /40 μl 1N NaOH/ 9.96 ml dH2O  (0.011 mM) 
 D-biotin 2mg /100 μl 1N NaOH /9.90 ml dH2O  (0.008 mM) 
iii) Transfer aMEM made to this point into a clean 1L bottle. In a cell culture cabinet, 
add:  
 Haemin, Adenine, Folic acid, D-biotin solutions;  
 gentamycin      1 ml     (50 ug/ml) 
iv) Sterile filter into an autoclaved 1 L bottle, using a bottle-top filter and vacuum 
pump. 
v) Add 
  Foetal Calf serum (heat inactivated) 100 ml     (10%) 
vi)  Store at 4 °C. 
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Reagent/consumable Supplier Cat. No. 
αMEM powder Sigma M0644 
24 well plate VWR 734-0020 
48 wel plate VWR 734-0028 
Adenine Sigma A2786 
D-Biotin Sigma B4639 
FBS Sigma F9665 
Folic acid Sigma F8758 
Gentamycin Sigma G1522 
D-Glucose Sigma G8270 
L-Glutamine Sigma G8540 
Haemin Sigma H5533 
HEPES Sigma H3784 
Na Glutamate Sigma 49621 
Na Pyruvate Sigma P5280 
NaHCO3 Sigma S5761 
NaOH Sigma S5881 
RPMI Sigma R0883 
Tryptone/trypticase Sigma T9410 
FastRead 102 disposable counting chamber ImmuneSystems BVS100 
Parafilm VWR 291-1212 
Slope tube  Fisher TKT-150-050B 
Bottle-top filter Fisher TKV-240-015F 
T25 culture flask SLS 353014 
T75 culture flask SLS 353024 
Vacuum pump Fisher FB70155 
 
A.9 List of suppliers  
Aapptec     www.aapptec.com 
Abcam      www.abcam.com 
Abgene     www.abgene.com 
Advanced Chromatography Technologies www.ace-hplc.com 
Agilent Technologies    www.genomics.agilent.com 
Applied Biosystems    www3.appliedbiosystems.com 
Bioline      www.bioline.com 
Bio-Rad     www3.bio-rad.com 
Chembio Diagnostics    chembio.com 
Dynex      www.dynextechnologies.com 
Eppendorf     www.eppendorf.co.uk 
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Eurofins MWG Operon   www.eurofinsdna.com 
Fisher Scientific    www.fisher.co.uk 
Genosphere Biotechnologies   www.genosphere.co.uk 
Jackson Labs      see Stratech 
Merck      www.merck-chemicals.co.uk 
MJ Research     www.mj-research.com 
MSE (Measuring and Scientific Equipment) www.mseuk.co.uk 
NEB (New England Biolabs)    www.neb.uk.com 
Oxoid      www.oxoid.com 
Promega      www.promega.com 
Rathburn Chemicals Ltd   www.rathburn.co.uk 
Qiagen      www1.qiagen.com 
Sigma-Aldrich     www.sigmaaldrich.com 
SLS (Scientific Laboratory Supplies)  www.scientificlabs.co.uk 
Stratech (for Jackson Labs)   www.stratech.co.uk 
Syngene     www.syngene.com 
UVP      www.uvp.com 
VWR      uk.vwr.com 
Zinsser Analytic    www.zinsser-analytic.com 
 
 
